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About this report
The EU drug markets report provides the first comprehensive overview of illicit drug markets 
in the European Union. The report combines Europol’s strategic perspective and operational 
understanding of trends and developments in organised crime with the EMCDDA’s ongoing 
monitoring and analysis of various aspects of the drug phenomenon in Europe and beyond.
The EU drug market is complex, and the analysis provided here spans numerous topics such 
as production, consumer markets, trafficking, organised crime and policy responses. Taking 
a multi-source approach, the report reviews the markets for heroin, cocaine, cannabis, 
amphetamine, methamphetamine, ecstasy and new psychoactive substances. It also provides 
concrete action points for the areas where the current EU response to the drug market and its 
consequent harms may be improved.
This publication is an essential reference for law enforcement professionals, policymakers, the 
academic community and indeed for anyone seeking up-to-date information and analysis on 
drug markets in Europe.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the hub of drug-related 
information in Europe. Its mission is to provide the EU 
and its Member States with ‘factual, objective, reliable 
and comparable information’ on drugs, drug addiction 
and their consequences. Established in 1993, it opened 
its doors in Lisbon in 1995 and is one of the EU’s 
decentralised agencies. With a strong multidisciplinary 
team, the agency offers policymakers the evidence base 
they need for drawing up drug laws and strategies. It 
also helps professionals and researchers pinpoint best 
practice and new areas for analysis. As well as 
gathering information on the demand and reduction of 
the demand for drugs, the agency in recent years has 
extended its monitoring and reporting on drug supply, 
supply reduction and illicit drug markets.
www.emcdda.europa.eu
About Europol
Europol is the European Union’s law enforcement 
agency. Its aim is to improve the effectiveness of, and 
cooperation between, the competent authorities in the 
EU Member States in preventing and combating serious 
international organised crime and terrorism. 
Operational since 1999 and based in The Hague, the 
organisation employs some 600 staff to support 
national law-enforcement agencies in their everyday 
work, including efforts to tackle illicit drug trafficking, 
money laundering, cyber crime and terrorism. Europol 
comes into play when an organised criminal structure is 
involved and two or more EU Member States are 
affected. Among others, it facilitates cross-country 
information exchange and provides analysis of 
operations.
www.europol.europa.eu
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7Drug trafficking—whilst illegal—is a highly profitable 
commercial activity. Understanding this market reality 
requires a holistic approach, following the economic 
chain from production to consumption via trafficking.
This report is the result of a cross-fertilisation between 
Europol and the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA), two EU agencies 
under my responsibility. For the first time, it provides 
to the law enforcement community, policymakers, the 
academic sphere and public at large a comprehensive 
picture of all illegal drug markets at EU level. In doing 
so, it goes beyond a mere statistical analysis or threat 
assessment to provide a strategic analysis of one of 
the most complex and invasive criminal phenomena of 
our times. Furthermore, it includes analyses of selected 
markets, reviews of policy responses and last but not 
least presents recommendations for the future.
Some of the key points revealed by the report—connections 
between cocaine and cannabis resin trafficking networks 
and between cocaine and heroin trafficking groups; growth 
in the number, type and availability of new substances 
in Europe; as well as the 
sheer speed of change in 
European drug markets—
clearly call for more action 
and cooperation at EU level.
These insights will feed the new EU policy cycle process on 
organised and serious international crime (new priorities 
and actions are to be adopted for the period 2013–2017).
No doubt there is a lot of work ahead of us. Illicit drug 
markets are a huge economic challenge. According 
to the United Nations Office on Drugs and Crime, 
70 % of the criminal proceeds of drug trafficking 
are laundered through the financial system and then 
penetrate our licit economy. We need to be better 
able to identify this impact on European society and 
on the EU economy. This is the reason why future 
work should aim to quantify and analyse how illicit 
drug markets interact with the licit economy.
Cecilia Malmström 
European Commissioner for Home Affairs
Foreword

9This is the first time that Europol and the EMCDDA have 
joined forces to produce a comprehensive analysis of the 
European drug market in its entirety. Previous joint 
publications from our agencies have focused on individual 
market elements, but up to now we have never brought these 
together within a single analytical framework. The big 
picture needs to be seen—the increasingly joined-up nature 
of the modern European drug market demands an equally 
joined-up analysis. 
Information and analysis are fundamental to the work of 
both Europol and the EMCDDA. But the organisations’ 
perspectives and relationships to data are different. This 
report benefits from Europol’s strategic perspective and 
operational understanding of trends and developments in 
organised crime that comes from working actively in the 
field to support European law enforcement efforts. This is 
complemented by the insight that comes from the EMCDDA’s 
ongoing monitoring and analysis of data covering various 
aspects of the drug phenomenon in Europe and beyond. The 
joint vision that the two agencies bring to this topic is a 
broad and complementary one, and we believe the analysis 
it generates is in many ways unique. The drug market is a 
complex place; we cannot fully understand the supply of 
drugs in Europe if we do not comprehend the changing 
nature of demand. Patterns of drug use in the EU are 
changing: new drugs enter the marketplace on a regular 
basis and drug users rarely restrict their consumption to 
specific substances. Equally, the criminality that the drug 
market generates can only be properly understood in the 
wider context of organised crime groups’ operations. 
It is also, we believe, an appropriate time for such an 
initiative. The European drug problem appears to be moving 
into a new phase. The substances and patterns that have 
characterised the European drug market for the last 30 
years now have to share the stage with a wide range of 
newer substances and behaviours. The drug market itself 
appears increasingly dynamic, innovative and quick to 
respond to challenges. In this report, we call for an equally 
dynamic, innovative and agile response. This is only 
possible if we can keep pace with developments and 
understand the factors that drive them. We must understand, 
for example, how the drug market is influenced by global 
issues and new technologies. These developments have an 
impact on all aspects of modern life, and they are now 
beginning to shape both a new kind of drug problem and a 
new kind of drug market. Our task here is to stimulate a 
debate so that responses can be configured and actions can 
be taken to ensure that Europe continues to tackle the drugs 
problem in a comprehensive and balanced way.
Being forward-looking, however, does not imply a disregard 
for the lessons we have learnt. A strong conclusion emerging 
from the analysis presented here is that we need to continue 
to invest in measures that have been shown to work, such as 
intelligence-led policing; the targeting of key organised 
crime figures, financial transactions and precursor chemicals; 
and coordinated actions and cooperation between national 
law enforcement bodies. Europe’s strategy on drugs is to 
combine holistically a rigorous demand and supply 
reduction approach. But within this strategy, the individual 
tools chosen for our interventions need to be continually 
reviewed and tested. Not all approaches work and, 
crucially, not all approaches that worked in the past will be 
effective in the future. History has shown us that good 
intentions do not necessarily deliver results in the drugs 
area. Most importantly, the dynamic and responsive nature 
of the drug market means that we are faced with a moving 
target, where any success is likely to be transient. This is why 
monitoring, analysis and assessment are essential tools for 
ensuring that our strategies and responses remain fit for 
purpose. 
The focus of this report is the drug market and how our 
enforcement actions can be made more effective. This, 
however, is only ‘one side of the coin’: achieving progress 
over time will depend on reducing both supply and demand. 
Europe’s balanced approach to drug policy is central here, 
as it is configured around the need to ensure 
complementarity between these two aspects. This is 
illustrated by the current decline in the use of heroin in 
Europe. Here, vigorous policing along the heroin routes 
bordering the European Union, and the success of our 
Member States in engaging those with heroin problems in 
effective drug treatment programmes, are both likely to have 
Introduction
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played a significant role. In the future, it will be no less 
important to maintain this balance and to engage positively 
with local communities that are affected by drug problems. 
Acknowledging the uncertainty that exists is a critical 
requirement of any informed analysis. In this report, we aim 
to provide a comprehensive analysis of the drug market, but 
to achieve this we must also be sensitive to the limitations of 
the information available. This is why we have taken a 
multi-source approach, testing data sets against one another, 
and recognising that conclusions need to be cautiously 
framed. We have resisted the temptation to quantify and 
present estimates where there is a lack of robust information, 
for example in the case of drug flows and the size of the 
European market. 
One of the themes running through this report is that the 
European drug market needs to be seen in the context of 
patterns of demand and supply in developing countries. 
Africa is a particular concern here, but it is not the only one. 
Currently, outside of North America, Australia and the 
European Union, the information available on the global 
drug market remains extremely weak. In Europe, we have 
invested in establishing monitoring capacity and mechanisms 
for the sharing of intelligence. We are better placed to 
identify important changes in the marketplace, but still we 
find that information resources in many areas are insufficient 
for our needs. The EMCDDA and Europol are working 
closely with the European Commission to help improve this 
situation. We conclude this report by focusing on critical 
information needs, and we note that this is an area in which 
modest investment is likely to reap significant benefits. 
The purpose of this report is to inform policies and actions. 
Concrete action points are provided in those areas which 
we identify as having potential for improving the EU 
response to the drug market and its consequent harms. 
Many of these issues will have resonance at national or 
even local level, but the focus is how our actions at an EU 
level can make a difference. Here, coordination and 
cooperation are crucial. This only comes, in our view, from a 
common understanding of the problem, a clear vision on the 
priorities for action and the determination to promote and 
remove obstacles to cooperation. We hope you will agree 
with us that this report makes a positive contribution to this 
endeavour, and we would like to thank all those who have 
been involved in its production. 
Wolfgang Götz Rob Wainwright 
Director, EMCDDA Director, Europol
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At a glance
Key issues
Summarised below are some of the interlinked factors 
which are important for understanding the development 
of the modern European drug market. These are drawn 
from the more extensive analysis that can be found in 
Chapter 10.
Interaction among the heroin, cocaine, cannabis and 
synthetic drug markets is increasing.
•  Diversification in trafficking: Trafficking routes are 
diversifying, with drugs being moved through multiple 
transit points and complex channels, and the use of 
legitimate commercial transport is increasing.
•  The changing face of organised crime: Organised 
crime groups take a multi-commodity perspective and 
take advantage of new methods to facilitate their 
activities within a drug market that is more global, 
dynamic and fluid.
Globalisation is a key driver for change, influencing drug 
flows, availability and demand, and resulting in a more 
dynamic and faster moving drug market.
•  The growing importance of the Internet: The Internet is 
emerging as an online marketplace for drugs and 
contributes to the rapid global diffusion of new trends 
by facilitating communication and providing access to 
knowledge, expertise and logistics.
•  The impact of new markets: Domestic demand for 
drugs in Africa, Asia and Latin America is growing and 
diversifying, and this is impacting on drug flows into 
and out of Europe.
•  The EU as a producing region: The European Union (EU) 
is an important source of knowledge and expertise, is a 
producer of synthetic drugs and cannabis and remains 
a significant source of heroin precursors.
•  Innovation: New technologies are having an important 
impact on the drug market, as seen in developments in 
production, the sourcing of non-controlled chemicals 
(including pre-precursors) and the manufacture and 
marketing of new psychoactive substances.
The significance of different drugs in the market is 
changing, and this has important implications for future 
demand and supply reduction policies and approaches.
•  The heroin problem is changing: This drug remains 
important, but a combination of supply and demand 
reduction measures appears to be contributing to an 
overall long-term decline.
•  A less discriminating drug marketplace: Stimulants, 
including cocaine and synthetic drugs, are of growing 
importance, for both demand- and supply-side reasons, 
and exist within a marketplace in which consumers will 
often substitute one drug for another or use multiple 
substances.
•  New drugs entering the market: Both unregulated new 
substances and controlled drugs that were previously not 
widely used are becoming more important and may be 
attractive to new groups of potential users. Examples of 
note here include synthetic cannabinoid receptor 
agonists, cathinones, ketamine and methamphetamine.
•  Cannabis market—pervasive and resilient: The 
cannabis market is characterised by high demand and 
a diversity of products, producers and sources. 
Domestic production is of growing importance and 
linked with violence and other criminal activities.
14
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Strategic recommendations
Provided here are the strategic recommendations for the EU 
that can be drawn from the analyses developed throughout 
this report. These are elaborated further and operationalised 
as action points in Chapter 10.
•  Ensuring that responses remain on target: Strategic 
analysis, with regular critical review, is necessary to 
ensure that responses remain fit for purpose and keep 
pace with a complex, faster moving and more globally 
interlinked drug market.
•  Proactive international engagement: Information 
sharing and cooperation with countries where drugs 
are produced, or transit en route to the EU, is a high 
priority. Changes in the flow of drugs into Europe 
means that new countries are now becoming important, 
or will be important in the future.
•   Operational partnerships within the EU: Intelligence 
sharing and coordinated law enforcement operations 
to disrupt the European drug market and the 
trafficking of drugs into the EU need to be scaled up 
to match the growing challenge of a more integrated 
drug market.
•   Focusing on high-value targets: A high priority should 
be given to targeted and intelligence-led actions 
against major organised crime groups (OCGs).
•   Strategic partnerships with industry: There is a need for 
greater investment in working with industries whose 
legitimate operations are exploited by the drug market. 
Of particular importance are the transportation, 
logistics, chemical (including drug precursors) and 
communication sectors. The Internet requires special 
attention, and engagement with service and payment 
providers is required to create strong effective barriers 
to the online sale of drugs.
•   Detecting, anticipating and responding to new threats: 
Increased capacity to detect, and share information on, 
important trends in the drug market is of growing 
importance given the speed of developments in the 
area of new and synthetic drugs. Investment in 
innovative approaches and forensic data sources has 
the potential to address critical information deficits, 
facilitate a rapid response and allow operational 
activities to be more effectively targeted and evaluated.
CONTEXT
16
illicit drugs fund their use through crime, and those involved 
in the trafficking and selling of drugs are often also involved 
in other criminal activities. Drug use patterns in Europe are 
changing, and new substances are appearing. Moreover, 
there is a risk that, in an increasingly globalised and 
‘connected’ world, illicit drug markets of different sorts may 
converge, and that illicit drug markets may become 
intertwined with other illicit markets, such as the trafficking 
of counterfeit goods and of human beings. Corruption also 
becomes an increasingly intractable problem with the 
involvement of OCGs. All these themes are addressed within 
the body of this report, which, alongside Europol’s Serious 
and Organised Crime Threat Assessment (SOCTA), will 
contribute to the definition of future EU security priorities.
The structure of this report
The next six chapters describe the markets for the main illicit 
drugs in Europe: heroin, cocaine, cannabis, amphetamine, 
methamphetamine and ecstasy. The chapters largely follow the 
same format. Each starts with a summary of key statistics ‘at a 
glance’, covering prevalence and treatment, seizures, drug law 
offences, prices and purity. The next section provides a global 
overview, setting the background against which the European 
drug market operates. This is followed by sections on 
production and precursor issues; the size and structure of the 
consumer market; trends in trafficking; the involvement of 
organised crime; and EU policy responses. Policy responses 
for synthetic drugs (amphetamine, methamphetamine, ecstasy) 
are discussed in Chapter 5, Amphetamine.
Of course, this structure assumes, somewhat artificially, that 
each market operates independently of the others. In reality, 
there is considerable overlap in structure, and in response. 
Thus, Chapter 5, on amphetamine, considers the role of 
OCGs in the markets for all synthetic drugs, and EU 
responses to these markets. Chapter 8 considers a range of 
‘new drugs’—largely, but not exclusively, synthetic ones. The 
final two chapters draw together the threads of the report. 
Chapter 9 identifies some important issues raised by the 
previous seven chapters, and this is followed by a 
concluding chapter that provides a synthesis of the report’s 
findings and draws out a list of specific action points.
Drug use and supply are topics that are directly and 
indirectly linked to European security and the public health 
agenda. They also impact on EU relations with third 
countries both directly, in terms of trafficking of drugs into or 
from the EU, and indirectly, through the nexus that exists 
between drug use and broader issues such as social stability 
and development, the fight against organised and serious 
international crime and terrorism, and measures to address 
corruption. The focus of this report is drug markets. This area 
is clearly central to the drugs problem, and thus a major 
focus of policies and actions. It also remains an area that is 
relatively poorly understood.
The analysis provided here is unique in that it combines 
information from the two major EU agencies working in the 
drugs area. For the first time, the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) and Europol have 
joined forces to provide a comprehensive overview of all 
aspects of the contemporary European drug market. 
Information and analysis are key concerns of both 
organisations. Here a synthesis can be found that unites 
Europol’s operational and strategic intelligence with data from 
the EMCDDA monitoring and analysis of the EU drug situation. 
This dual perspective is reflected in each chapter of this 
document. It can also be found in the conclusions and 
recommendations of this report, which are focused on how 
cooperation and coordinated actions can add value to 
European efforts to address the drug market. Other valuable 
input has been provided by key institutional partners, such as 
Eurojust and the European Commission (EC), although the 
responsibility for the analysis and recommendations provided 
here remains with the EMCDDA and Europol. The approach is 
deliberately pragmatic and applied. This is a difficult area to 
address with any certainty and, clearly, all data sources have 
their limitations. However, in combining information from 
multiple sources, and informed by the agencies’ different 
perspectives, it is possible to produce a convincing overview of 
the current state of the European market and draw conclusions 
which are grounded in the best evidence that is available.
This is a complex problem, and the analysis provided here 
has had to span many topics. The emergence of high-value 
drug markets has many consequences and is inextricably 
linked to other forms of offending. Some of those who buy 
Chapter 1 | Context
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production and trafficking of drugs. Under the umbrella of 
the EU Drugs Strategy 2005–2012 (1) and action plans (2), 
the European (external) Security Strategy (3), the Stockholm 
Programme (4), the EU Internal Security Strategy (5), the two 
European pacts to combat international drug trafficking—
disrupting cocaine and heroin routes (6) and against 
synthetic drugs (7)—and the EU policy cycle for organised 
and serious international crime (8), the EU is currently 
developing a wide range of operational actions on all fronts 
of the fight against drugs. The aim is to tackle drugs within a 
policy framework balancing supply and demand 
approaches through measures within the EU, at external 
borders and with our international partners. Action in this 
field should intensify in future, on the basis of a renewed 
financial framework for 2014–2020 (9).
The Internal Security Strategy
Internally, the EU is stepping up prevention, detection and 
disruption of organised crime activities through more 
efficient measures, addressing information and intelligence 
exchange, training needs and the penetration of the licit 
economy. In this regard, the Commission has proposed more 
robust EU legislation on asset recovery and will shortly table 
legislative proposals pertaining to money laundering, 
terrorist financing and a new legal basis for Europol. A 
European Training Scheme is also foreseen. This would 
notably address cross-border investigations with a view to 
contributing to the development of a common law 
enforcement culture with similar levels of performance for 
law enforcement officials. An EU Anti-corruption report will 
be released in Spring 2013.
In the Stockholm Programme, the European Council called 
on the Council of the European Union (the Council) to 
develop a strategy on organised crime within the framework 
of the EU’s Internal Security Strategy. Consequently, in 2010 
the Council adopted Council conclusions on the creation 
and implementation of an EU policy cycle for organised and 
serious international crime (Council of the European Union, 
2010b). This was based on the work of the Standing 
Committee on Operational Cooperation on Internal Security 
(COSI), established by a Council Decision in 2009 following 
Article 71 of the Treaty on the Functioning of the European 
Data and sources
Systematic and routine information on illicit drug markets 
and trafficking is still limited. Drug seizures are often 
considered as an indirect indicator of the supply, trafficking 
routes and availability of drugs; however, they also reflect 
law enforcement priorities, resources and strategies, the 
vulnerability of traffickers and reporting practices. Data on 
the purity or potency and price of illicit drugs, the 
availability, reliability and comparability of which are often 
limited, may facilitate an understanding of drug markets. 
Intelligence information from law enforcement agencies 
usefully completes the picture, along with overviews on 
organised crime based on Europol analysis work files 
(AWFs). The EMCDDA (1) collects national data on drug 
law offences, drug seizures, drug purity (and potency) and 
drug retail prices in Europe. Other data on drug supply 
come largely from the United Nations Office on Drugs and 
Crime (UNODC)’s information systems and analyses, 
complemented by additional information from Europol. 
Information on drug precursors originates from the 
International Narcotics Control Board (INCB), 
complemented by data from Europol, UNODC and the EC, 
all of which are involved in international initiatives to 
prevent the diversion of precursor chemicals used in the 
manufacture of illicit drugs. These information sources are 
not always concordant, and work is currently under way to 
improve the compatibility and quality of existing data in 
some of these areas. As many parts of the world lack 
sophisticated information systems related to drug supply, 
some of the estimates and other data reported, though 
representing the best approximations available, must be 
interpreted with caution.
(1)  Data analysed in this report cover the 30 EMCDDA reporting 
countries, which are designated by the term ‘Europe’ in the text 
and comprise the 27 European Union Member States, Croatia, 
Turkey and Norway.
The framework of European 
policy initiatives
The European Union has used a set of policy tools to 
develop a strategic response to the threats posed by the 
(1) http://register.consilium.europa.eu/pdf/en/04/st15/st15074.en04.pdf
(2) http://ec.europa.eu/justice/anti-drugs/law/index_en.htm
(3) http://consilium.europa.eu/uedocs/cmsUpload/78367.pdf
(4) http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2010:115:0001:0038:en:PDF
(5) http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:52010DC0673:EN:NOT
(6) http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/jha/114889.pdf
(7) http://www.consilium.europa.eu/uedocs/cms_Data/docs/pressdata/en/jha/125709.pdf
(8) http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/jha/122514.pdf
(9) http://ec.europa.eu/budget/reform/
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psychoactive substances. Furthermore, it provides for the 
training of law enforcement officers to detect, examine and 
dismantle clandestine laboratories. Responsibility for the 
coordination of the different activities being undertaken 
within the scope of the pacts rests with COSI.
The EU policy cycle for organised and serious international 
crime for the years 2011–2013 defined eight strategic 
priorities, four of them concerning drug trafficking. 
Operational action plans (OAPs) have been adopted and 
are being implemented (see box above).
The EU Drugs Strategy (2005–2012)
The EU Drugs Strategy (2005–2012) sets out the European 
approach to drug policy, which is built on a balanced 
approach that aims to reduce both the supply of and 
demand for drugs. It seeks to protect and improve the 
well-being of society and the individual, to protect public 
health and to offer a high level of security for the general 
public. The strategy complements and adds value to the 
activities of the EU Member States. Its aims are expressed 
across the demand and supply reduction pillars and the 
three cross-cutting themes of coordination, international 
Union (Lisbon Treaty). The remit of the committee is to 
‘facilitate, promote and strengthen coordination of 
operational actions of the Member States competent in the 
field of internal security’ (Council of the European Union, 
2009a).
A key instrument in the implementation of the EU’s security 
and drug policies is the European pact to combat 
international drug trafficking—disrupting cocaine and heroin 
routes. It supports operational activities in law enforcement 
directed at trafficking in heroin and cocaine, and targets the 
proceeds of crime (Council of the European Union, 2010c). 
This involves information and intelligence exchange; keeping 
drug issues as a core part of EU external relations; targeting 
the illicit trade in precursors; and improving interception 
capabilities. The European pact on cocaine and heroin 
invited the Council, the EC and relevant EU agencies to 
focus their activities in 2011 on counteracting synthetic 
drugs, in particular in the field of information sharing, 
specialised trainings and combating smuggling of precursors 
in close cooperation with relevant third countries.
The European pact against synthetic drugs (Council of the 
European Union, 2011a) tackles the production and 
trafficking of synthetic drugs and precursors as well as new 
The EU policy cycle for organised and serious crime
The multiannual policy cycle is designed to address the most 
important criminal threats in a way that ensures effective 
cooperation among the law enforcement agencies of the 
Member States, EU agencies and relevant third parties (Council 
of the European Union, 2010b). The initial shorter policy cycle 
runs between 2011 and 2013, while the fully fledged policy 
cycle will run between 2013 and 2017.
It consists of four steps:
In step 1, the SOCTA developed by Europol is used to present a 
picture of the threats facing the EU and form a basis for 
policymaking.
In step 2, policy priorities are set and addressed through 
multiannual strategic action plans (MASPs), providing a 
multidisciplinary, integrated and integral approach to criminal 
threats.
The European Multidisciplinary Platform Against Criminal 
Threats (EMPACT) provides the cooperation framework for step 
3, through which the crime priorities identified in step 2 are 
addressed through OAPs.
Evaluation forms a key part of the policy cycle, and in step 4 
COSI reviews and assesses the effectiveness and impact of the 
OAPs on the criminal threats.
The starting point of the EU policy cycle is Europol’s SOCTA, 
which will deliver analytical findings that can be translated into 
political priorities, strategic goals and OAPs in order to 
implement the EU policy.
In implementing the policy cycle, the Council adopted eight 
crime priorities in 2011. Subsequently, COSI, which is attached 
to the Council, set out a series of strategic goals for these 
priorities and translated them into OAPs managed by project 
groups that report to COSI. 
Key priorities relating to illicit drugs are:
Priority A: Weaken the capacity of OCGs active or based in 
West Africa to traffic cocaine and heroin to and within the EU.
Priority B: Mitigate the role of the Western Balkans as a key 
transit and storage zone for illicit commodities destined for the 
EU and logistical centre for OCGs, including Albanian-
speaking OCGs.
Priority D: Reduce the production and distribution in the EU of 
synthetic drugs, including new psychoactive substances.
Priority E: Disrupt the trafficking to the EU, particularly in 
container form, of illicit commodities, including cocaine, heroin, 
cannabis, counterfeit goods and cigarettes.
19
Chapter 1 | Context
cooperation and information, and research and 
evaluation. Two consecutive four-year action plans, 
covering 2005–2008 and 2009–2012, support the 
implementation of the strategy, which provides the 
framework, objectives and priorities for the action plans. 
A new EU Drugs Strategy (2013–2020) has been adopted 
recently and will be implemented through corresponding 
action plans.
Actions aimed at improving collaboration form a key part of 
EU policy. The EU Drugs Strategy (2005–2012) underlines 
the importance of cooperation with third countries, including 
European Neighbourhood Policy (ENP) partner countries and 
countries that are a key source of drugs or transit countries 
for drugs. The ENP was designed to strengthen the prosperity 
and security of countries near the new borders of the EU 
following its enlargement in 2004. The EU Drugs Action Plan 
(2009–2012) supports this through, for example, Action 45, 
which aims to ensure that EU relations with third countries 
support the objectives of the EU Drugs Strategy. In addition, 
15 Member States have concluded bilateral agreements with 
third countries addressing cooperation on drug issues 
(Council of the European Union, 2004, 2008; EC, 2010a). In 
this context, the EU has focused on the fulfilment by ENP 
countries of their obligations under the 1988 United Nations 
(UN) convention, as well as the provision of assistance in 
capacity building to national authorities engaged in demand 
and supply reduction activities.
One mechanism for achieving the EU Drugs Action Plan 
(2009–2012) objectives in the area of international 
cooperation is activities under the European Neighbourhood 
and Partnership Instrument (ENPI), which became active in 
2007. The EU Drugs Action Plan (2009–2012) required two 
drug action plans to be put in place, one in the Central 
Asian republics and one in the Western Balkan states. This 
was achieved in the first half of 2009 (EC, 2010a). The two 
action plans cover the period from 2009 to 2013, providing 
a coherent framework for cooperation activities between the 
EU and both groups of countries (Council of the European 
Union, 2009b,c).
The EC and the EU Member States fund initiatives aimed at 
creating a set of ‘filters’ between opioid production sites in 
Afghanistan and heroin consumer markets in Western 
Europe. In Central Asia, these initiatives include the Border 
Management Programme in Central Asia (BOMCA) and the 
Central Asian Drug Action Programme (CADAP). Examples 
in the Western Balkans include the Instrument for Pre-
Accession Assistance (IPA). The Central Asian and Western 
Balkan drug action plans help coordinate the different 
aspects of these EU programmes and regional initiatives 
(Council of the European Union, 2009c).
The fight against drug precursors in the EU
Drug precursors are essential chemicals used in the 
manufacture of illicit drugs. However, they have a wide 
variety of licit uses, and are produced and traded for 
legitimate purposes on national, regional and global 
markets. They are diverted by traffickers from licit 
distribution channels for the illicit production of drugs.
Thus, controlling drug precursors is a key component in the 
fight against illicit drugs. Taking into account the many 
legitimate uses of drug precursors, their trade cannot be 
prohibited. A specific regulatory framework, both at 
international and at EU level, has been put in place to 
monitor their legal trade and to identify suspicious 
transactions, thus preventing their diversion for illicit use. 
Effective cooperation between the competent authorities 
and the industry is key to the implementation of this 
regulatory framework.
The EU legislation on drug precursors, which is based on 
the 1988 United Nations Convention against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances, is 
composed of:
•  Council Regulation (EC) No 111/2005 laying down rules 
for the monitoring of trade between the Community and 
third countries in drug precursors;
•  Regulation No 273/2004 (1) of the European Parliament 
and the Council on drug precursors (intra-EU trade);
•  Commission Regulation No 1277/2005 (2) implementing 
rules for the above-mentioned Regulations.
On 27 September 2012, the EC adopted two proposals 
to amend the EU legislation on drug precursors. COM 
(2012) 548 (3) and COM (2012) 521 (4) propose to 
strengthen controls over drug precursors used in heroin 
and methamphetamine production, namely acetic 
anhydride and ephedrine/pseudoephedrine contained in 
medicinal products. These proposals seek to reinforce 
certain provisions in the current EU legislation, thus 
contributing at an early stage to the prevention of illicit 
drug production, by reducing the supply of drug 
precursors, which is an important pillar of the EU Drugs 
Strategy.
(1)  As amended by Regulation (EC) No 219/2009 of 11.3.2009.
(2)  As amended by Commission Regulations Nos 297/2009 of 
8.4.2009 and 225/2011 of 7.3.2011.
(3)  COM (2012) 548: http://ec.europa.eu/enterprise/sectors/
chemicals/documents/specific-chemicals/precursors/index_
en.htm
(4)  COM (2012) 521: http://ec.europa.eu/taxation_customs/
customs/customs_controls/drugs_precursors/legislation/
index_en.htm
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trafficking. This involves establishing Joint Maritime Control 
Units in key ports and Joint Maritime Intelligence Units. 
While the first phase focuses on West African countries, the 
second will involve a selected number of countries in Latin 
America and the Caribbean (EC, 2011b). 
Run by the UNODC, the World Customs Organization 
(WCO) and Interpol, the Airport Communication Project 
(AIRCOP) aims at establishing effective communication and 
exchange of intelligence to target drug trafficking routes 
involving seven countries in West Africa (Ivory Coast, Cape 
Verde, Ghana, Mali, Nigeria, Senegal and Togo) and Brazil 
while Guinea Conakry and Morocco are scheduled to join 
the project. The USD 3.2 million project financed by the 
European Union and Canada involves setting up Airport 
Anti-Traffics Cells (CAAT) to facilitate anti-drugs operations 
in the international airports of these countries. Driven by an 
intelligence-based approach, the project seeks to reinforce 
sub-regional, regional and international capacities and to 
promote operational cooperation (14).
International initiatives
Alongside these European actions there are several 
international initiatives in which EU Member States are 
involved. Two of those, which are directly related to the 
subject of this report, are briefly outlined here.
The Cargo Container Programme (CCP) is a joint initiative 
between the UNODC and the WCO. Operational since 
March 2006, the programme aims to minimise the use of 
maritime shipping containers to smuggle drugs and other 
illicit commodities. It does this by helping national authorities 
in key locations to enhance the effectiveness of their control 
structures and processes in sea ports. Central to this 
approach is the establishment of inter-agency port control 
units (PCUs) based in or near container terminals, which 
bring together law enforcement specialists to target high-risk 
containers. UNODC is responsible for the programme’s 
administration, while responsibility for its training component 
rests with WCO. Since it was piloted at ports in Ecuador, 
Ghana, Pakistan and Senegal, the CCP has been extended 
to Afghanistan, Benin, Cape Verde, Costa Rica, Guatemala 
Togo, Panama and Turkmenistan. PCUs are planned for sites 
in Azerbaijan, Iran, Georgia, Jamaica and Morocco 
(UNODC and WCO, 2009, 2012).
At external borders
With the setting up of the European border surveillance 
system (EUROSUR) (10), the EU will be able to improve its 
border intelligence and offer added value to investigations 
into cross-border drug trafficking. EUROSUR will make use 
of new technologies, such as satellite imagery, to detect and 
track targets at the maritime border by, for example, tracing 
fast vessels transporting drugs to the EU.
The implementation of the Internal Security Strategy has 
enhanced the contribution of Frontex at external borders, 
with annual reports on specific cross-border crimes forming 
the basis of joint operations with Member States. Common 
risk management strategies for the movement of goods 
across external EU borders are being developed in order to 
improve EU capabilities in the areas of risk analysis and 
targeting. The coordination of border checks by national 
authorities will be addressed, and best practices for 
interagency cooperation will be developed.
International partners
At international level, the EU is engaged in partnerships with 
third countries, notably through follow-up of the G8 
conference on transatlantic cocaine routes in May 2011, at 
which a political declaration (11) and an action plan (12) were 
adopted. The EU is currently implementing an EU strategy 
for security and development in the Sahel (13) to strengthen 
capacity in the areas of security, law enforcement and the 
rule of law in the fight against criminal threats.
The EU supports various international cooperation platforms 
along the main trafficking routes. For example, in the 
Maritime Analysis and Operation Centre—Narcotics 
(MAOC-N), EU Member States work together with the 
United States and several other third countries to fight drugs 
trafficking along the cocaine route. And in West Africa, 
through the information exchange platforms in Dakar and 
Accra, EU liaison officers participate in anti-drugs capacity-
building projects.
The Seaport Cooperation Programme (SEACOP) was 
initiated by the EU under the Instrument for Stability 
Programme 2009–2011, and will run until 2014. SEACOP 
aims to strengthen cooperation in combating maritime 
(10)  http://europa.eu/legislation_summaries/justice_freedom_security/free_movement_of_persons_asylum_immigration/l14579_en.htm
(11)  http://www.g20-g8.com/g8-g20/g8/english/the-2011-summit/declarations-and-reports/appendices/political-declaration-of-the-ministers-
responsible.1244.html
(12)  http://www.g20-g8.com/g8-g20/g8/english/the-2011-summit/declarations-and-reports/appendices/action-plan-aimed-at-strengthening-
transatlantic.1245.html
(13)  http://www.eeas.europa.eu/africa/docs/sahel_strategy_en.pdf
(14)  Further information on AIRCOP can be consulted at: http://www.unodc.org/westandcentralafrica/en/wsaircop.html
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authorities (CNAs) in participating countries to operate its 
Pre-Export Notification (PEN) system. This facilitates 
transaction visibility and monitoring of importers and 
exporters. The INCB also runs Project Prism (see Chapter 5), 
which targets precursors used to manufacture synthetic drugs 
(INCB, 2012a).
Project Cohesion is an international initiative running since 
2005, under the auspices of the INCB, aimed at preventing 
the diversion of precursor chemicals used in the illicit 
manufacture of heroin (acetic anhydride) and cocaine 
(potassium permanganate). In order to monitor the licit trade 
in chemicals, the INCB uses a system of central national 
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Introduction
Throughout the 1990s, Europe experienced a heroin 
epidemic, with increased rates of injecting and growing 
concern about drug-related human immunodeficiency virus 
(HIV) and hepatitis C virus (HCV) infections, overdose 
deaths and associated criminality. Today, overall indicators 
suggest that heroin use may be in decline, and that heroin 
may have become less available in Europe. In some 
countries the drug is being replaced by other substances, 
including synthetic opioids (15) such as diverted medicines, 
illicitly produced fentanyl (a high-potency synthetic opiate 
associated with many overdose deaths) and even stimulants 
such as cathinones.
The heroin market practically collapsed almost a decade 
ago in some northern European countries, and has never 
fully recovered. More recently, short-term market shocks, 
probably resulting from successful interdiction efforts on the 
Balkan trafficking route, have also been reported. In 2010, 
a number of countries with large populations of heroin users 
experienced a significant heroin drought, from which the 
market only partially recovered. Europe may now be moving 
into a new era in which heroin, and opioids generally, could 
play a less central role than in the past. Nevertheless, for the 
time being, opiate problems still predominate in the 
European drug treatment system, and the cost of treating this 
population will remain a major burden on health budgets for 
many years to come. In addition, in spite of some law 
enforcement success in recent years, the trafficking of heroin 
remains a significant source of revenue for OCGs.
Global overview
Opium poppies are grown illicitly in three main regions: 
South-West Asia (Afghanistan, Pakistan and India), 
supplying Africa, South-West Asia, East Asia including 
China, the Middle East, Europe and Oceania; South-East 
Asia (Myanmar and Laos), supplying mainly South-East Asia, 
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China and Oceania; and the Americas (especially 
Colombia, Mexico and Guatemala), supplying the 
Americas. At present, and in spite of a recent increase in 
estimated production in South-East Asia and the Americas, 
more than 80 % of the global detected illicit opium output of 
about 7 000 tonnes comes from Afghanistan (Figure 1).
Global illicit production of heroin was estimated at 467 
tonnes in 2011, a significant increase from the 396 tonnes 
estimated in 2010, when a poppy blight affected the Afghan 
opium crop, but still a relatively low figure compared with 
levels reached in the mid-2000s including 629 tonnes in 
2006 and a peak of 757 tonnes in 2007 (see ‘Production 
and precursor issues’, p. 26) (UNODC, 2011a, 2012a).
In 2010 (16), for the fourth consecutive year, quantities of 
heroin seized worldwide increased to peak at 81 tonnes 
(15) This chapter is largely concerned with opiates (i.e. opium-derived opioids), but some discussion is given over to synthetic opioids).
(16) The last year for which global seizure data were available at the time of writing.
Heroin
Heroin is a crude preparation of diamorphine. It is a 
semisynthetic product obtained by acetylation of morphine, 
which occurs as a natural product in opium, the dried latex 
of certain poppy species, especially Papaver somniferum. 
Diamorphine is a narcotic analgesic used in the treatment 
of severe pain. Illicit heroin may be smoked or solubilised 
with a weak acid and injected.
Whereas opium has been smoked for centuries, diamorphine 
was first synthesised in the late nineteenth century. The latex 
from the seed capsules of the opium poppy is allowed to dry. 
This material (opium) is dispersed in an aqueous solution of 
calcium hydroxide (slaked lime). The alkalinity is adjusted by 
adding ammonium chloride, causing the morphine base to 
precipitate. The separated morphine is boiled with acetic 
anhydride. Sodium carbonate is added, causing the crude 
diamorphine base to separate. Depending on the region, 
this may be used directly, further purified or converted into 
the hydrochloride salt.
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from Afghanistan to Western Europe via Iran and Turkey, 
continued to report by far the largest seizures of heroin in 
the world, in spite of a decrease in heroin seizures in 
Western Europe and Russia in recent years.
In 2010, there were an estimated 26–36 million users of 
opioids worldwide, about 50 % of whom were thought to be 
using opiates, especially heroin. Most opioids users are 
thought to live in North America, Oceania, Eastern Europe, 
including Russia, and South-East Europe. Whereas 
prescription opioids (e.g. oxycodone) are now used more 
than heroin in North America and Oceania, heroin continues 
to be the most frequently used opioid product in Europe, 
although other opioids, such as fentanyl, are used there too. 
UNODC suggests that the prevalence of opioids use could 
be increasing in Asia and in Africa, although this is based on 
expert opinions rather than data from established monitoring 
systems. Meanwhile, in Western Europe, use of opioids is 
reported to be stable or decreasing, although it remains a 
serious problem in many countries (UNODC, 2012a).
(76 tonnes in 2009). By contrast, global quantities of opium 
seized declined from 653 tonnes in 2009 to 500 tonnes in 
2010, 82 % of which was seized in Iran. This reduction in 
global quantities of opium seized may be a reflection of the 
drop in opium production in Afghanistan in 2010, although 
2010 opium seizures continued to be high compared with 
levels in the early to mid-2000s (e.g. about 350 tonnes in 
2005) (UNODC, 2012a).
As has been the case for more than 10 years, Iran seized 
the largest quantities of heroin in the world in 2010 
(27 tonnes), accounting for 33 % of the global total seizures, 
followed by Turkey (13 tonnes, or 16 %) and Afghanistan 
(9 tonnes, or 11 %). In 2010, quantities seized in the EU, 
Norway and Croatia continued to decline and reached 
about 6 tonnes (7 % of the world total), above China’s 
5.4 tonnes, Pakistan’s 4.2 tonnes and Russia’s 2.6 tonnes 
(UNODC, 2012a; EMCDDA, 2012a). Broadly speaking, this 
means that in 2010 the countries on the historical ‘Balkan 
route’, along which opiates have traditionally been trafficked 
Table 1: Heroin in Europe at a glance
Problem opioid users (1)
Estimated number (million)
1.4 
Number (% of all drug admissions)
Drug treatment (2) (2010)
All admissions 186 228 (44 %)
First admissions 43 371 (28 %)
Estimated number
Drug-related deaths (2010) (all drugs) (3) 7 000 
Number (% of all drug offences)
Drug law offences (2011)
All offences 75 049 (6 %)
Offences for drug use/possession for use 46 527 (5 %)
Offences for drug supply 22 654 (11 %)
Seizures (4) (2011)
Quantities (tonnes) EU (including Croatia, Norway and Turkey) 5 (12)
Number EU (including Croatia, Norway and Turkey) 44 000 (49 000)
Heroin base ’brown’
Mean retail price (2011) (EUR per gram) Range (IQR) (5) 24–143 (30.1–57.5)
Mean purity (2011) (%) Range (IQR) (5) 6–44 (8.4–15.0)
Notes
(1) Estimate of the extent of problem opioid (mainly heroin) use within the EU and Norway.
(2)  Information is available on about 470 000 drug users entering specialist treatment in Europe (EU, Norway, Croatia, Turkey). Units coverage may 
vary across countries.
(3)  Opioids, alone or in combination with other drugs, are present in over three-quarters of the reported drug-related deaths in Europe. 
(4)  The 2011 figures should be considered as estimates; where 2011 data were not available (United Kingdom), 2010 data were used in their place in 
European totals. Data include all types of heroin seized except liquid heroin.
(5)  IQR, interquartile range, or range of the middle half of the reported data.
Source: EMCDDA/Reitox national focal points, EMCDDA (2012a).
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supplier, although some heroin from South-East Asia may 
also be found in Europe.
Afghanistan is estimated to have produced 5 800 tonnes of 
opium in 2011, about 83 % of the global total, up from an 
exceptionally low 3 600 tonnes in 2010. The poor harvest 
of 2010 was due to a blight that affected much of the 
country’s poppies, but it would now seem that opium 
production in Afghanistan is on its way back to the high 
levels of 6 000 tonnes and above estimated since the 
mid-2000s. Indeed, farm gate prices for opium continued to 
rise sharply in Afghanistan even after production recovered 
in 2011, indicating that demand for opium is still high 
(UNODC, 2012a).
At 635 tonnes in 2011, estimated opium production is also 
rising in the second largest opiate producing region of the 
world, South-East Asia. Production increases in Laos 
(25 tonnes) and Myanmar (610 tonnes) resulted in the 
largest estimated regional harvest since 2003’s 930 tonnes. 
Farm gate prices for opium are also reported to have 
increased in Myanmar since 2010 (UNODC, 2012a).
A change in UN methodology in 2010 resulted in a sharp 
downward revision of Afghan heroin production estimates 
for 2004 to 2011. UNODC used to estimate that the entire 
global opium crop was processed into heroin, and provided 
global heroin production estimates on that basis. Before 
2010, a global conversion rate of about 10 kg of opium to 
1 kg of heroin was used to estimate world heroin 
production (17). For instance, the estimated 4 620 tonnes of 
opium harvested worldwide in 2005 was thought to make it 
possible to manufacture 472 tonnes of heroin (UNODC, 
2009a). However, UNODC now estimates that a large 
proportion of the Afghan opium harvest is not processed 
into heroin or morphine but remains ‘available on the drug 
market as opium’ (UNODC, 2010a). The opium illicitly 
produced in the rest of the world, including in South-East 
Asia and India, where consumer markets for opium exist, is 
still estimated to be entirely processed into heroin.
In 2011, an estimated 3 400 tonnes of Afghan opium was 
not transformed into heroin or morphine. Compared with 
previous years, this is an exceptionally high proportion of 
the total crop, representing nearly 60 % of the Afghan 
opium harvest and close to 50 % of the global harvest in 
2011. UNODC explains that it used regional seizure data to 
While western heroin consumer markets such as the EU and 
North America, which used to be viewed as the largest in 
the world, now appear to be shrinking, illicit opium 
production in key regions of Asia shows no sign of decline. 
If most of the opium harvested in South-West and South-East 
Asia does not end up as heroin on western markets, then 
where does it go? At present, answers to this question are 
only speculative (see box above).
Production and precursor issues
Afghanistan is by far the world’s largest illicit producer of 
opium, the raw material for heroin, and Europe’s main 
What happens to the Afghan opium that is 
not processed into heroin or morphine?
There are three main possible answers: seizure, 
consumption and stockpiling. The latest statistics indicate 
that 500 tonnes of opium was seized worldwide in 2010, 
some 95 % of which was confiscated in just three countries, 
Afghanistan, Iran and Pakistan. This represents only about 
14 % of the UNODC’s 2011 estimate of annual opium 
production in Afghanistan, which would amount to 3 400 
tonnes of unprocessed opium.
UNODC estimated that there were 4 million opium users 
worldwide in 2008, 80 % of whom lived in Asia, 
consuming a total of 1.3 tonnes of raw opium. However, 
UNODC also estimated global consumption of raw opium 
at 1 300 tonnes in 2009. Reconciling these figures is 
clearly difficult suggesting the need for further analysis in 
this area.
As far as stockpiling is concerned, UNODC estimated that 
some 2 600 tonnes of opium or an equivalent amount of 
morphine and heroin was stockpiled in Afghanistan and 
along the trafficking routes in 2009. The UN agency 
estimated that existing opium stockpiles totalled 10 000–
12 000 tonnes in 2011, which is equivalent to about two 
annual Afghan opium harvests at 2011 level (UNODC, 
2011a,b, 2012a). Although it is known that limited 
quantities of opium are stockpiled as a form of savings by 
some Afghan producers, there seems to be little empirical 
evidence confirming the existence of large stockpiles of 
opium in Afghanistan and along the trafficking routes.
(17)  In 2009, UNODC reported that it applied a 10:1 opium to heroin conversion rate to estimated opium production outside Afghanistan. For Afghanistan, 
UNODC reported using an unspecified conversion rate obtained from the Afghan Opium Surveys, but in fact it seems that the conversion rate applied to 
Afghanistan was close to the 10:1 ratio used for the rest of the world (UNODC, 2009a, Table 1, p. 34). In 2010, UNODC reported that the opium to 
heroin conversion rate in Afghanistan was 7:1 (UNODC, 2010a).
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known consumer market for it, at least not of a size that 
could explain the multi-tonne seizures of morphine made 
every year in countries close to Afghanistan. It is therefore 
estimate the quantities of ‘opium not processed’ in 2011 but 
gives few additional details (UNODC, 2012a).
This development evidently has a major impact on the 
estimated quantity of heroin manufactured worldwide 
(467 tonnes in 2011). Indeed, if the entire 5 800 tonnes of 
opium estimated to be harvested in Afghanistan in 2011 
were converted into heroin, the global heroin production 
estimate would be more than twice as large, at 948 tonnes 
(UNODC, 2012a).
Most of the heroin consumed in Europe is manufactured 
from Afghan opium, but relatively little information is 
available on where this manufacturing takes place, 
especially in recent years. The latest data available are from 
2008, when Afghanistan reported dismantling 69 heroin 
laboratories (UNODC, 2011b). A review of eight World 
drug reports published between 2005 and 2012 indicates 
that Afghanistan is the only country of the Middle East and 
South-West Asia region to report seizures of opiate 
laboratories since 2002. This confirms that large quantities 
of opium are processed into heroin in Afghanistan.
However, evidence suggests that there are also opiate 
laboratories elsewhere. In addition to seizures of opiate-
processing laboratories, seizures of illicit morphine may be 
viewed as an indicator of opiate-processing activities. 
Indeed, morphine is an intermediary product between 
opium and heroin but, unlike opium or heroin, there is no 
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probable that some or all of the morphine seized outside 
Afghanistan is destined to be transformed into heroin outside 
of that country. A review of morphine seizures since the year 
2000 would suggest that, even if less morphine has been 
exported out of Afghanistan after 2005, it is likely that at 
present some heroin continues to be manufactured in Iran 
and Pakistan (see Figure 2).
Acetic anhydride
Acetic anhydride is used as an acetylation agent to process 
morphine into heroin, and is the principal chemical used in 
the manufacture of heroin. It is subject to international 
control. However, given the large size and growth of global 
legitimate manufacture and trade in acetic anhydride, and 
the fact that comparatively small amounts are required for 
drug manufacturing, preventing diversion to illicit ends is a 
difficult task (see Figure 3).
Acetic anhydride has many licit uses, particularly in the 
pharmaceutical industry (e.g. to manufacture aspirin). An 
estimated 216 000 tonnes is manufactured legitimately every 
year in 13 countries in the Americas, Asia and Europe (18). 
The United States and China appear to be the largest 
manufacturing countries (UNODC, 2011a). Between 2005 
and 2010, nearly 1.3 million tonnes was transported in 
international shipments notified to the INCB (INCB, 
2012a) (19). In 2010, global reported seizures of illicit acetic 
anhydride shipments increased to almost 65 tonnes (up from 
21 tonnes in 2009), which was confiscated in a total of 14 
countries. Six countries reported seizing more than 1.08 
tonnes (1 000 litres) in 2010, including Bulgaria, which seized 
about 23 tonnes, accounting for practically all seizures in the 
EU that year. However, the largest acetic anhydride seizure in 
the EU in recent years was made in Slovenia, where some 98 
tonnes destined for Turkey and falsely labelled as ‘fabric 
softener’ was confiscated in June 2008. Early reports indicate 
that about 7 tonnes of acetic anhydride was seized in 
Hungary in April 2011 (see below) (EC, 2011a; INCB, 2012a).
Between 2005 and 2010, 38 governments reported seizing 
a total of about 419 tonnes, with 10 countries, including 
Bulgaria, Hungary, Russia, Slovenia and Turkey, accounting 
for 94 % of the total. This would confirm that most of the 
acetic anhydride seized was destined to process Afghan 
opium into heroin. Nevertheless, fairly large amounts have 
also been seized in connection with illicit methamphetamine 
production in recent years (e.g. in Mexico); acetic anhydride 
is used in the manufacturing of methamphetamine when this 
starts from phenylacetic acid, a precursor of 1-phenyl-2-
propanone (BMK, P2P) (INCB, 2012a).
The trafficking routes of acetic anhydride are notoriously 
difficult to document, but recent research is contributing to fill 
the information gap. According to UNODC (2011b), three 
main trafficking routes would be used to deliver acetic 
anhydride to heroin laboratories in Afghanistan and 
(18)  According to UNODC (2011a), the 13 countries legitimately manufacturing acetic anhydride are Argentina, China, France, Germany, India, Iran, Italy, 
Japan, Mexico, Russia, the United Kingdom, the United States and Uzbekistan.
(19) One litre of acetic anhydride weighs 1.08 kg, and 1 kg of acetic anhydride occupies a volume of 0.926 litres (INCB, 2012a).
A seizure of 6.5 tonnes of acetic anhydride
OCGs originating in the EU have emerged as important 
suppliers of acetic anhydride. In April 2011, about 6.5 
tonnes of acetic anhydride was seized by the Hungarian 
police. The consignment was stored in a warehouse used 
by members of an OCG. This seizure was the result of 
extensive cooperation between Slovakia, Hungary and 
several other EU Member States, with the support of 
Europol and Eurojust. These investigations led to the 
dismantling of a major organised criminal network heavily 
involved in acetic anhydride trafficking. Several places 
were searched in the Czech Republic, Slovakia, Hungary 
and Slovenia, and the main suspects were arrested. The 
OCG was involved in the trafficking of at least 30 tonnes of 
this precursor. The seizure is highly significant in terms of 
the quantities involved and the amount of heroin that could 
have been produced.
Estimating acetic anhydride requirements 
for heroin manufacture in 2011
Between 1 and 4 litres of acetic anhydride is required to 
manufacture 1 kg of heroin (INCB, 2012a). Thus, in 2011, 
between 467 000 and 1.87 million litres (504–2 017 
tonnes) of diverted acetic anhydride would have been 
required to manufacture the 467 tonnes of heroin estimated 
to have been produced worldwide (UNODC, 2012a).
In Afghanistan, where 7 kg of opium is needed to produce 
1 kg of heroin (UNODC, 2010a), some 343 tonnes of heroin 
could have been manufactured from an estimated 2 400 
tonnes of Afghan opium potentially transformed into heroin 
in 2011 (UNODC, 2012a), using between 343 000 and 
1.37 million litres (370–1 482 tonnes) of acetic anhydride.
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shipments totalling 650 tonnes being prevented from 
reaching Iraq between 2008 and 2010. The intended final 
destinations were unclear, but Iraq could be a hub for acetic 
anhydride trafficking to heroin-manufacturing countries. 
Judging by recent seizures of heroin and opium (UNODC, 
2012a), some heroin may also now be manufactured in Iraq 
(Cockburn, 2007, 2008). Whatever the case, the situation in 
Iraq warrants careful monitoring since the country has also 
been identified in recent years as a probable location for 
diversion of the methamphetamine precursors 
pseudoephedrine and BMK (INCB, 2011, 2012a).
Consumer markets for opioids in Europe
Opioid use, and in particular heroin use, has been central to 
the drug problem in Europe for more than 40 years. Despite 
signs of a stabilisation or decline in the use of opioids, the 
potential for addiction and overdose and the attendant 
dangers associated with injection justify continued concern.
Overall, the first decade of the twenty-first century witnessed a 
stabilisation or a decline in the extent of opioid use. Between 
2005 and 2011, in almost all EU countries the proportion of 
heroin clients amongst those entering drug treatment for the 
first time remained stable or declined. Earlier data are more 
difficult to summarise, showing greater variation both within 
countries across time and between countries.
Obtaining an indication of the scale of the problem is 
difficult. As a relatively small, hidden population undertaking 
a stigmatised activity, opioid users are not well captured in 
the general population surveys used to estimate prevalence 
of use of other drugs. National estimates obtained by 
indirect methods of either problem opiate use or the broader 
measure of problem drug use are available for almost all 
countries in the EU. Although these vary by year and 
methodology, an estimate has been made of the extent of 
problem opiate use within the EU and Norway of 4.2 cases 
per 1 000 in the age group 15–64 years, or approximately 
1.4 million individuals. This confirms its continued 
importance, placing it on par with ‘last year’ prevalence 
estimates of drugs such as amphetamines and ecstasy (6 per 
1 000), but below that of cocaine (12 per 1 000) and far 
below that of cannabis (68 per 1 000).
Addiction to opioids continues to dominate treatment in 
Europe. Users seeking treatment for opioid use, as a 
proportion of all reported treatment entrants, remained 
stable in 2010/2011 at approximately half, amounting to 
just over 200 000 individuals. The picture for those 
entering treatment for the first time is slightly different, with 
opioids taking second place to cannabis, although, at 
about 30 % of first-time treatment entrants, opioid users 
neighbouring countries. These routes are reported to be 
broadly the same as those along which Afghan opiates are 
transported to their consumer markets in the EU, Russia and 
Asia, but operating in the opposite direction. The ‘Balkan 
route’ involves diversion in the EU, transport by land to 
Turkey and onward shipment by land or sea to Afghanistan, 
Iran or neighbouring countries including Iraq, Syria and 
Georgia. The ‘southern route’ involves shipment, mainly by 
sea, from Asia (typically China and Korea) to Iran or 
Pakistan and thence to Afghanistan. Finally, in the ‘northern 
route’ acetic anhydride, thought to be sourced mainly in 
Russia and to a lesser extent in China, goes overland to 
Afghanistan’s northern borders via Central Asia. The 
UNODC suggests that most acetic anhydride is smuggled 
into Afghanistan via the southern route while the northern 
route accounts for least.
There is some evidence that a branch of the acetic 
anhydride Balkan route is developing in Iraq. The INCB 
(2012a) has documented a growth in orders placed by Iraqi 
firms with mainly European suppliers since 2008, and 14 
Estimated annual world
production (216 000 tonnes)
Estimated quantities needed to
manufacture 396 tonnes of 
heroin (1 064 tonnes)
Seizures (65 tonnes)
 
 
 
Figure 3:  Acetic anhydride: estimated annual world production, 
estimated requirements for heroin manufacture and 
seizures in 2010
Note:  Between 1.08 and 4.32 kg of acetic anhydride is required to 
manufacture 1 kg of heroin (INCB, 2012a). Therefore, in 2010, 
between 417 and 1 711 tonnes (a mid-range point of 1 064 
tonnes) of diverted acetic anhydride would have been needed to 
manufacture the 396 tonnes of heroin estimated to have been 
produced worldwide (UNODC, 2011a).
Sources: UNODC (2011a), INCB (2012a).
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short-term changes. For example, Sweden has reported an 
increase in opioid-related deaths over the past decade.
Trends in heroin trafficking in Europe
Seizures
The number of heroin seizures in Europe has been generally 
falling since the mid-1990s. Although these stabilised at 
around 50 000–55 000 cases a year between 2005 and 
2010, they further declined to 45 000 cases in 2011 
(Figure 4). Quantities of heroin intercepted in the EU 
increased from 5 tonnes in 1995 to an all-time peak of 12 
tonnes in 2001 but have been declining since then. This 
trend contrasts with that in Turkey, where a three- to fourfold 
increase was reported in the decade 2001–2010, making it 
the largest seizing country in Europe. However, substantial 
declines in quantities intercepted were reported in both the 
EU and Turkey in 2010 and 2011. This reversal of the trend 
in Turkey may reflect changes in both trafficking flows and 
law enforcement activity.
From South-West Asia to Europe
The vast majority of the heroin found on European markets is 
manufactured in Afghanistan and, to a lesser extent, Iran and 
Pakistan—the three South-West Asian countries are sometimes 
referred to collectively as the ‘Golden Crescent’ (see 
‘Production and precursor issues’, p. 26). Most of it reaches 
Europe via the large and expanding network of passenger 
and freight transport systems spanning Europe, Asia, the 
Middle East and Africa. Heroin source, transit and destination 
countries are now linked by a web of land, sea and air 
connections, which, coupled with traffickers’ unending ability 
seeking treatment still amount to approximately 50 000 
individuals.
Heroin is the reported primary drug for 88 % of drug users 
entering treatment for opioid use in the EU, although in 
specific countries other opioids now predominate. In Estonia, 
the more potent substance fentanyl is identified as the main 
opioid for which individuals are entering treatment, and 
buprenorphine is reported to have displaced heroin in the 
Finnish opioid market, a trend which started early this 
century (Finland: Reitox, 2011). Denmark also reports that 
fewer individuals enter treatment for heroin use than for 
other opioids. There is as yet no evidence of the widespread 
misuse of oxycodone that has characterised the drug 
situation in parts of America and Australia, and this may be 
avoided given existing prescription drug control in Europe.
Injecting opioids presents an increased risk of infection with 
blood-borne diseases such as HIV and hepatitis. In the EU, 
about 40 % of heroin users entering treatment report 
injecting their primary drug, although there is substantial 
variation amongst countries, with relatively low rates of 
injection amongst those countries that experienced an early 
growth in heroin use, such as the Netherlands and the 
United Kingdom. In broad geographic terms, contrasts are 
sometimes made between patterns of use in Western and 
Eastern Europe. It is suggested that the former, having longer 
experience of the drug, is now witnessing declining rates of 
injection and an ageing core of users, whereas the latter, 
being more recently exposed to heroin, has higher rates of 
injection and younger users. As it relies on treatment data 
on mean age and injecting behaviour, this distinction should 
be made with caution (Barrio et al., 2011).
In late 2011, qualitative information was gathered to try to 
understand fragmentary reports of a reduction in the supply 
of heroin in Europe. Evidence of this phenomenon was 
collected between November 2010 and March 2011 from 
Bulgaria, Ireland, Hungary, Slovakia, the United Kingdom, 
Switzerland and some regions in Russia, whereas heroin 
remained available, with possible increases in purity, in 
Belgium and France. There were some reports of a shift to 
alternative drugs (buprenorphine, fentanyl, stimulants, 
cathinones) and of injecting of these drugs, but again 
findings differed between countries (EMCDDA, 2011d).
Opioids, alone or in combination with other drugs, are 
present in over three-quarters of reported drug-related 
deaths in Europe. Trends in the total number of drug-related 
deaths in Europe provide some evidence to support a stable 
or declining opioid market, having fallen from a high of just 
over 8 200 deaths in 2000 to just under 7 400 in 2009, 
and estimated to be around 7 000 in 2010. However, the 
European figures mask individual country experiences and 
Adulterants of powdered drugs
For reasons of profitability, adulteration is common practice 
with all powdered drugs. Paracetamol and caffeine are 
common adulterants used in the heroin trade, and 
pre-mixed bags of brown paracetamol/caffeine powder 
have been seized by law enforcement. When heroin is in 
short supply, the extent of adulteration increases further to 
satisfy market demand.
In Europe, cocaine is almost always adulterated with 
substances such as lidocaine, benzocaine and phenacetin, 
which can be sourced online cheaply and in large 
quantities from China. Some of these adulterants cause 
concern owing to their undesirable side-effects; for 
example, phenacetin is known to be carcinogenic.
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Middle East and Europe. Since 2003, Turkey has become 
the largest seizing country reporting to the EMCDDA for 
heroin, with a peak at 16 tonnes in 2009. It now intercepts 
1.5 times as much heroin as the entire EU (compared with 
2001 when quantities seized in Turkey were only one-third 
of those in the EU). The average size of seizures is large, of 
the order of several kilograms. The same is true of Bulgaria, 
and seizure size is also significant, but not quite as large, in 
Hungary (1.1 kg, 2009–2011) and middling in the Czech 
Republic (400 g, 2009–2011), suggesting trafficking at 
wholesale level. Elsewhere in the region, trafficking, 
although in more limited quantities, is also suggested by the 
size of the seizures (100–200 g in 2009–2011) in Croatia, 
Greece, Malta and Austria (20).
At the end of the route, north-western countries such as the 
Netherlands (and recently Belgium) retain their role as 
important distribution centres for heroin in Europe, thanks to 
their well-developed commercial and transport infrastructure. 
Quantities of heroin intercepted there are, however, limited, 
around half a tonne in recent years in the Netherlands, 
to invent new concealment techniques, has resulted in a major 
diversification of trafficking routes and methods.
That said, most of the heroin leaving the ‘Golden Crescent’ 
area for Europe still seems to be transported by land along 
two loosely defined trafficking routes. The main one is 
probably the ‘Balkan route’ (discussed more fully below), 
running west through Turkey, into Balkan countries such as 
Bulgaria, Romania or Albania and on to Central, Southern 
and Western Europe. It may branch out at various points 
into the Middle East, the Arabian Peninsula and/or Africa 
before reaching Europe, again by land, air or sea. The 
‘northern’ or ‘silk’ route heads north to Russia via the former 
Soviet republics of Central Asia. Some shipments follow a 
third ‘Black Sea route’, but there is little evidence of intensive 
activity here in recent years.
The Balkan route
Turkey continues to play a central role in the Balkan route 
owing to its extensive trade and travel links with Asia, the 
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Figure 4:  Seizures of heroin in Europe, 2001–2011
Note:  All 30 European countries are included, except the Netherlands and Poland where Number of seizures data are not available. In the absence of 2011 
data for the United Kingdom, 2010 data were used in their place.
Sources: EMCDDA/Reitox national focal points, EMCDDA (2012a).
(20)  Heroin interceptions are usually of a smaller size than cocaine and cannabis interceptions, with data from 16 out of 28 reporting countries revealing 
average sizes of under 100 g over the period 2009–2011.
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Africa and possibly the Arabian Peninsula. The extent to 
which this will impact on the flow of the drug through the 
Balkans is difficult to evaluate but is deemed to be 
significant.
Trends in organised crime involvement 
with heroin in Europe
In recent years, organised crime has been characterised by 
increasing collaboration across national, ethnic and 
business boundaries. Heroin consignments to the EU are not 
controlled by a single criminal organisation, but rather 
facilitated by several, increasingly cooperating, OCGs. That 
said, some criminal networks continue to play a pivotal role 
in importation of heroin into the EU, notably Turkish and 
Albanian OCGs, while Pakistani OCGs, linked in the past 
mostly with importation of heroin into the United Kingdom, 
now seem more active across the EU.
Turkish OCGs continue to play an important role, reflecting 
the fact that the Balkan route retains its supremacy, despite 
challenges. They import heroin themselves or act as facilitators 
for other criminal organisations. Traditionally, Turkish OCGs 
are involved in various stages of the heroin trade from 
down from annual seizures of over a tonne earlier in the last 
decade. Despite sharp increases in 2009 and 2010, the 
annual amounts of heroin intercepted in Belgium are still 
comparatively small, about 300 kg a year in 2009–2010 
and down to 140 kg in 2011, with individual seizures also 
relatively small at 90 g, on average, over the period 
2009–2011.
The United Kingdom is clearly a final destination market for 
some of the heroin smuggled along the Balkan route, 
although direct importation by air from Pakistan is also 
frequently mentioned. Heroin interceptions in the United 
Kingdom peaked at nearly 4 tonnes in 2001, but have 
been declining since then, reaching 833 kg in 2010. Italy 
also remains a key location because of its extensive 
coastline, air and maritime transport infrastructure, large 
consumer market for heroin and concentration of organised 
criminal groups (Europol, 2011a). It is the only country after 
Turkey and the United Kingdom repeatedly reporting 
annual seizures greater than a tonne in the period 2001–
2009, which makes it the second largest seizing country in 
the EU. France is, to a lesser extent, likely to act as both an 
importation area, with possible transit further south and 
north, and a destination market for the drug. From a few 
hundred kilograms at the turn of the new century, seizures 
in France have increased to stabilise around the tonne mark 
since 2006.
Whereas in the past heroin was predominantly smuggled in 
lorries, today passenger vehicles and cars are used much 
more often. Smaller amounts of heroin are also smuggled in 
buses, either in baggage or within clothing. A range of 
smuggling methods has been encountered in recent years, 
from crude concealment among household items through to 
particularly innovative caches, for example within the 
threads of carpets. Traffickers also take advantage of postal 
services or private package delivery enterprises.
Maritime transportation, especially containerised, appears 
to be used more frequently than in the past, often reaching 
Europe from Iranian and Pakistani ports via African ports. 
East and West Africa, two regions through which heroin has 
been shipped to Europe for several decades, may now have 
become a major hub for trafficking of South-West Asian 
heroin to Europe, primarily by air and container shipments. 
But heroin traffickers not only exploit the possibilities 
presented by large ports handling thousands of containers a 
day; they also use smaller vessels including sailing boats or 
speedboats, for instance to transport drugs from Albania to 
Italy and even from Turkey to Spain.
There is increased evidence of a shift towards routing heroin 
shipments directly into the EU by air (passenger and freight) 
from Pakistan directly or with stopovers in West and East 
Figure 5:  Heroin and cocaine packets seized from an Albanian-
speaking criminal group, Mulhouse region, France, 
October 2012
Source: Europol.
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container shipments to Europe, sometimes transiting ports in 
Africa and the Arabian Peninsula (e.g. Dubai).
Intra-European secondary distribution is centred on North-
Western Europe, where, alongside distribution networks run 
by Turkish and Albanian OCGs, a more important role of 
domestic groups can be noted, with different examples of 
EU OCGs supplying heroin to various parts of Europe.
Lithuanian OCGs have links with Albanian OCGs and play 
a role in the distribution of heroin in North-East Europe. 
Their connections with Russian-speaking OCGs grant them 
access to heroin trafficked via the Central Asian republics, 
although the latter are also involved in the distribution and 
supply of heroin in the Baltic and some of the Nordic 
countries.
Several EU-based OCGs, cooperating with each other, have 
emerged as important suppliers of acetic anhydride. Recent 
investigations have revealed that many individuals within 
these OCGs have been actively engaged in illicitly 
smuggling acetic anhydride consignments over a number of 
years; they have developed various strategies for 
transportation and warehousing and have set up a number 
of other infrastructures to support their activities. Criminal 
brokers are strategically located in Europe, sometimes 
operating their own trading companies as ‘cover’ for their 
illicit activities, while several own transportation facilities.
Responses to heroin trafficking at 
European and international level
European policy initiatives
The 2009–2012 EU Drugs Action Plan has built on previous 
work to develop policies to address the production of 
opiates in Afghanistan and the associated drug trafficking in 
countries located on the Balkan and ‘northern’ routes. This 
has included programmes to help producer countries 
develop alternatives to poppy cultivation. The EC and 
several Member States have been doing this in Afghanistan 
for many years. Between 2002 and 2006, EUR 250 million 
was contributed by the EC towards sustainable alternatives 
to poppy cultivation for farmers in north and north-east 
Afghanistan. The emphasis was on integrated rural 
development, and not just crop substitution. Thus, rural roads 
were built to facilitate access to markets, alongside support 
for small business and community development initiatives. 
Another strand of work is to strengthen producer countries’ 
law enforcement and justice systems. A consolidated 
framework for action in Afghanistan was set out by the 
Council of the European Union in 2006 in its Action 
South-West Asia to the wholesale markets in Europe. They 
have established strong connections with suppliers in source 
countries. Iranian groups are believed to act as brokers 
between Afghan producers and Turkish OCGs, which work 
closely with criminal counterparts based in Belgium, France, 
Germany, the Netherlands and the United Kingdom.
The OCGs from the Western Balkans are important partners 
of the Turkish OCGs in the heroin trade. Albanian-speaking 
OCGs based in Albania, the former Yugoslav Republic of 
Macedonia and the Kosovo area use the region for storage 
and repackaging of heroin shipments. These groups seem to 
control a significant part of the heroin trade in many 
European countries, with criminal activities identified in 
almost all EU Member States.
Albanian-speaking organised crime is characterised by 
poly-drug and poly-criminal activities (illegal migration, 
trafficking in human beings, thefts and robberies, distribution 
of counterfeit currencies, firearms trafficking, etc.). Within 
the region, Albanian-speaking OCGs are increasingly 
involved in the trafficking of cocaine, but also of synthetic 
drugs and cannabis. These groups interact with criminal 
organisations in source areas for illicit drugs, and 
proactively identify new criminal opportunities.
Heroin is also brought into the EU by groups based within 
the region, often relying on connections with organised 
crime outside the region, largely Turkish or Albanian. Italian 
organised crime works closely with Turkish and Albanian 
partners in supplying Italy, a large consumer market for 
heroin. Others, for example Romanian or Bulgarian OCGs, 
benefiting from years of facilitating the heroin trade for 
Turkish groups, are now in a position to supply their own 
domestic markets, but also other EU markets.
West African networks have been increasingly involved in 
importation and redistribution of heroin into the EU. West 
African OCGs, especially Nigerian but also from French-
speaking countries, are amongst the most successful in 
poly-drug trafficking, organising the transport of cocaine, 
heroin, herbal cannabis and ecstasy to EU destination 
markets. West African groups are noted for their flexibility 
regarding routes and trafficking methods.
Afghan and Pakistani OCGs are increasingly active in 
Europe, facilitating heroin shipments and establishing 
businesses for that purpose. This development is likely to 
reflect the significant volume of drugs estimated to exit 
Afghanistan into Pakistan. Heroin is transported on various 
air routes to EU consumer markets such as the United 
Kingdom, Spain or Germany by air couriers. Intelligence 
suggests that the trade is very well organised, with 
significant quantities transported by air, but also via 
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severe offences (whether by substance or quantity), and not 
all countries have definitions of ‘large quantities’. 
Nevertheless, in the few countries that do, a chart 
interpreting the EMCDDA’s overviews of drug trafficking 
penalties and threshold quantities (23) serves to illustrate the 
wide variety of penalty ranges established across the EU for 
supply of a certain amount of a certain substance (Figure 6). 
These may be due to Member States’ differing 
interpretations of the Framework Decision’s requirement that 
penalties should be ‘effective, proportionate and dissuasive’ 
(Article 4(1)). The effect of these differing penalties on the 
drug market is as yet unknown.
Operational initiatives
Europol plays a central role in the EU’s response to heroin 
trafficking. It provides support for the three OAPs 
concerned with West Africa, the Western Balkans and 
Orientated Paper addressing production and trafficking 
issues (Council of the European Union, 2006).
One of the three main commitments of the European pact to 
combat international drug trafficking (see Chapter 1) has 
been to disrupt routes for trafficking heroin, and it has 
encouraged the adoption of a common approach to heroin 
trafficking by Member States.
Efforts are being made to bring court penalties for drug 
trafficking into closer alignment (under EU legislation on 
trafficking, Framework Decision 2004/757/JHA (21)). 
However, progress to date has been judged to be limited 
(see EC COM(2009) 669 and SEC(2009) 1661 (22)). The 
Framework Decision requested longer maximum penalties 
when the offence involves ‘large quantities’ or ‘those drugs 
which cause the most harm to health’ (Article 4(2)), but left 
the definition of these criteria to Member States. Not all 
countries have established separate penalty ranges for more 
(21)  http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32004F0757:EN:HTML
(22)  http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2009:0669:FIN:en:PDF
(23)  EMCDDA’s European Legal Database on Drugs, Topic Overviews, at http://www.emcdda.europa.eu/html.cfm/index5036EN.html
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Figure 6:  Prescribed penalty ranges for supplying heroin in some European countries
Note:  This figure is based on estimates, with some penalty ranges calculated using an assumed purity or street price. In some cases, the quantities chosen 
span two different penalty ranges in a country. The penalty ranges do not take into account all aggravating or mitigating circumstances or judicial 
discretion, and they are nominal sentences. They are those to be awarded by the judge according to the legal framework; regardless of the actual 
sentences awarded and executed. In Ireland, the prescribed penalty range extends to life imprisonment.
Sources: EMCDDA/Legal Correspondents Network.
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trafficking. Two high-level meetings were subsequently held 
in Moscow and Vienna, producing declarations in 2006 
and 2012 reaffirming political support for the pact. The 
UNODC performs a central coordination role in the 
initiative. The Consultative Mechanism and Automated 
Donor Assistance Mechanism (ADAM) was established 
under the first phase of the initiative. This was aimed at 
improving border controls in West and Central Asia, 
supporting the establishment of legal and institutional 
structures in key countries and improving regional 
cooperation between Europe and West and Central Asia. 
During phase 2, the network of National Strategic Analysts 
(NSAs) was established. The analysts work with UNODC’s 
field office staff to construct a picture of opiate trafficking. 
The Rainbow Strategy was also launched during phase 2, 
providing a framework to implement actions agreed by the 
partners on a range of issues. Among these are the three 
phases of Operation TARCET (targeted anti-trafficking 
operation in the region that will enhance communication, 
expertise and training), which have focused on precursor 
control (UNODC, 2011c,d).
Finally, the INCB has operated Project Cohesion (see 
Chapter 1) since 2005. It aims to prevent the diversion of 
precursor chemicals used in the manufacture of heroin, such 
as acetic anhydride. Although acetic anhydride is a key 
precursor in the manufacture of heroin, it has a variety of 
licit uses and is widely traded, with global licit trade 
amounting to some 200 million litres a year (INCB, 2012a).
container shipments that translate the EU crime priorities A, 
B and E of the EU policy cycle 2011–2013 into action (see 
Chapter 1). Through its Project Heroin and the dedicated 
focal point in the AWF on serious and organised crime, 
Europol gives operational support to Member States 
undertaking investigations into large-scale heroin 
trafficking. As a result of the exchange and analysis of 
criminal intelligence, the Europol team responsible for the 
project is able to identify links and associations between 
OCGs. These data are then provided to operational teams. 
Targeted action is coordinated by Europol through a 
dedicated sub-project addressing trafficking in acetic 
anhydride from EU sources. As a result of this activity, 
Europol has coordinated and provided operational support 
to EU law enforcement investigations, resulting in the 
seizure of more than 37 tonnes of acetic anhydride in the 
2010–2011 period.
International initiatives
Launched in 2003, the Paris Pact Initiative involves over 70 
countries and several international organisations in a 
partnership approach to address the trafficking and 
consumption of opiates from Afghanistan. This approach 
was adopted at the Ministerial Conference on Drug Routes 
from Central Asia to Europe, at which the Paris Pact was 
established. Shared responsibility for the problem was 
recognised and agreement made to increase national 
capabilities and regional partnerships against heroin 
For conclusions and recommendations relating to the heroin market, please refer to pages 131–133 in Chapter 10.
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Introduction
Cocaine is a natural product extracted from the leaves of 
Erythroxylum coca Lamarck and Erythroxylum 
novogranatense (coca leaves). These tropical shrubs are 
cultivated widely in the Andean–Amazonian region, and 
are the only known natural source of cocaine (24). There are 
two forms of cocaine in Europe: cocaine powder (a 
hydrochloride salt, HCl) and the less common crack 
cocaine (25). The drug is typically snorted (powder) or 
smoked (crack), while injection is less common. The crack 
cocaine available in Europe is typically manufactured from 
cocaine hydrochloride in locations close to where it is 
retailed and used and, therefore, cocaine in crack form 
generates very little cross-border or long-distance 
trafficking.
The picture of cocaine use and trafficking in Europe is 
complex. A significant proportion of the global cocaine 
output is now destined for Europe. Available estimates 
suggest an overall stable annual production of pure cocaine 
over the last decade, at between 800 and 1 000 tonnes, 
while interceptions in Europe, after a sharp increase at the 
beginning of the century, are now also relatively stable. 
New trafficking routes and entry points have emerged. 
Cocaine use and related health and social problems have 
increased markedly in Europe since the mid-1990s. Some 
countries (e.g. Spain, Denmark and the United Kingdom) 
have a long-established cocaine problem, while several 
others (e.g. France, Germany, Portugal) have seen a rapid 
increase in cocaine use in recent years. Other countries, 
mainly in Eastern and Northern Europe (e.g. Latvia, 
Lithuania and Finland), still report low figures for both 
cocaine use and seizures. 
Global overview
Cocaine hydrochloride is manufactured from coca cultivated 
in the Andean–Amazonian region of South America. Total 
global production of coca (and cocaine hydrochloride) is 
almost exclusively concentrated in just three countries: 
Bolivia, Colombia and Peru. Coca is regarded as a sacred 
leaf by some of the indigenous American communities of the 
Andes and Amazon Basin. Bolivian and Peruvian laws allow 
the growing of some coca in order to supply licit domestic 
consumer markets for coca leaves and to supply 
decocainised flavouring agents to international 
manufacturers of soft drinks. Consequently, the legal status 
of coca is sometimes ambiguous in South America, 
complicating efforts to control cocaine production.
In 2010, the number of cocaine users in the world was 
estimated to have stabilised at between 13 and 20 million, 
or about 0.3–0.4 % of the adult population aged 15–64 
years. Most users live in North America, South America and 
West and Central Europe, which are estimated to be the 
largest cocaine markets in the world. Cocaine use is 
estimated to have decreased in recent years in the United 
States, the largest national market in North America and 
possibly in the world, with prevalence levels among adults 
dropping from 3 % in 2006 to 2.2 % in 2010. In South 
America, cocaine use appears to be stable or increasing 
slightly, with a rise reported in Brazil, possibly the largest 
South American cocaine market, a decrease in Chile and 
stability in Argentina. Meanwhile, the situation in Europe is 
reported as generally stable. However, cocaine markets 
could be expanding in non-EU East European countries such 
as Russia, as well as in other emerging consumer markets in 
South-East Asia and Oceania (UNODC, 2012a).
A global phenomenon worth mentioning in the past decade 
is a strong expansion of the European market for cocaine 
and a corresponding shrinkage in the United States, as 
measured by estimated quantities consumed in the two 
markets. Quantities of cocaine estimated to be consumed in 
Europe doubled from 63 tonnes in 1998 to 124 tonnes in 
2009, while corresponding estimates in the United States 
dropped from 267 tonnes in 1998 to 157 tonnes in 2009 
(UNODC, 2011a). Although these estimates should be 
(24) It is possible to obtain synthetic cocaine through various methods, but this is rare and is less economic than the extraction of the natural product.
(25) Crack is a form of smokable ‘free base’—the base form of cocaine, as opposed to the salt form.
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Table 2: Cocaine in Europe at a glance
Age group  
(years)
Estimated number 
of users (million)
% of European population 
(range between countries)
Consumption (1)
Lifetime
15–64 15.5 4.6 (0.3–10.2)
15–34 8 6.3 (0.7–13.6)
Last year
15–64 4 1.2 (0.1–2.7)
15–34 3 2.1 (0.2–4.4)
Last month
15–64 1.5 0.5 (0.0–1.3)
15–34 1 0.8 (0.0–2.0)
Number (% of all drug admissions)
Drug treatment (2) (2010)
All admissions 63 707 (15%)
First admissions 32 999 (21%)
Number (% of all drug offences)
Drug law offences (2011)
All offences 112 489 (9 %)
Offences for drug use/possession for use 77 7011 (8 %)
Offences for drug supply 30 912 (15 %)
Seizures (3) (2011)
Quantities (tonnes) EU (including Croatia, Norway and Turkey) 61 (62)
Number EU (including Croatia, Norway and Turkey) 87 000 (89 000)
Mean retail price (2011) (EUR per gram) Range (IQR)(4) 50–98 (55.9–77.0)
Mean purity (2011) (%) Range (IQR)(4) 22–60 (28.3–48.1)
Notes
(1)  European estimates are computed from national estimates weighted by the population of the relevant age group in each country. They are based 
on surveys conducted between 2004 and 2010/11 (mainly 2007–2010) and therefore do not refer to a single year.
(2)  Information is available on about 470 000 drug users entering specialist treatment in Europe (EU, Norway, Croatia, Turkey). Units coverage may 
vary between countries.
(3)  The 2011 figures should be considered as estimates; where 2011 data were not available (United Kingdom), 2010 data were used in their place in 
European totals. Data include only cocaine hydrochloride (powder). Cocaine base (‘crack’) is not included (in 2011, there were 7 400 seizures of 
cocaine base, amounting to 80 kg, in Europe, including Croatia and Turkey).
(4) IQR: interquartile range, or range of the middle half of the reported data.
Sources: EMCDDA/Reitox national focal points, EMCDDA (2012a).
interpreted with caution, it is likely that Europe is now a 
larger cocaine market than it was 15 years ago.
The overwhelming majority of cocaine interceptions take 
place in the Americas, with South America, North America 
and Central America combined reporting 620 tonnes, or just 
under 90 % of the world total of 694 tonnes in 2010 (732 
tonnes in 2009). Three countries, Colombia (211 tonnes), the 
United States (163 tonnes) and Panama (53 tonnes), 
intercepted about 62 % of the global total, while West and 
Central Europe seized 9 % of the world total, or about 61 
tonnes, in 2010 (UNODC, 2012a).
Production and precursor issues
In 2010, the global acreage of coca bush cultivation was 
estimated, depending on the source, to lie between 
149 200 (UNODC, 2012a) and 187 500 hectares (US 
State Department, 2012) (26). Although both UN and US 
sources reported moderately decreasing trends in total coca 
cultivation in the 2006–2010 period, they diverged 
regarding the coca acreages of Colombia and Peru. 
Whereas the UN estimated the area under coca cultivation 
in Colombia to be between 57 000 and 62 000 hectares 
(UNODC, 2012a), the US estimate was almost twice as high 
(26)  It should be noted that both the UNODC (2011a) and the US State Department (2012) warn that their estimates of coca acreages and cocaine production are 
‘approximations’ owing to the difficulty inherent in obtaining reliable data on illicit activities carried out across vast pieces of often rugged terrain.
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Overall, reported attempts at diversion and seizures of illicit 
potassium permanganate shipments have declined sharply 
since 2005, suggesting that traffickers are circumventing 
controls. They may be doing this in several ways:
•  using an alternative chemical as a precursor (but there is 
little evidence of this happening on any scale);
•  manufacturing potassium permanganate in the cocaine-
producing countries, especially from manganese dioxide 
and potassium manganate (30) (there is evidence for this 
and there was a large (605 tonnes) seizure of potassium 
manganate in Colombia in 2010 (INCB, 2012a), but it 
seems to be less prevalent than a decade ago);
•  diverting potassium permanganate from licit shipments in 
neighbouring South American countries—or 
manufacturing it in those countries—and smuggling it into 
Bolivia, Colombia or Peru;
•  diverting or illicitly manufacturing potassium 
permanganate in countries not traditionally associated 
with cocaine production and whose authorities are less 
able (or less inclined) to control potassium permanganate 
shipments (31).
Cocaine laboratories: a complex issue
The latest data available suggest that most cocaine 
hydrochloride is manufactured in Bolivia, Colombia and 
Peru, as together these countries dismantled more than 
90 % of cocaine HCl-manufacturing facilities reported in 
2009 (UNODC, 2011e). However, there is evidence that 
some cocaine HCl is refined elsewhere in South America, 
further along the trafficking routes, and possibly also in 
Europe.
Coca leaves, and the two intermediary products, coca paste 
and cocaine base, may all be exported to neighbouring 
countries for processing into cocaine HCl. Cocaine 
laboratories were found in countries such as Argentina, 
Chile, Ecuador and Venezuela in 2008 or in 2009 
(UNODC, 2011e). In addition, some cocaine HCl is likely to 
at 100 000 hectares. Conversely, in Peru the UN estimated 
that approximately 61 200 hectares was under coca 
cultivation in 2010 while the US estimated 53 000 hectares. 
The two sources agreed, however, in estimating that Bolivia 
had the third largest area under coca, estimated at 31 000 
hectares by the UN and 34 500 hectares by the United 
States (27).
Andean aggregate potential production of pure 
cocaine (28) was estimated in 2010 at between 788 and 
1 060 tonnes by the UNODC and at 850 tonnes by the 
United States. Both estimates fall within the 800–1 000 
tonnes range reported over the last decade, reflecting a 
stable situation.
Cocaine precursors: potassium permanganate
Potassium permanganate is an essential chemical in the illicit 
manufacture of cocaine. It is mostly used to turn coca paste 
into cocaine base, a process which seems to be carried out 
mainly in Bolivia, Colombia and Peru but probably also in 
neighbouring countries on a more limited scale. Potassium 
permanganate is listed in Table I of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988 (29). It is also a chemical 
used extensively by industry throughout the world, for 
instance in drinking water treatment, which complicates 
efforts to control illicit trafficking.
Thus, between 2005 and 2010, 38 countries exported a 
total of 118 564 tonnes of potassium permanganate to 160 
importing countries. Together, the three Andean coca-
producing countries accounted for less than 1 % of the 
global volume of licit trade in 2005–2010. In 2010, 
worldwide seizures of illicit potassium permanganate 
shipments amounted to 32 tonnes, representing merely 18 % 
of the peak in 2005, when almost 183 tonnes were seized. 
As in previous years, in 2010 Colombia accounted for over 
80 % of the potassium permanganate seized worldwide 
(about 26.5 tonnes) (INCB, 2012a).
(27)  The UN and US coca acreage estimates for Bolivia and Peru include areas dedicated to licit coca crops. In Bolivia, for instance, national legislation (Ley 
1008) allows the cultivation of up to 12 000 hectares of coca to supply the licit national consumer market.
(28)  The figures for illicit cocaine production published by the UNODC and the US government are estimated amounts of ‘pure cocaine’ (UNODC, 2009b; US 
State Department, 2012) contained in the cocaine hydrochloride that could be potentially manufactured from the coca leaf output estimated for a given 
year. Thus, assuming that an estimated 1 054 tonnes of ‘pure cocaine’ was produced in Colombia in 2010 and that, on average, the Colombian cocaine 
hydrochloride contains 85 % ‘pure cocaine’ (UNODC, 2008b), it may be estimated that in 2010 some 1 240 tonnes of cocaine hydrochloride could 
potentially have been manufactured in Colombia.
(29)  The corresponding EU legislation is set out in Council Regulation (EEC) No 3677/90 (as later amended), which governs trade between the EU and third 
countries.
(30)  Colombian illicit facilities typically convert manganese dioxide into potassium manganate, which is then converted into potassium permanganate (INCB, 
2012a).
(31)  The second largest national total of potassium permanganate seized in 2010 was reported by Kazakhstan (3.3 tonnes), while another Central Asian 
country, Uzbekistan, ranked third (630 kg). In 2009, multi-tonne shipments to Mozambique and Syria were stopped, and in 2007 attempted shipments to 
Côte d’Ivoire, Nigeria and Morocco were suspended (INCB, 2008, 2011, 2012a).
41
Chapter 3 | Cocaine
That said, it is likely that the majority of the cocaine 
laboratories dismantled in the EU are ‘secondary extraction’ 
laboratories. These are used to remove the cocaine from 
other materials in which it has been incorporated—and 
therefore concealed—before exportation to Europe. 
Cocaine base, and more frequently HCl, may be 
incorporated into a range of materials including beeswax, 
fertiliser, various types of plastic, clothing, herbs, liquids, 
guano and upholstery. The incorporation process may be 
fairly simple, for instance by soaking pieces of clothing in a 
mixture of cocaine and water. But it can also be more 
complex, requiring a chemical process, for example to 
incorporate cocaine HCl within plastic. In this case, a 
reverse chemical process will be required to extract the 
cocaine from the plastic. After secondary extraction, the 
cocaine can then be adulterated with different cutting 
agents and pressed into the form of traditional cocaine 
bricks embossed with logos, probably to convince buyers 
that they are purchasing original high-purity cocaine. Recent 
reports from Member States have revealed that about 30 
cocaine ‘secondary extraction’ laboratories of various sizes 
were dismantled in the European Union in 2008 (Europol, 
2009).
In addition, there may be some laboratories in some EU 
neighbouring countries, such as Albania and Moldova. In 
2008, the Moldovan authorities reported dismantling one 
cocaine laboratory.
be refined in Brazil, Panama and Paraguay, and possibly 
also on some Caribbean islands and in Mexico.
Facilities refining cocaine HCl from base have also been 
dismantled outside South America in recent years. For 
instance, in March 2011, a large facility converting 
cocaine base into cocaine HCl was dismantled in 
Honduras (INCB, 2012a). Even if current international and 
European data-reporting practices do not always allow 
differentiation between base-to-HCl, HCl-to-crack and 
secondary extraction facilities (see below), or between 
seizures of HCl and base, similar facilities may also have 
been dismantled elsewhere. Since 2004, Australia, Hong 
Kong, Mexico, South Africa and the United States have 
reported the dismantling of at least one cocaine illicit 
laboratory to the UNODC (2007, 2008a, 2009a,c, 
2010a). Some cocaine base may also be refined into 
hydrochloride in Africa, especially West Africa (UNODC, 
2009b) (32).
Last but not least, a fairly large number of illicit cocaine 
facilities have been found in the EU in recent years, and 
some of them may be cocaine base-to-HCl facilities. 
Between 2008 and 2010, three countries reported cocaine 
laboratories to the UNODC and/or the EMCDDA: Greece 
(one in 2008 and one in 2009), the Netherlands (four in 
2008) and Spain (25 in 2008, 13 in 2009 and 35 in 
2010) (UNODC, 2011a; Spain: Reitox, 2011). The Spanish 
data differentiate between several types of cocaine 
laboratories. Although the vast majority of the cocaine 
facilities reported by Spain to the UNODC and the 
EMCDDA since 2008 are secondary extraction laboratories 
(see below), some of the others could be base-to-HCl 
facilities (33). For instance, in 2009, Spain reported one 
‘processing’ laboratory to the EMCDDA, and in 2010 two 
‘cocaine processing’ or ‘crack cocaine processing’ 
laboratories (Spain: Reitox, 2010, 2011). Finally, on 7 
January 2011, a large cocaine facility, which the INCB 
(2012a) reported as a ‘processing laboratory’, was 
dismantled near Madrid, and the authorities seized 33 
tonnes of essential chemicals including very large quantities 
of methyl ethyl ketone, acetone and toluene, which are 
often used to refine cocaine base into HCl. In 2012, Europol 
received information on the dismantling of three 
laboratories (two in the Netherlands and one in Poland), 
one of which was of a large scale.
(32)  Very large quantities of acetone and methyl ethyl ketone, two solvents placed under international control and which are often used to manufacture cocaine 
(and heroin), were seized in Benin and Guinea in 2010 (INCB, 2011).
(33)  In 2009, the Spanish focal point reported to the EMCDDA that all 25 cocaine laboratories dismantled in Spain in 2008 were secondary extraction 
laboratories (Spain: Reitox, 2009). However, the data reported to the UNODC by Spain for 2008 mention 24 cocaine secondary extraction laboratories 
and one ‘other’ cocaine laboratory (UNODC, 2011c).
Figure 7:  Cocaine incorporated in palm oil seized in Albania  
in 2011
Source: Spanish Guardia Civil via Europol.
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of cocaine is decreasing—something that future surveys 
will clarify. 
By contrast, France reported a steady increase in prevalence 
among young adults, from 0.5 % in 2000 to 1.9 % in 2010, 
and in Germany prevalence is relatively stable, reported at 
1.8 % in 2010. In both countries prevalence remains below 
the 2.1 % European average. Hence, cautious signs of a 
flattening or decline in European prevalence, largely 
influenced by movements in the high-prevalence countries, 
must be offset against the suggestion of continued growth or 
stable demand in individual countries, some with large 
populations.
Treatment data can provide a second perspective on the 
cocaine market (34). All the high-prevalence countries apart 
Consumer markets for cocaine in Europe
Labelled at one point as the ‘champagne of drugs’ because 
of its high price and associations with the rich and famous, 
cocaine snorted in powder form has found acceptance 
amongst drug users in recreational settings. However, the 
numbers of primary cocaine users in treatment belie the 
drug’s benign image. The profile of a more problematic user, 
engaging in polydrug use, injecting the drug, or smoking it 
as crack, presents a contrasting and darker picture of 
cocaine use. On the basis of the most recent surveys, an 
estimated 5 % of Europeans aged 15–64, some 15.5 million 
individuals, report having used cocaine at least once in their 
life. This makes the drug the second most used illicit drug 
within Europe, after cannabis.
In terms of more recent use, the consumer market for cocaine 
amongst young adults is characterised by relatively high 
prevalence in a handful of countries: Spain, the United 
Kingdom, Italy, Ireland and Denmark. These five countries 
alone account for 1.7 million (or 62 %) of the estimated 2.7 
million users ‘in the last 12 months’ in the 15–34 age group, 
with prevalence levels of between 2.6 % and 4.4 %. The 
European prevalence rate for ‘last 12 months’ use amongst 
young adults stands at 2.1 %.
At the other end of the spectrum, a set of East European 
countries, Lithuania, Poland and the Czech Republic, along 
with Hungary, Romania and Greece, report prevalence 
levels of 0.5 % or less, suggesting relatively small markets 
for cocaine. This could in part be explained by the historical 
predominance of alternative stimulants and the relatively 
recent arrival of the drug in these countries.
Of interest given the Netherlands’ role in cocaine trafficking, 
recent cocaine use amongst the 15–64 age group is 
reported as in line with the 2005 European average of 
1.3 % (The Netherlands: Reitox, 2010). Unfortunately, 
changes in methodology in the 2009 Dutch National 
Prevalence Survey prevent more recent comparisons.
Over time, the consumer market may be showing signs of 
levelling off or declining in the five high-prevalence 
countries, which would also reduce the overall European 
average. Amongst the five high-prevalence countries, there 
appears to have been a general increase amongst young 
adult recent users over the first seven or eight years of the 
century. However, the most recent surveys for each of 
these countries, four of them conducted in 2010, show a 
drop. This suggests that prevalence of cocaine use may 
have peaked in these countries, and that the attractiveness 
(34) However, the data inevitably reflect not only demand for treatment but also the supply of services, and recording practices are of variable quality.
Wastewater analysis to estimate cocaine 
consumption
Sewage epidemiology or wastewater analysis is a rapidly 
developing scientific discipline with the potential for 
monitoring real-time and objective population level trends 
in illicit drug use and for assessing the efficacy of drug 
control interventions. 
By sampling a source of wastewater (e.g. a sewage influent 
to a wastewater treatment plant), scientists can estimate the 
total of drugs consumed by a community by measuring the 
levels of illicit drug metabolites excreted in urine. 
In March 2011, this approach was simultaneously applied 
for the first time in 19 European cities making it possible to 
directly compare illicit drug loads in Europe over a 
one-week period. This European pilot study covered a 
combined population of approximately 15 million 
Europeans (Thomas et al., 2012).
Data showed distinct spatial and temporal patterns in 
cocaine use across Europe. The results varied widely 
between countries and cities, with the highest levels found 
in cities in Western and Central Europe (up to 1998 mg per 
day per 1 000 inhabitants). The lowest estimates were for 
cities in Northern and Eastern Europe (between 2 and 
146 mg per day per 1 000 inhabitants). Within the same 
country, cocaine use is higher in more urbanised towns/
cities. In general, cocaine loads were more elevated during 
the weekend compared with weekdays, reflecting the 
recreational use of the drug. By extrapolation, it was 
estimated that 365 kg of cocaine was used everyday in 
Europe during the study period.
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Trends in cocaine trafficking in Europe
Based on seizure data, cocaine would appear to be the 
third most intensively trafficked drug in Europe, after 
cannabis resin and cannabis herb, particularly in a few 
countries in the western part of the region.
The total number of interceptions of cocaine in Europe has 
been on the increase since the mid-1990s, with the upward 
trend becoming even steeper from 2004 to 2007. 
Numbers stabilised at just under 100 000 between 2007 
and 2009, and have declined since then (Figure 8). The 
total quantity of cocaine recovered also increased from 
1995, but after peaking in 2006 at 120 tonnes, reflecting 
exceptional seizures in both Spain and Portugal, 
decreased sharply, stabilising at around half this amount 
between 2008 and 2011.
The 2006 peak and the subsequent falls in cocaine 
amounts intercepted in Europe, and in particular in the 
Iberian Peninsula, should be interpreted with caution as 
they are influenced by a range of factors, including 
from Denmark report high proportions of first-time clients 
citing cocaine as their primary drug. Spain, with its long 
experience of the drug, reported that half of new clients 
cited cocaine as their primary drug in 2009, and in Italy in 
2010 the proportion was one-third. Furthermore, all 
countries except Italy showed an increase in this proportion 
in the first years of the decade up to around 2008, followed 
by a recent decline, consistent with a levelling off or decline 
in the market.
Amongst the other countries, the Netherlands reports a 
relatively high proportion of new clients (one-fifth) citing 
cocaine as their primary drug—but this represents a fall 
from around 40 % in the first few years of the century. In 
France, the proportion of new clients using cocaine as their 
primary drug is still low, at around 6 %, and remained 
stable between 2008 and 2010, despite growing 
prevalence amongst young adult recent users. In the smaller 
countries, the proportion of new clients reporting cocaine as 
their primary drug is more volatile; it is notable that in 
Portugal it reached 14 % in 2010.
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Figure 8:  Seizures of cocaine in Europe, 2001–2011
Note:  All 30 European countries are included, except the Netherlands and Poland where Number of seizures data are not available. Quantities intercepted 
in the Netherlands in 2008 and 2009 were estimated from UNODC data.
Sources: EMCDDA/Reitox national focal points, EMCDDA (2012a), UNODC (2012d).
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eastwards, intended to supply both western EU markets 
and eastern markets outside the EU. Together with the 
reported decline in global cocaine production mentioned 
above, the data may indicate that cocaine availability in 
Europe has decreased. Yet, the fact that cocaine 
consumption has remained relatively high, while retail price 
trends continued to decline, would seem to point in the 
opposite direction.
changes in trafficking routes, traffickers’ practices and 
national law enforcement strategies, resources and 
priorities. In addition, some of the cocaine seized in 
Europe may in fact be destined for non-EU markets such as 
Russia and China, whose importation routes may have 
changed. A number of recent major seizures in the eastern 
part of Europe may suggest that cocaine trafficking, 
although still limited in the region, may be expanding 
to transit countries
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Figure 9:  Main trafficking flows of cocaine to Europe
Note:  Trafficking flows represented on the map are an attempt to synthesise the analysis of a variety of international and national organisations (EMCDDA, 
Europol, INCB, UNODC, WCO). Such analyses are based on information related to drug seizures along the trafficking routes, but also on other 
intelligence information from other sources, such as law enforcement agencies in transit and destination countries, and anecdotal reports. The main 
trafficking routes represented on the map should be considered as indicative rather than accurate descriptions of the main flows, based on the 
knowledge that there may often be deviations to other countries along the routes, and that there is a multitude of secondary subregional routes that 
are not represented on the map. Such ‘stopovers’ may change very rapidly depending on constraints (e.g. law enforcement control points) and 
facilitating factors (e.g. commercial routes, corruption).
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Cocaine is transported from South America to the EU across 
the Atlantic by air and maritime routes. Multi-tonne shipments 
travel by sea from Argentina, Brazil, Chile, Colombia, 
Ecuador, Mexico, Peru and Venezuela to Spain and Portugal, 
the large ports of the Netherlands and Belgium and to major 
container ports in Germany, France, Italy and the United 
Kingdom. Although maritime shipments pose the greatest 
problem because large quantities can be transported at any 
one time, and detection is difficult, individual couriers and air 
freight also play an important role.
There are three main sea routes to Europe: the northern route 
(passing through the Caribbean and the Azores to Portugal 
and Spain); the central route (from South America via Cape 
Verde or Madeira and the Canary Islands to Europe); and the 
African route (from South America to West Africa and from 
there mainly to Spain and Portugal), which has attracted 
international attention recently (see Figure 9).
Importation to Europe and distribution
Although it is clear that the vast majority of the cocaine 
trafficked into Europe initially lands in countries bordering 
the Atlantic, the situation in the Black Sea and the Balkans, 
and, to a lesser extent, in the Eastern Baltic Sea area, 
suggests a diversification of trafficking routes and landing 
points, reflecting an eastward expansion of cocaine 
trafficking in Europe. The proportion of the interceptions 
(35) Estonia, Latvia, Lithuania, Poland (only for quantities), Bulgaria, Hungary, Romania, Greece, Slovakia and Turkey.
(36) Based on UNODC data for 2009.
made in 10 countries located on the Eastern border of 
Europe (35), albeit still very limited, increased from 0.1 % in 
2001 to 1.8 % in 2011. This development needs to be 
closely monitored as trafficking in the region may eventually 
contribute to the diffusion of cocaine use into countries that 
are comparatively unaffected at present.
The west coast: a traditional cocaine 
entry point into Europe
Cocaine importation and distribution in Europe is mainly 
concentrated in West European countries. The Iberian 
Peninsula is considered the main entry point for cocaine into 
Europe. Spain is the main seizing country in Europe, 
accounting for 40–50 % of the quantities of cocaine 
intercepted over 2001–2010 and 27 % in 2011, and close 
to 50 % of the number of seizures. Portugal has also at times 
intercepted large amounts of cocaine, in particular in 2005 
and 2006, when it seized 18 and 34 tonnes respectively. 
Since 2008, however, this has fallen to 3–4 tonnes a year, 
totalling 10 tonnes over 2009–2011—compared with 
Spain’s figure of 67 tonnes over the same period. However, 
the size of cocaine seizures in Portugal has always been 
very large, usually the largest in Europe, with annual 
averages of multi-kilogram seizures in the last decade 
(2.2 kg in the years 2009–2011).
In comparison, seizures in Spain are of moderate size, on 
average about 0.5 kg per case in 2009–2011. While in 
Portugal law enforcement would seem to focus mainly on 
importation (and exportation) of the drug, Spanish 
authorities would appear to report interceptions at all levels 
of the supply chain, probably reflecting the fact that Spain is 
not only a major importation and transit area for other 
European markets but also has a rather large domestic 
market. However, the sharp decrease (by 34 %) in the 
quantities of cocaine intercepted in Spain in 2011 together 
with increases in amounts recovered in other major seizing 
countries (Belgium, France, Italy) that year may indicate a 
recent change in trafficking patterns and/or in law 
enforcement, both in Spain and elsewhere.
The other significant cocaine importation and distribution 
area in the region is centred on the Netherlands and 
Belgium. The Netherlands has long been the second largest 
seizing country in Europe, except in 2005 and 2006, when 
Portugal reported record quantities. An estimated 30 tonnes 
was recovered in the Netherlands in the period 2009–
2011 (36), while Belgium reported about 19 tonnes. The 
The West African route
The West African route, mainly passing through countries 
along the Gulf of Guinea and the Sahel and Sahara 
areas, has been used for some time as a transhipment, 
repackaging and storage region for cocaine from South 
America, especially Venezuela, destined, mainly, for the 
EU. The region started attracting international attention 
between 2004 and 2008, when many large seizures of 
cocaine were made both in the region and off its coasts. 
The countries that appeared most affected then were 
Guinea, Guinea-Bissau, the Gambia and Senegal, as well 
as Ghana, Togo, Benin and Nigeria. However, since 
2009 both the number of cocaine seizures and the 
quantities of cocaine seized in the region have fallen 
noticeably. This is more likely to reflect a change in 
trafficking methods and/or routes than an effective 
shrinking of cocaine flows towards the region (EMCDDA–
Europol, 2010; UNODC, 2011f).
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Black Sea. For instance, in June and July 2010, Ukrainian 
authorities seized a total of approximately 775 kg of 
cocaine in two operations in the port of Odessa from ships 
arriving from Chile and Venezuela (RILO, 2010).
Quantities intercepted in Romania, Bulgaria, Turkey and 
Greece are relatively small, totalling 4 tonnes over the 
three-year period 2009–2011, but exceptionally large 
seizures have been made at times in all these countries. 
Although the four countries still account for only a small (2 %) 
proportion of the total number of seizures reported in Europe, 
this proportion has tripled since 2001. Greece has for long 
been the country recovering the largest quantities seized in 
the region, while interceptions in Turkey have increased from 
just a few kilograms a year in the early 2000s to 600 kg in 
2011 (ahead of Greece at 500 kg). Compared with the other 
three countries, the size of the shipments intercepted in 
Bulgaria would seem to be much larger (multi-kilogram), 
pointing to the likely role of the country as a transit point for 
cocaine heading both west and east.
An increasing number of nationals of Balkan countries, 
including Bulgaria and Romania, have become involved in 
cocaine trafficking in recent years (e.g. as couriers). 
Additionally, Albania has been used as a storage country 
for cocaine, alongside its traditional role in the Balkan route 
for heroin trafficking and storage (Europol, 2007a). This may 
indicate that the trafficking infrastructure established in the 
region, especially for cigarettes, human beings and heroin, 
is now being used for the shipment of increasingly large 
amounts of cocaine. Trade liberalisation and the presence of 
pre-established transnational criminal networks are likely to 
be important explanations for the transit of cocaine through 
the Black Sea and the Balkans.
The Eastern Baltic Sea area: the next emerging 
cocaine entry point into Europe?
At present, indicators do not point to a strongly emerging 
cocaine problem in the former Communist countries around 
the Baltic Sea. However, recent trends indicate that the 
region may become of concern in the future. In April 2010, 
200 kg of cocaine was seized in the port of Riga, Latvia, 
from a ship bound for Novgorod, Russia (RILO, 2010), and 
in December 2010 80 kg was seized at Riga seaport from a 
container bound for Uzbekistan (WCO, 2011). Some 48 kg 
of cocaine was seized at Tallinn airport, Estonia, in early 
October 2010. Meanwhile, a consignment of almost 400 kg 
of cocaine shipped from South Africa was seized at the port 
of Klaipeda, Lithuania, in 2010 (Lithuania: Reitox, 2011). 
These occasional seizures do not form a pattern, but they do 
show that the Baltic Sea is already used by some cocaine 
traffickers. The occurrence of these large seizures in recent 
traditionally large average size of seizures in Belgium 
(1.8 kg over 2009–2011) appears to confirm the role of the 
country as a major entry point for cocaine imported to 
Europe (similar data for the Netherlands are not available). 
Belgium and the Netherlands, where retail prices in 2011 
were amongst the lowest in Europe and purity of the drug 
amongst the highest, could be the countries where 
availability of cocaine is at its highest level in the region.
France and Italy are also important countries for trafficking 
of cocaine and may serve as direct entry points into Europe, 
although cocaine found in France is often smuggled in via 
Spain. Both countries have large domestic markets to supply, 
but they are also used as transit for cocaine shipments 
intended for further distribution to other (mostly western) 
markets. France intercepts the third largest quantities of 
cocaine in Europe, just after the Netherlands, with 20 tonnes 
recovered over the period 2009–2011, while Italy comes 
fifth (after Belgium) with 14 tonnes.
The shipments intercepted in France are also comparatively 
very large, between 1 and 3 kg on average in the last 
decade, confirming the role of the country as a transit area 
for further distribution, beyond the direct supply of its 
domestic market. The United Kingdom is probably the 
largest European market for cocaine, ahead of Spain. In 
2009, the UK’s Serious Organised Crime Agency (SOCA) 
estimated that 25–30 tonnes of cocaine was imported into 
the country annually (HMG, 2010). Interceptions are, 
however, relatively limited, totalling 8 tonnes over the period 
2008–2010. Most of them are likely to result from activity 
taking place in the lower parts of the supply chain; the 
average size of seizures has decreased in the last decade 
and remained at 110–130 g over the period 2008–2010.
Europol information indicates that cocaine is increasingly 
reaching Europe by maritime container shipments, although 
this modus operandi has been in use for some years (Zaitch, 
2005). Since 2007, cocaine seizures in containers have 
increased, especially in Spain, Germany, the United 
Kingdom and Belgium. At the same time, the amount found 
on board vessels (not in containers) has decreased, 
following the general downwards trend in Europe related to 
cocaine seizures.
The Black Sea/Balkan area: a new cocaine entry point 
into Europe
While the majority of shipments of cocaine from South 
America continue to be directed to Western Europe (see 
Figure 9), substantial seizures of cocaine, often concealed in 
containers, have occurred in recent years in important 
Bulgarian, Greek, Romanian and Ukrainian ports on the 
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At the same time European OCGs, including Western 
Balkan and Italian groups, have increased their presence 
in South America and Africa. Africa, in particular West 
Africa, plays an increasing role in supplying European 
cocaine markets. Groups from Colombia, as well as 
Argentina, Bolivia, Brazil, Peru and Venezuela, have been 
involved in cocaine trafficking towards West Africa. These 
groups have established air and sea supply routes and 
storage facilities. Porous and poorly controlled borders 
between states, weak governmental control and high levels 
of corruption facilitate their activities. Intelligence suggests 
that cocaine is now increasingly imported via East and 
Southern Africa as well.
West African networks are prominent organisers of cocaine 
trafficking by air couriers. Moroccan groups are involved in 
trafficking cocaine to Europe, using the North African route 
for cannabis resin. Moroccan traffickers already have an 
important role in cannabis and cocaine redistribution in 
Europe, in key locations such as Spain and the Netherlands.
Despite the liberalisation of the cocaine market, 
Colombians continue to play a key role in the supply of 
cocaine for the European market. They have settled in EU 
Member States to organise and facilitate their operations, 
and cooperate with most European groups such as Italian 
and Spanish criminal organisations. Nevertheless, 
intelligence suggests that European OCGs also arrange 
cocaine deals with the Mexican cartels, which are taking a 
more significant role in the supply chain between 
producing countries and destination markets. The extent of 
their impact on the European organised crime situation is 
difficult to assess at the moment and needs a close 
follow-up of the situation. However, the greater profit 
margins may act as drivers for their increased presence as 
suppliers for the European markets.
A common method by which to import large quantities of 
cocaine is through associations between interested groups. 
Cocaine trafficking is characterised, perhaps more than 
other types of drug trafficking, by the sharing of loads, risks 
and costs. Recent cases have provided proof of cooperation 
between Colombian, Western Balkan, Bulgarian, Slovenian, 
Italian and Swedish organised criminals, built around 
individuals with a history of trafficking cocaine.
Recent investigations confirm that OCGs from the Western 
Balkans, particularly those composed of Serbians, 
Montenegrins or Croatians, have achieved a more important 
position in the cocaine trade. They have established their 
own contacts in source countries and manage their own 
trafficking networks. Intelligence suggests that some of these 
have invested in the legal economy in Western Balkan and 
EU countries. With the cover of legal commercial routes, 
years has led to a substantial increase in the amounts 
intercepted in the three countries: over 800 kg in 2010, 
falling to 90 kg in 2011, compared with just a few kilograms 
in previous years (between 1 and 50 kg intercepted 
annually between 2001 and 2009).
Another development is what appears to be an increasing 
trend in the use of nationals from countries on the Eastern 
Baltic Sea as cocaine couriers, either locally or elsewhere in 
Europe and in Latin America. The Lithuanian Reitox national 
focal point reported in 2009 that 46 Lithuanian nationals 
had been arrested in separate cases in Central and South 
American countries and in European countries for 
possessing or attempting to smuggle amounts of cocaine 
ranging between 0.6 and 28 kg. In total, the cocaine seized 
from Lithuanian nationals abroad amounted to 99 kg in 
2009 and to almost 665 kg in 2010 (Lithuania: Reitox, 
2009, 2010). In 2010, both Polish and Estonian Reitox 
national focal points reported that their nationals were 
frequently used as couriers to smuggle amounts of cocaine 
of about 2–3 kg (Poland, Estonia: Reitox, 2010). Finally, 
Latvia has expressed concern about the increasing number 
of Latvian nationals arrested and sentenced on cocaine 
smuggling charges in Europe and the Americas.
In the Baltic Sea area, criminal networks presently involved 
in the trafficking of synthetic drugs such as amphetamines 
and synthetic opioids (e.g. fentanyl)—mostly to the consumer 
markets of Sweden, Norway and Finland—could find it both 
convenient and feasible to diversify into larger-scale cocaine 
trafficking in the future.
Trends in organised crime involvement 
with cocaine in Europe
The large-scale importation of cocaine to the EU has been 
largely organised by non-EU criminals. Nevertheless, 
developments in recent years have created new 
opportunities for EU-based OCGs. Some of the most 
complex organised crime networks are involved in cocaine 
trafficking.
Current information suggests an increased liberalisation of 
the cocaine market, with a greater number of OCGs being 
able to import cocaine in Europe. Colombian organised 
crime has become more fragmented, with a greater number 
of groups interested in new partnerships. Groups active in 
Bolivia and Peru have an interest in accessing a bigger 
share of the European market. Some have moved their 
operations to other Latin American countries, such as 
Argentina, Chile or Uruguay. Some Central American and 
Caribbean countries have also become refuge and 
redistribution points.
48
EU drug markets report: a strategic analysis
Running or infiltrating legal businesses to facilitate drug 
trafficking and money laundering is a common denominator 
for most OCGs. Organised criminal groups own or have 
control over companies involved in transport, fishing and the 
import/export of fruits, vegetables and other commodities. 
For example, the trade in exotic fruits offers a very good 
cover to export cocaine from South America to Europe, due 
to the large volumes transported and the perishable nature 
of the goods.
Available information indicates that organised crime 
increasingly uses containers to transport not only cocaine 
but also heroin, cannabis and synthetic drug precursors. 
One of the preferred methods of shipping cocaine in 
containers, the so-called ‘rip-on rip-off’ method, involves 
corruption of port employees and influence at both 
departure and arrival ports and a high level of organisation 
and coordination. The container seal is illegally removed 
and replaced with a counterfeit at departure, after the drugs 
have been placed inside. A similar procedure is followed at 
the destination.
Responses to cocaine trafficking at 
European and international level
European policy initiatives
The EU has set out its strategies for responding to problems 
such as the trafficking of cocaine in:
they have become desirable partners for Latin American 
OCGs.
In addition, some Bulgarian OCGs appear to be involved in 
large-scale importation of cocaine, in association with 
Spanish, Italian and Colombian OCGs.
Outlaw motorcycle gangs (OMCGs) are poly-criminal and 
poly-drug trafficking groups, largely dealing with the import 
and distribution of drugs in the Nordic countries. They have 
the benefit of an extended transnational network with 
chapters in strategic locations for drug trafficking. They are 
active in the trafficking of cocaine from South-West Europe 
and the Balkans, and of synthetic drugs from North-West 
Europe. They also have links with Moroccan groups for the 
supply of cannabis resin.
Intelligence indicates that Russian-speaking residents in Latin 
America are facilitating and organising the trafficking of 
cocaine to the EU and Russia. EU citizens are recruited as 
couriers by Russian criminal groups. Georgian groups are 
also involved in importing cocaine from South America to 
Russia and the Caucasus.
North-Western Europe continues to be used as the main 
redistribution hub for large consignments of cocaine. 
Investigations show that in some cases cocaine entering 
South-West Europe is transported first to locations in 
North-West Europe. This could mean that groups active in 
the latter area have developed efficient redistribution 
networks, using the region’s extensive transport infrastructure 
to their advantage.
A case study in judicial and law enforcement 
cooperation
In March 2012, a highly organised drug trafficking network 
was brought to trial in Sweden. Eight members of the group are 
currently facing criminal charges for trafficking multi-tonne 
shipments of high-quality cocaine from South America to 
Europe. Further prosecutions for money laundering are 
expected in Spain.
This was the result of more than three years of close 
collaboration between law enforcement and judicial officials in 
Sweden, Spain and France, with support from Eurojust and 
Europol and the assistance of 12 other countries. A joint 
investigation team (JIT) was set up, partly funded by the JIT 
Funding Project. The JIT legal framework enabled a prompt 
exchange of information to take place without lengthy rogatory 
procedures.
The JIT had its first success in 2010. The French authorities 
seized 1.4 tonnes of cocaine on a 15-metre yacht in the 
Caribbean bound for Europe. They arrested the only person on 
board, a 56-year-old Swede. Further investigations identified 
accomplices who were linked to a network of companies 
created to facilitate money laundering and property 
acquisitions.
More than 30 people were arrested worldwide. The leader of 
the network, a 39-year-old Swede with a long and serious 
criminal record, was arrested near Bogota, Colombia, and 
deported to Sweden. Five other suspects were arrested in 
Sweden and Spain. The Spanish authorities froze several bank 
accounts as part of the investigations into money laundering, 
and around EUR 6 million was seized in five different countries.
Europol provided operational analysis and helped identify 
key players in Colombia, the United States, France, Spain 
and Sweden. Additionally, they provided expertise and 
investigative support in asset recovery. Eurojust facilitated the 
exchange of information and coordination of investigations, 
hosting 13 coordination/JIT meetings, and provided expertise 
in relation to the yacht interception.
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initiatives, in line with Action 53 of the EU Drugs Action Plan 
(2009–2012).
In addressing coca production in the Andean region and 
accepting its shared responsibility in the area, the EU 
developed the Andean Community High-Level Specialised 
Dialogue on Drugs (EU-CAN) (EC, 2007). This unique 
sub-regional cooperation forum was instituted in 1995, and 
senior officials meet annually. In addition, the EU has signed 
bilateral agreements on precursor chemicals with Bolivia, 
Colombia, Chile, Ecuador, Mexico, Venezuela and Peru 
(Council of the European Union, 2012).
In April 2007, the EC signed the regional strategy for 
cooperation with the Andean Community (CAN), allocating 
EUR 50 million for the period 2007–2013 (EC, 2007). One of 
the three priority areas for cooperation was to support CAN 
Member States in the fight against drugs. For example, 
PRADI-CAN (Progama Antidrogas Ilícitas en la Comunidad 
Andina) established a network of national observatories on 
drug trafficking and supports the control of chemical 
precursors in the CAN countries. The EU is contributing 80 % 
of the programme’s total budget of about EUR 4 million.
Using the European Development Fund, the EC funds a 
number of bilateral projects in West Africa that address 
organised crime and drug trafficking. These include a 
regional three-year project, Law Enforcement and 
Intelligence Cooperation Against Cocaine Trafficking from 
Latin America to West Africa (CO-LA-CAO), and a 
EUR 16 million programme to support the Economic 
Community of West African States’ (ECOWAS) action plan 
to combat drugs (EC, 2010a).
There is significant work under the auspices of COSI and the 
European pact to combat international drug trafficking, 
discussed in Chapter 1. This includes support for regional 
information exchange centres in West Africa, linking them in 
with other structures including MAOC-N and CeCLAD-M 
(see below).
Although a range of policies and measures are in place to 
coordinate action by the EU and its Member States against 
the production and trafficking of cocaine internationally, 
differences exist in national responses to the problem. This 
variation is visible in the threshold quantities and associated 
sentencing ranges applied in different Member States. An 
illustration of this situation is shown in a sample of countries 
in Figure 10 (see also Chapter 2).
• the Internal Security Strategy of the EU;
• the EU Drugs Strategy (2005–2012); and
• the EU Drugs Action Plan (2009–2012).
Action 46 of the EU Drugs Action Plan is about improving 
cooperation between the EU and its international partners. 
The mechanism for cooperation and coordination with Latin 
American and Caribbean countries (EU–LAC) is a central 
initiative in this respect. Launched in 1995 to address 
cocaine production and trafficking from Latin America and 
the Caribbean into Europe, EU–LAC is a forum for inter-
regional cooperation on drug-related problems.
A significant development was a G8 (36) conference in 2011 
on transatlantic cocaine routes, organised at the initiative of 
France, then assuming the presidency of the G8. This led to 
a political declaration and an action plan setting up 
measures to improve intelligence sharing; facilitate maritime 
interception; improve legal tools and law enforcement 
expertise and capacity; and raise additional finance for 
tackling trafficking (G20–G8 France, 2011a,b).
The Cooperation Programme on Drug Policies between Latin 
America and the European Union (COPOLAD) was 
launched by the EC in 2009. It complements the EU-LAC 
mechanism and implements Action 47 of the EU Drugs 
Action Plan 2009–2012, which aims to address drug-related 
concerns in source and transit countries. COPOLAD focuses 
on strengthening the coherence, balance and impact of drug 
policies in participant countries through information 
exchange and bi-regional cooperation (Council of the 
European Union, 2012). The EC provided EUR 6 million in 
funding in 2010 (EC, 2010a).
Along with the UNODC, the EC implements and co-finances 
the PRELAC (37) project. Started in 2009 with funding from 
the Instrument for Stability, the project targets the diversion 
of chemical precursors used to manufacture illicit drugs. The 
project involves developing a web-based information system 
to facilitate information exchange, standardising 
mechanisms for precursor control and improving inspection 
and investigation techniques. The EU contributed 
EUR 3 million to the project in 2012 (Council of the 
European Union, 2012).
The EU is a major donor to projects to prevent drug 
production and trafficking in Latin America. By the end of 
2009, European funding for projects in the region totalled 
EUR 360 million, focusing on alternative development 
(36)  The G8 or ‘group of eight’ is an annual forum, established in 1975 on the initiative of France, for eight of the world’s largest economies: http://www.
g20-g8.com/g8-g20/g8/english/photos-et-videos/photos/may/meeting-on-the-fight-against-transatlantic-cocaine.1118.html
(37) PRELAC — Prevention of the diversion of drug precursors in the Latin American and Caribbean Region.
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agents. As part of the project, Europol works closely with 
Member States’ law enforcement agencies, providing 
on-the-spot support to investigations, assistance in the 
dismantling of cocaine laboratories and operational analysis.
Information systems focus on specific drugs and their 
production and transport form a central part of Europol’s 
work. In respect to cocaine, a number of tools have been 
built as part of Project Cola. These include the Europol 
Cocaine Logo System (ECLS), the Europol Specific Means of 
Concealment System (ESMC) and its alert system. The ECLS 
facilitates the gathering of information on modus operandi, 
photographic and basic forensic information on cocaine 
seizures and information on logos or markings on drugs and 
their packaging. This enables identification of matches 
between seizures with a view to promoting international law 
enforcement cooperation against criminal groups. Within the 
framework of the ECLS, the ESMC focuses on the 
concealment methods or packaging of cocaine. Relevant 
information regarding the specific means of concealment 
that have been reported by the Member States and third 
Operational initiatives
Europol provides support in the implementation of the 
strategic goals related to the EU priorities for the fight 
against organised crime of the EU policy cycle 2011–2013 
through the EU annual OAPs (see Chapter 1). The three key 
priorities related to cocaine trafficking are those concerned 
with West Africa, the Western Balkans and container 
shipments (A, B and E respectively).
Specific measures against cocaine trafficking in Europe 
undertaken by Europol also support the delivery of the EU 
Drugs Strategy (2005–2012), its action plans and the pact 
against cocaine trafficking. Project Cola and its dedicated 
focal point in the AWF on serious and organised crime play 
an important role in supporting Member States and putting 
Action 27 of the EU Drugs Action Plan (2009–2012) into 
place by developing intelligence and investigation capacity 
(EC, 2010a). It does this by collecting intelligence associated 
with the activities of organised crime networks involved in the 
production, processing or trafficking of cocaine, including 
intelligence relating to essential chemicals and cutting 
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Figure 10:  Prescribed penalty ranges for supplying cocaine in some European countries
Note:  This graph is based on estimates, with some penalty ranges calculated using an assumed purity or street price. In some cases, the quantities chosen 
span two different penalty ranges in a country. The penalty ranges do not take into account all aggravating or mitigating circumstances or judicial 
discretion, and they are nominal sentences. They are those to be awarded by the judge according to the legal framework, regardless of the actual 
sentences awarded and executed. In Ireland, the prescribed penalty range extends to life imprisonment.
Sources: EMCDDA/Legal Correspondents Network.
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de Coordination pour la Lutte Anti Drogue en Méditerranée 
(CeCLAD-M).
International initiatives
The UNODC, with support from Interpol, the WCO and the 
EC, undertakes targeted initiatives against the methods and 
routes used to traffic cocaine. One such joint initiative is 
AIRCOP (see Chapter 1), of which Operation COCAIR 
involved 25 international airports located in 22 countries, 
covering different parts of key cocaine routes in Western 
and Central Africa, Latin America, the Caribbean and South 
Africa. The EU contribution to the operation, which is set to 
run between 2010 and 2014, is EUR 4.8 million (EC, 
2011b). The operation aims to put in place joint airport 
interdiction task forces (JAITFs), that are connected to 
Interpol’s I-24/7 and the WCO’s CENcomm information 
systems (UNODC, 2011f).
parties is collated and stored in a database. When new 
information concerning means of cocaine concealment is 
received, the information is immediately forwarded to all 
Member States and other partners via an alert message 
through the Europol Information Exchange.
An important measure against cocaine trafficking through 
West Africa was taken in September 2007 when seven EU 
Member States (38) signed a formal treaty to set up the 
MAOC-N. This regional initiative is supported by funding 
from the EC, and its objectives include coordinating air and 
sea interdiction efforts in the Atlantic region. During its first 
two years of existence, MAOC-N, on behalf of its partners, 
coordinated the seizure or led to the jettisoning of a total of 
about 45 tonnes of cocaine. In September 2008, France 
launched another anti-drug coordination centre targeting 
maritime drug trafficking in the Mediterranean to combat 
cannabis resin (hashish) and cocaine trafficking—the Centre 
(38)  The co-founders of this project are Ireland, Spain, France, Italy, the Netherlands, Portugal and the United Kingdom, but it is open to other Member States.
For conclusions and recommendations relating to the cocaine market, please refer to pages 134–136 in Chapter 10.
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Introduction
Cannabis is a natural product, the main psychoactive 
constituent of which is tetrahydrocannabinol (Δ9-THC). It can 
be cultivated outdoors in most parts of the world and 
anywhere indoors given access to water and electricity, 
making it the most widely produced illicit drug in the world. 
The illicit cultivation of cannabis usually produces two 
distinct cannabis products: herbal cannabis (‘marijuana’) 
and cannabis resin (‘hashish’). Herbal cannabis is produced 
by drying the flowering tops of the plants, and resin is the 
product of processed plant secretions that are compressed 
into blocks. Globally, it appears that herbal cannabis tends 
be produced for sale on domestic markets and in 
neighbouring regions rather than for export outside the 
region. As a result of this, herbal cannabis is less likely to be 
intercepted by authorities in relation to trafficking. In 
contrast, it seems that cannabis resin is produced largely for 
export (UNODC, 2006a, 2011g, 2012a).
Improved cultivation methods, including indoor techniques 
and selective plant breeding, have resulted in cannabis 
plants that are more potent, faster growing and higher 
yielding than before. These factors are likely to have 
played a role in increased levels of domestic production in 
Europe, and may have contributed to a shift in the 
consumer market.
According to a recent analysis, in two-thirds of European 
countries cannabis consumption is now dominated by herbal 
products, which constitute 90 % or more of the overall 
cannabis markets of Bulgaria, Czech Republic, Greece, 
Lithuania, Luxembourg, Hungary, Poland, Slovenia, Slovakia 
and Croatia. User demand and preferences in some 
previously resin-consuming countries in Western Europe now 
appear to be centred on the herbal unfertilised female 
flower buds (sinsemilla), which are often higher in THC 
(EMCDDA, 2012b).
Global overview
Cannabis is not only the world’s most consumed illicit drug, 
but is also produced on a global scale. Increasingly 
countries are producing cannabis for their own domestic 
market. For instance, the UNODC (2008a) has estimated 
that, between 2002 and 2006, herbal cannabis was 
produced in 122 countries and cannabis resin in 65 
countries. Because illicit cannabis cultivation is 
widespread, and carried out in a range of indoor and 
outdoor settings, it is very difficult, if not impossible, to 
estimate how much cannabis is produced worldwide 
annually.
Europe continues to be one of the world’s largest consumer 
markets for cannabis resin, the majority of which is sourced 
from Morocco. The Middle East, North Africa and South-
West Asia also have large consumer markets for resin, and 
significant resin production occurs in these regions. Europe 
and North Africa are reported as having a mixed profile 
consumer market, using both herb and resin, with the rest 
of the world predominantly consuming herb (UNDOC, 
2012a).
The regions identified as major producers of cannabis resin 
are North Africa, the Near/Middle East and South-West 
Asia, with the main producer countries reported to be 
Afghanistan, Morocco, Lebanon, Nepal and India. 
Afghanistan appears to be emerging as a leading force in 
cannabis cultivation, with the UNODC suggesting that it has 
now overtaken Morocco in terms of resin production, 
although caution is required here (see below).
In 2010, West and Central Europe were the world’s largest 
cannabis resin-seizing regions (47 %). Despite interceptions 
dropping to under 400 tonnes, Spain continues to seize 
the largest amounts of resin in Europe and worldwide, 
accounting for 34 % of world seizures in 2010. The Near/
Middle East and South-West Asian regions account for 
35 % of world seizures. The largest quantities were 
intercepted in Pakistan (19 %) and Afghanistan (8 %). Since 
Afghanistan resin seizures dropped in 2008, seizures in 
neighbouring countries (in particular Pakistan) have 
increased. Pakistan has reported that the 212 tonnes of 
resin it seized in 2010 all originated from Afghanistan. 
North Africa accounted for 14 % of global resin seizures, 
mainly reflecting seizures in Morocco (10 %).
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Production issues
Outdoor cultivation
Successful outdoor cannabis cultivation depends upon 
natural daylight cycles, with the plant flowering only when 
the days begin to shorten. Outdoor cannabis crops may be 
planted as a single crop or hidden within other crops such 
as maize, with outdoor-growing crops usually producing one 
or two harvests per year. Factors such as cannabis strains 
After reaching a peak of 6 295 tonnes in 2003, worldwide 
herbal cannabis seizures declined sharply in 2004 to 4 092 
tonnes. This was followed by a steady increase to 6 251 
tonnes in 2010. North America appears to be the dominant 
herbal cannabis-seizing region, accounting for 69 % of 
global herb seizures, with Mexico (37 %) and the United 
States (31 %) seizing the largest quantities. The next region 
is South America, at 8 %, where Colombia seizes the largest 
quantities (UNODC, 2012a).
Table 3: Cannabis in Europe at a glance
Age group  
(years)
Estimated number 
of users (million)
% of European population 
(range between countries)
Consumption (1)
Lifetime
15–64 80.5 23.7 (1.6–32.5)
15–34 42.5 32.5 (3.0–49)
15–24 18 29.7 (3.0–52.2)
Last year
15–64 23 6.8 (0.3–14.3)
15–34 16 12.4 (0.6–20.7)
15–24 9.5 15.4 (0.9–23.9)
Last month
15–64 12 3.6 (0.1–7.6)
15–34 8.5 6.6 (0.2–14.1)
15–24 5 7.8 (0.5–17.2)
Number (% of all drug admissions)
Drug treatment (2) (2010)
All admissions 107 697 (25 %)
First admissions 58 833 (38 %)
Number (% of all drug offences)
Drug law offences (2011)
All offences 940 757 (73 %)
Offences for drug use/possession for use 790 276 (78 %)
Offences for drug supply 111 706 (56 %)
Cannabis resin Herbal cannabis
Seizures (3) (2011)
Quantities (tonnes) EU (including Croatia, Norway and Turkey) 490 (514) 90 (146)
Number EU (including Croatia, Norway and Turkey) 348 000 (370 000) 389 000 (439 000)
Mean retail price (2011) (EUR per gram) Range (IQR) (4) 3–18 (7.0–12.8) 5–24 (7.8–11.5)
Mean potency (2011) (%) Range (IQR) (4) 4–16 (5.3– 10.5) 1–16 (5.6–9.9)
Notes
(1)  European estimates are computed from national estimates weighted by the population of the relevant age group in each country. They are based 
on surveys conducted between 2004 and 2010/11 (mainly 2007–2010) and therefore do not refer to a single year.
(2)  Information is available on about 470 000 drug users entering specialist treatment in Europe (EU, Norway, Croatia, Turkey). Units coverage may 
vary between countries.
(3)  The 2011 figures should be considered as estimates; where 2011 data were not available (United Kingdom), 2010 data were used in their place. 
An additional 4.6 million cannabis plants and 33 tonnes of cannabis plants were seized (37 000 seizures in total) in Europe, including Croatia 
and Turkey, in 2011.
(4) IQR: interquartile range, or range of the middle half of the reported data.
Sources: EMCDDA/Reitox national focal points, EMCDDA (2012a).
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reduce the smell of used soil, reducing the risk of detection. 
Despite a general perception to the contrary, this method 
does not appear to be commonly used, because of the high 
set-up costs and the high level of expertise required 
(UNODC, 2006a, 2010b; Bouchard, 2007; Leggett and 
Pietschmann, 2008).
Harvesting to create a marketable product
Cannabis is harvested by cutting the plant at the base and 
then drying it in low-humidity conditions either by hanging 
or placing it upon drying shelves, which in general takes 
approximately two weeks (UNODC, 2006a). To prepare 
herbal cannabis, once the plant is dry the flowers are 
‘manicured’ (either manually or with a machine) to remove 
the leaves and stems, leaving the ‘bud’, which is the material 
usually sold on the market (see Figure 11).
and cultivation methods used, plant density, water supply 
(irrigated or rain-fed crops), soil acidity or alkalinity and 
climate have all been noted to affect the yield of outdoor 
crops (Clarke, 1998; UNODC, 2006a).
A recent EMCDDA analysis revealed that in 8 out of 29 
reporting countries (Bulgaria, Denmark, Estonia, Greece, 
Italy, Portugal, Croatia and Slovenia), cannabis was mainly 
cultivated outdoors (EMCDDA, 2012b).
Indoor cultivation
Indoor cultivation takes many forms, ranging from small-
scale home growing to professional operations run by 
criminal networks in industrial warehouses. The control that 
can be exercised over growing conditions (e.g. light, heat, 
density of plants, pest control) allows for continuous 
cultivation throughout the year and can result in four to six 
full harvests per year. Recent research into indoor cultivation 
in Belgium has suggested that both plant density and light 
density are important factors when determining yield in 
indoor set-ups, but that the crucial factor is the strain of 
cannabis (Vanhove et al., 2012a).
The benefits of indoor cultivation include lower risks of 
detection, control over conditions that permits high yields, 
and the ability to manipulate strains to produce high 
potency. Indoor growing was identified as the preferred 
method of production in at least 16 of 29 countries reporting 
data to the EMCDDA (2012b). Hydroponic cultivation 
(growing plants in nutrient-rich water instead of soil) can 
Grow shops
One potential indicator of the spread in domestic 
production in Europe, in particular indoor production, is the 
apparent rise in the number of ‘grow shops’ during the last 
decade. A grow shop is a horticulture shop selling products 
specifically—although not always explicitly, given legal 
considerations—for the cultivation of cannabis plants, and 
in 2009, 15 European countries reported the existence of 
such shops. Grow shops have increased in popularity since 
the 1990s both in North America and in Europe.
Some grow shops sell not only cultivation equipment but 
information, literature and smoking paraphernalia, 
suggesting that they can be regarded as ‘centres of 
learning’ about domestic cultivation (Jansen, 2002). In a 
few countries (Belgium, France, the Netherlands) it has also 
been suggested that some grow shop operators sell seeds, 
buy their customers’ harvests and dispose of their waste 
products (EMCDDA, 2012b).
Sinsemilla and cannabidiol (CBD)
Cannabis content in cannabinoids, including THC, varies 
widely depending on factors such as genetic strain, 
growing environments, cultivation techniques, processing 
methods, packaging, transportation, storage and freshness. 
Over time, the search to produce plants with an increased 
psychoactive effect has resulted in a preference amongst 
some growers and consumers for sinsemilla (unfertilised 
female plants). Selective breeding, which mainly focuses on 
achieving a high THC content, has also resulted in the 
selection of strains containing less of another cannabinoid: 
cannabidiol (CBD).
Research in the United Kingdom found that both high-THC 
sinsemilla (13–16 %) and other herbal cannabis containing 
less THC (3–8 %) contained very low concentrations of 
CBD (under 0.1 %), whereas resin, with a moderate THC 
content (4–6 %), presented much higher levels of CBD 
(around 4 %). Analysis of cannabis preparations sold in the 
Netherlands in 2011 confirmed these results, although 
imported resin contained more THC (14 %) and also more 
CBD (7 %) (Hardwick and King, 2008; Potter et al., 2008; 
Rigter and Niesink, 2011).
CBD is known for its antipsychotic properties (Zuardi et 
al., 2006). Therefore, any variation in the relative 
proportions of THC and CBD in illicit cannabis has 
possible implications for the overall negative health 
consequences associated with consumption of the drug. 
Given current concerns on the possible association 
between some forms of mental illness and cannabis use, 
the potential spread of high-potency sinsemilla should be 
carefully monitored.
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Although Europe is one of the world’s largest consumer 
markets for cannabis resin, it relies very largely upon 
production sources outside the region, predominantly 
Morocco, although Afghanistan may be re-emerging as a 
producer for European resin markets.
A quick glance at global cannabis resin production 
estimates would suggest that Afghanistan has now become 
a much larger producer than Morocco, but important 
caveats emerge upon closer examination. Moroccan 
cannabis resin production is estimated to have dropped by 
about 75 % since 2003 to reach 760 tonnes in 2010, while 
resin production in Afghanistan was estimated at between 
1 200 and 3 700 tonnes that year. However, two issues 
affect comparisons of the production estimates for the two 
countries. First, the cannabis resins produced in Morocco 
and Afghanistan are reported to be ‘different products’ 
(UNODC, 2010b), with Afghan resin appearing to be less 
potent. Therefore, comparisons based purely on weight may 
be misleading. Second, and more importantly, analysis of 
seizures in countries located along Moroccan resin 
trafficking routes indicates that the size of Moroccan 
production is underestimated. Indeed, combined resin 
seizures in Algeria, Morocco and Spain totalled about 525 
tonnes in 2010, which would mean that only about 235 
tonnes of Moroccan resin actually reached European (and 
global) consumers. Meanwhile, the EMCDDA has estimated 
that some 1 300 tonnes of cannabis resin is consumed in 
Europe every year (see below), and 22 European countries 
indicate Morocco as a source of cannabis resin (UNODC, 
2003a, 2012a; EMCDDA, 2012b).
In producing cannabis resin, two main methods can be 
used: hand-rubbing and sieving. These are used to dislodge 
glandular trichomes, resulting in a fine powder that is high 
in THC. Sieving is reported to produce much more resin than 
hand-rubbing, although in both cases several ‘grades’ of 
resin may be produced (39). However, even resins produced 
by the same methods can appear to be substantially 
different products, as is the case for resins produced by 
sieving in Morocco and Afghanistan (Clarke, 1998; 
UNODC, 2006a, 2010b).
Producing for European markets
A recent EMCDDA analysis identified five world regions 
(and dominant countries) as the main sources of the 
imported cannabis products available on European markets. 
Three of those regions, North Africa (Morocco), South-West 
Asia (Afghanistan) and the Middle East (Lebanon), supply 
cannabis resin, while the remaining two, the Balkan region 
(Albania) and sub-Saharan Africa (South Africa), primarily 
supply herb (EMCDDA, 2012b).
(39)  Some cannabis resin products are produced in Western countries by extraction methods based on chilled water or the use of electric tumbler/sieving 
machines.
Figure 11:  A dry cannabis inflorescence (a) before and (b) after 
manicuring
Note:  The separated sinsemilla floral material is the preferred material 
that is ready for use. The leaf and stem material may be discarded 
or processed further to make a resin with a very high THC content.
Source: Potter, EMCDDA (2012b, p. 37).
Recent changes in external supply of herbal 
cannabis to Hungary
In Hungary, domestic production is supplemented by large 
quantities of cannabis smuggled into the country by 
Vietnamese groups from plantations operated by 
Vietnamese producers located in Slovakia, the Czech 
Republic and Poland. The drug is transported across 
borders mainly by car or public transport. It has also 
become common for Vietnamese sellers in Hungary to send 
their Hungarian customers directly to Vietnamese suppliers 
in the Czech Republic, thus avoiding the risk of transporting 
the drug themselves. As a result, the amount of cannabis 
imported into Hungary from the Czech Republic today has 
reached or even surpassed the amount imported from the 
Netherlands (Hungary: Reitox, 2011).
a)
b)
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and nature of the phenomenon seem to vary considerably. Of 
the 29 countries, 25 reported outdoor cultivation, 26 reported 
indoor cultivation and 12 reported hydroponic cultivation. 
Indoor cultivation sites have been reported as emerging in 
Lithuania, Poland and Romania (UNODC, 2012a), while both 
the Czech Republic and Slovakia note an increase in 
industrial indoor cultivation (INCB, 2012b).
Seizures of whole cannabis plants are generally thought to 
be an indicator of domestic cannabis cultivation in the 
country where they occur. The number of seizures of 
cannabis plants in Europe has been increasing in the last 10 
years, peaking at an estimated 39 000 in 2010, followed 
by a slight decline, to 36 000, the following year. Countries 
report the quantity seized either as an estimate of the 
number of plants seized or by weight. The total number of 
plants seized in Europe remained stable at about 2.5 million 
annually in 2005–2009, and then increased to 3.1 million in 
2010 and to 4.6 million in 2011 (40). The Netherlands has 
been the main seizing country for years, intercepting nearly 
half of the 2011 total, followed by Italy with a record 
number of 1 million plants seized that year. Seizures 
reported by weight of plants trebled between 2005 and 
2008, before slightly decreasing to 35 and 33 tonnes in 
2010 and 2011 respectively. Spain continues to account for 
most of this amount with 26 tonnes intercepted in 2011, 
followed by Bulgaria with nearly 5 tonnes.
Overall, data on the number of cannabis plantations 
dismantled in Europe point to an increase in cannabis 
domestic production in most countries reporting data since 
2004. The Netherlands and the United Kingdom would 
seem to be the countries in Europe dismantling the largest 
number of plantations—several thousands a year. However, 
data are to be interpreted with caution as definitions and 
reporting practice vary considerably between countries.
Globally, it appears that herbal cannabis tends be produced 
for sale on domestic markets and in neighbouring countries 
rather than for export outside the producing region. Europe 
is no exception to this trend. Historically, the Netherlands 
has been an important source of herbal cannabis supply 
within Europe. It remains the most frequently identified 
source of imported cannabis products in Europe, especially 
in Western Europe, with the majority of countries reporting 
importation of some kind of cannabis product including 
seeds, resin and herb (EMCDDA, 2012b).
Major herbal cannabis-producing countries in the Balkan 
region supply the markets of Central, Eastern and South-
Eastern Europe: Albania, Serbia, Bulgaria and to some 
extent Kosovo. Europol (2011a) has noted that Albania has 
emerged as an important outdoor producer and exporter, 
usually via Greece, but it has also been noted that the 
product is distributed throughout Italy, Slovenia and 
Hungary (INCB, 2011). The Czech Republic has also been 
identified as a producer, with domestic product exported to 
Central and Western Europe. Some 80–90 % of the herbal 
cannabis produced in Latvia is exported, predominantly to 
Sweden and Estonia, and to a lesser extent to other 
Scandinavian countries and Lithuania (EMCDDA, 2012b).
Extent of production in Europe
Herbal cannabis production is widespread throughout Europe 
and appears to be increasing, with all 29 European countries 
that recently reported to the EMCDDA (2012b) recording 
some form of domestic cannabis cultivation, though the scale 
(40)  Data for the Netherlands for the years 2008 and 2009 were obtained from the UNODC (2012a). This analysis does not include seizures made in Turkey 
as these have not been reported since 2005; for information, 20 million cannabis plants were intercepted in 2004 in Turkey.
Figure 12:  Indoor cannabis production site dismantled in Alicante 
Province, Spain, November 2010
Source: Spanish Guardia Civil via Europol.
Concentrated production in the 
Amsterdam–Amstelland region
A study on the cannabis market in the Amsterdam–
Amstelland region of the Netherlands revealed that in 
2009, 310 cannabis plantations were dismantled in that 
region, with a total of nearly 100 000 plants seized. The 
mean size of the plantations was calculated to be over 300 
plants, indicating that commercial production is widespread 
within this region (Netherlands: Reitox, 2011).
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quarter (24 %) of 15- to 64-years olds in the EU are thought 
to have tried the drug at least once in their lifetime, some 80 
million individuals, and use within the last 12 months 
amongst young adults (15–34 years) is at about one in eight 
(12 %) or about 16 million individuals.
Cross-European estimates mask country variations, though 
countries with low prevalence tend to be the exception. The 
nine countries where lifetime prevalence rates among all 
adults are 20 % or above—which include some of the most 
populous countries in Europe (Germany, Spain, France, Italy 
and the United Kingdom)—account for almost 70 % of the 
European population. At the other end of the spectrum, only 
six countries report levels of less than 10 % and together 
account for less than 20 % of the European population, with 
Poland and Romania the most populous amongst these.
The dichotomy is even more pronounced when considering 
recent use amongst young adults, the age group most likely 
to be taking drugs. Fifteen countries, accounting for 73 % of 
the European population of young adults, report last year 
prevalence of around 10 % or higher (up to a maximum of 
21 %). Only five countries, making up approximately 16 % 
of the young adult population, report prevalence at around 
5 % or less.
The spread of cannabis consumption is often thought to have 
begun in the 1960s and 1970s, although comparisons 
across time for most countries are made difficult by the lack 
of comparable survey data before the 1990s. In some 
western countries, such as the United Kingdom and the 
Netherlands, growth started from low levels in the late 
1960s and early 1970s, and was followed by periods of 
stabilisation or decline, and then resurgence at the end of 
the century (Korf, 2002; Vicente et al., 2008). More 
recently, relatively high levels at the start of the century have 
given way to a further period of stabilisation or decline in 
many European countries. This pattern is not evident for all 
EU countries and in some, such as Bulgaria, Estonia and 
Italy, national studies show a steady increase in last year 
prevalence amongst young adults.
This picture of recent stabilisation or decline of use is further 
supported by data on young people, aged 15–16 years, 
available from the 2011 European School Survey Project on 
Alcohol and other Drugs (ESPAD). The survey has been 
carried out every four years since 1995. Findings reveal a 
discernible overall pattern of decline in the prevalence of 
cannabis use, or stabilisation, since 2003.
Although patterns of use fluctuate and the most recent data 
suggest hope for the future, the ‘big picture’ remains one of 
increases across Europe since the 1960s and 1970s. Other 
developments in cannabis consumption are also less 
Trends in domestic production of herbal cannabis
As cannabis cultivation techniques have advanced and 
indoor cultivation has spread, the intra-European import–
export market for cannabis has changed and a 
phenomenon of ‘import substitution’—whereby increases in 
domestic production have reduced demand for imported 
cannabis products—has been noted.
The following countries have experienced increases in 
domestic cultivation in the last five years: Austria, Belgium, 
the Czech Republic, Denmark, Finland, Germany, Hungary, 
Ireland, Poland, the Netherlands, Norway, Slovakia, 
Sweden and the United Kingdom (Potter, 2008; Reitox, 
2009; ACPO, 2012; UNODC, 2012a). Furthermore, Italy, 
France and Spain have reported recent increases in 
cannabis production.
Denmark, Germany, Sweden, the United Kingdom and 
Norway have reported increases in the number of houses or 
commercial properties in which large-scale cannabis 
production has taken place. Some commercial cannabis 
growers, in particular operators of indoor cultivation sites in 
Belgium, the Netherlands and the United Kingdom, 
increasingly tend to run multiple small-scale plantations (e.g. 
plantations of 250 plants maximum) rather than a single 
large site. This strategy allows them to better avoid detection 
(small cultivation sites are easier to hide and consume less 
electricity) and, if they are caught, the penalties incurred for 
running small sites are lower than for large ones. In 
addition, this approach reduces the financial loss incurred 
as a result of theft, fire or detection (Decorte, 2008; 
Belgium, Netherlands: Reitox, 2009).
Consumer markets for cannabis in Europe
Cannabis use, in one form or another, is evident in every 
country of the EU. In almost all countries prevalence levels 
dwarf those of the other major drug groups. Almost a 
Grower motivations
Cannabis growers can be divided into two broad 
categories: commercial and non-commercial. Whereas the 
first group is mainly driven by the prospect of financial 
gain, the second group is driven by several other factors, 
ranging from ideological reasons through the need to cater 
for personal or social supply, to ensuring the quality and 
integrity of the product and avoiding exposure to the 
criminal element of the market. Cannabis production 
amongst this group generally tends to be small in scale.
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Overall, cannabis is by far the most used and widespread 
illicit drug in Europe. Some positive signs of a levelling off 
or decline in use are evident in both national surveys and 
school surveys, but the level of use remains high. In many 
countries, cannabis is increasing in importance as the 
primary drug for which treatment is sought, and there is 
growing evidence of the potential for problem cannabis 
use. The market is now more diverse, with evidence of 
some herbal cannabis that is of greater potency than 
cannabis resin. These changes suggest a less benign 
image of the drug and a far more organised, commercial 
supply than the popular characterisation of cannabis in the 
1960s and 1970s.
Trends in cannabis trafficking in Europe
Seizures
Cannabis resin has long been the drug most seized in 
Europe, ahead of herb. After a steady increase in the 
encouraging. Treatment data reflect not only need but 
availability, specifically of cannabis treatment. Nevertheless, 
amongst clients entering treatment for the first time, the 
proportion citing cannabis as their primary drug grew in 
most countries between 2005 and 2010. During this period, 
cannabis never accounted for less than half of reported new 
treatments in Germany, France and Hungary. By 2010, 
cannabis treatment also exceeded half of new treatments in 
Cyprus, Denmark and the Netherlands.
Information on the frequency of cannabis use is becoming 
increasingly available from national surveys, and with it an 
idea of how important the drug has become for some 
individuals. It is estimated that 1 % of those aged 15–64 
years in the EU and Norway, or some 3.4 million 
individuals, smoke cannabis on a daily or near-daily basis 
(EMCDDA, 2012c). Attempts are being made to measure the 
potential for problems associated with cannabis use, 
particularly amongst the young, by introducing questions 
from the Cannabis Abuse Screening Test (CAST) into ESPAD 
and other surveys (Hibell et al., 2012).
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Figure 13:  Seizures of herbal cannabis in Europe, 2001–2011
Note:  All 30 European countries are included, except the Netherlands and Poland where Number of seizures data are not available. In the absence of 2011 
data for the United Kingdom, 2010 data were used in their place.
Sources: EMCDDA/Reitox national focal points, EMCDDA (2012a).
61
Chapter 4 | Cannabis
calculated average size of seizures by country, these indirect 
indicators (41) may point to varying trafficking patterns.
Trafficking cannabis resin
Moroccan cannabis resin is typically smuggled into Europe 
through the Iberian Peninsula, with the Netherlands and 
Belgium having a role as secondary distribution and storage 
centres and more limited trafficking elsewhere.
South-West gateway
Spain has long been the principal country for cannabis resin 
seizures in Europe (and the world); in 2011 it accounted for 
about 70 % of seizures in the region by both number and 
total quantity, despite the latter reaching its lowest level (356 
tonnes) since 1997. Spain and Portugal appear to be the 
number of seizures of both cannabis resin and herb over the 
last decade, resin seizures declined in 2010 and 2011 and, 
for the first time in 2010, were outnumbered by seizures of 
herbal cannabis. The amounts recovered have been 
fluctuating for both products, with an all-time peak of 1 080 
tonnes in 2004 for resin and another peak at 930 tonnes in 
2008; analysis of quantities of intercepted herb reveals two 
peaks at 140 tonnes, in 2001 and 2008, and a record high 
of 146 tonnes in 2011 (see Figure 13).
A discrepancy exists in respect to what cannabis products 
appear to be targeted by interdiction measures. 
Consumption of cannabis is dominated in two-thirds of 
Europe by herbal products and in the other one-third by 
resin (EMCDDA, 2012b). Moreover, tentative consumption 
estimates suggest that resin accounts for about half of the 
cannabis quantities consumed in the region (see box). 
However, resin seizures, despite declining in recent years, 
remain twice as high as those of herb (2011). This is 
explained in part by the difficulty of detecting domestic 
production, especially when occurring indoor. In addition, 
since the trafficking of domestically produced cannabis is 
usually intraregional, and on a relatively small scale, it 
requires little crossing of borders and is therefore at less 
risk of detection. This is evidenced in the tentative 
interception rates that may be derived from the total 
cannabis consumption estimates for the EU and Norway, at 
around 30 % for resin and below 10 % for herbal 
cannabis. It would seem that there is, in general, less 
pressure from law enforcement on the market for 
domestically grown herb than for resin. Yet prices of herbal 
preparations appear to be increasing while resin prices 
remain relatively stable. The development of new strains 
and cultivation techniques to increase the potency of the 
herbal material produced in Europe may have had an 
impact on the price paid at retail level, although data on 
potency are not conclusive at this stage.
The estimated market sizes of each cannabis product may 
be used to calculate interception rates at European level, as 
it may be safely assumed that all cannabis seized in Europe 
is destined for European markets. Similar analysis cannot be 
carried out at national level, however, as it cannot be 
assumed that cannabis seized in a country is destined for 
that country’s market, given levels of intraregional trafficking 
of cannabis. For this reason, this section presents analyses of 
the relative size of national seizures (total quantities 
intercepted) compared with the estimated size of the 
national market (total consumption). Combined with the 
(41)  To eliminate the effect of exceptional annual variations, both the average size of seizures and the proportion of domestic consumption that is intercepted 
are based on three-year averages calculated from 2009–2011 seizure data. Seizures of cannabis plants are not included in the indicators referring to 
herbal cannabis.
Annual consumption of herbal cannabis in the 
EU and Norway
Although imported cannabis resin has been partly replaced 
by domestically produced herbal material in some regions, it 
is estimated that resin is still being used by about half of the 
22.5 million cannabis users in the EU and Norway. This 
means that around 1 300 tonnes of cannabis resin and 
1 200 tonnes of herbal cannabis could be consumed 
annually (1). Cannabis resin consumption would seem to be 
concentrated in a few countries, with three-quarters of the 
estimated total quantity being consumed in only three 
countries—Italy (30 %), Spain (27 %) and France (20 %)—
followed at a distance by Germany (6 %) and the United 
Kingdom (5 %). Use of herbal cannabis seems to be more 
evenly spread across Europe, with the United Kingdom as the 
largest market (accounting for one-fifth of total consumption), 
followed by Germany (16 %), Italy (14 %), France (12 %) and 
Spain (1 %). The Czech Republic, the Netherlands and 
Poland each account for about 4–5 %. These are tentative 
estimates, and should be treated with caution.
(1)  Estimates of market sizes (national consumption) are arrived at 
using a demand-side approach based on estimated market 
shares of each product, data on prevalence of use and 
individual annual consumption estimates. The last, derived from 
Kilmer and Pacula (2009)—150 g for last month users and 
15 g for last year (but not last month) users—have a substantial 
impact on the end results. Further methodological details and a 
discussion of the caveats of the method can be found in 
EMCDDA (2012b).
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demand, indicating that transit may be limited and that most 
of what is imported could be destined for a domestic market 
estimated to be the largest in the EU (ahead of Spain).
North-West 
Belgium and the Netherlands have been identified as 
leading sources of resin trafficked throughout Europe. The 
quantity of resin seized in Belgium is about the same as 
estimated domestic consumption, suggesting that the country 
is used as a transit area, whereas in the Netherlands, which 
reported a substantial fall in herbal seizures in 2011, resin 
seized would amount to only 9 % of estimated domestic 
demand. Despite variations over time, interceptions are 
generally large in Belgium (over 1 kg on average) (similar 
data for the Netherlands are not available). The resin 
imported in the region may have two main destinations. 
Some may be used to supply domestic resin markets, 
although these are small compared with the markets for 
herbal cannabis. Larger quantities are probably re-exported 
to Germany, France, Italy, the United Kingdom and the 
Nordic countries, underlining the region’s key role as a 
secondary distribution and storage centre (Europol, 2011a).
Average seizure sizes greater than 1 kg suggest that Ireland 
is also an entry point for Moroccan resin into Europe. Resin 
seizures represent about 15 % of estimated national 
consumption; it is likely that some of the resin entering Ireland 
eventually ends up in the United Kingdom, where the market 
for resin, although smaller than the market for herb, is still 
rather large, estimated to be about seven times the size of the 
Irish market. Seizures in the United Kingdom are on average 
smaller than in Ireland (under 1 kg) and represent one-third of 
estimated national demand, which may indicate that the 
United Kingdom is targeting drugs at importation both from 
across the Atlantic and from continental Europe.
North/Nordic
Amounts of cannabis resin intercepted in Estonia are limited 
(under 100 kg seized a year), but the average size of the 
cases has been at times relatively large (over 1 kg), suggesting 
that the country may be a transit area for resin destined for 
Russia and the Nordic countries. Annual quantities intercepted 
in Denmark (around 2 tonnes) are larger than in other Nordic 
countries and individual seizures are also slightly larger on 
average (200–300 g) than in Finland, Sweden and Norway 
(100–200 g), pointing to the likely role of Denmark as a transit 
area to other Nordic countries.
main entry and dissemination points for Moroccan resin in 
Europe, with seized amounts estimated to be 15 % larger 
than the national market in Spain and nearly as large (80 %) 
as the national market in Portugal. On average, Spain 
intercepts around 2 kg per seizure and Portugal an even 
larger quantity, suggesting importation of large quantities of 
resin. Some of the resin entering the Iberian Peninsula is 
smuggled on to France, from where it is either distributed 
locally or transported further north and east to other markets.
Seizures in France, which are the second largest after those 
in Spain (56 tonnes in 2011), are estimated to represent 
about 20 % of domestic consumption, pointing to France’s 
dual role as a destination market and a transit area. Indeed, 
the comparatively small average size of seizures (0.5–
1 kg) (42) there suggests that France is not a major entry 
point for Moroccan resin but that trafficking at wholesale 
level is common.
Shipments seized in Italy are large, on average over 3 kg, 
suggesting that, like the Iberian Peninsula, the country could 
be used as an entry point for Moroccan resin. However, 
Italian seizures represent only 5 % of estimated local 
Using light planes to smuggle drugs across 
borders
Although use of light aircraft to smuggle drugs across 
borders is not new, it may have increased between the 
African coast and the Iberian Peninsula in recent years. The 
drug trafficked is primarily cannabis resin, which is flown 
from Morocco in batches of between 100 kg and 1.5 tonnes 
per flight. Most flights occur at night or at dawn; planes fly 
low and without lights so as to avoid detection. Crashes of 
light aircraft may be used as an indirect indicator of the 
phenomenon. Moroccan, Spanish and Portuguese authorities 
indicate that a total of about 30 light planes have crashed in 
the three countries since 2007. Crashes occur mostly 
because pilots take ill-considered risks when attempting to 
land on improvised strips, often flying old and poorly 
maintained planes. Moroccan authorities indicate that light 
planes have been used to export drugs for about 10 years. 
Most drug flights would depart from the northern Atlantic 
coast of Morocco. However, drug smuggling by small 
aircraft also occurs elsewhere. On 12 May 2012, a man 
was arrested in northern France while attempting to smuggle 
63 kg of amphetamine and 6 kg of cocaine across the 
Channel in a microlight aircraft.
(42)  The size of the seizures was larger in the period 2001–2006 in France, over 1 kg in average. This may suggest a change since 2007 in trafficking 
practices or in law enforcement targeting, or a combination of both.
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Greece appears to be also a major transit country for herbal 
cannabis, with average seizures around 1 kg, and annual 
interceptions representing about 70 % of the estimated 
national consumption—an exceptionally high proportion. 
This points to intense cross-border trafficking with 
neighbouring countries, with some of the herb likely to be of 
Albanian origin (Europol, 2011a).
South-West
Since 2009, Italy has been the third largest seizing country 
in Europe (11 tonnes in 2011) after Turkey and the United 
Kingdom. As with resin, herbal cases are very large, on 
average around 2.5 kg, but the total amount seized is 
estimated to represent only 5 % of the local market. This 
may indicate importation of herbal material (for instance 
from the Balkan region) or domestic production.
Seizures in Portugal at the start of the new century suggest 
trafficking at middle and wholesale levels, and possibly 
importation, most likely from Africa, but there is less evidence 
of this in recent data. The average size of seizures has declined 
from around 2 kg between 2001 and 2003 to 100–200 g in 
recent years, and the annual quantity seized has also declined, 
except in 2009, when an exceptional amount of 5 tonnes of 
herb was seized (mainly due to two maritime seizures).
North-West
Data point to Belgium and the Netherlands being a 
trafficking hub for both cannabis products. The amounts of 
herbal cannabis intercepted would be equivalent to about 
15 % of the estimated national market in the former and 9 % 
in the latter, which is not a negligible proportion compared 
with other countries; Belgian seizures are generally of 
medium size (250 g on average). A blurring of the 
boundaries between Belgium and the Netherlands has been 
suggested with respect to domestic cannabis production and 
the supply of herbal products for both domestic and export 
markets (EMCDDA, 2012b).
The United Kingdom and Germany are estimated to be the 
largest European markets for herbal cannabis in the EU. The 
relatively small average size of seizures (100–200 g) in both 
countries is likely to reflect the large proportion of seizures 
made at user level (43), but also may point to a combination 
of importation operations from other producing countries 
(e.g. the Netherlands) and a lower level trafficking of 
domestically produced material. The amounts of herb 
intercepted would be equivalent to 8 % of national demand 
in the United Kingdom and 2 % in Germany.
South-East
Analysis of resin interceptions show that Turkey has become 
a major seizing country, with 29 tonnes recovered in 2010 
and 21 tonnes in 2011 (compared with 300 kg in 2001); as 
a result, Turkey ranks third after Spain and France (56 
tonnes, 2011) in annual quantities of resin intercepted. 
Turkey has a large population and is likely to provide a 
substantial market for both cannabis products, but there are 
no data from which to draw conclusions about the relative 
size of seizures compared with national demand. However, 
Turkey may play a role in servicing the resin consumption 
markets in Europe, including its own market. Averages of 
multi-kilogram seizures were previously common in Turkey, 
and although the average size of the cases may have 
declined somewhat since 2009, it remains above 1 kg, 
pointing to bulk trafficking of the drug. Cannabis resin 
seized in Turkey is likely to have been produced in South-
West Asia, the Middle East or locally.
Trafficking herbal cannabis
The shift towards domestic production of herbal cannabis 
has meant that cross-border trafficking has decreased, with 
the majority of countries now appearing to be relatively 
self-sufficient. Interceptions have declined in size, and more 
steeply than resin seizures. Thus, the average weight of 
herbal cannabis seizures fell from 1.4 to 0.3 kg between 
2001 and 2011; and of resin from 2.6 to 1.8 kg. This 
probably reflects the increase in domestic supply of herbal 
cannabis and in trafficking of smaller quantities at local or 
regional level. However, some cross-border trafficking does 
occur in the following regions.
South/South-East
In recent years, Turkey has emerged as a major seizing 
country, with a fivefold increase in the amount of herbal 
cannabis intercepted annually since 2005, reaching a 
record of 55 tonnes in 2011. In contrast, the trend has 
remained relatively stable in the EU over the same period. 
Turkey now reports the largest amounts of herbal cannabis 
seized in Europe (twice as much as the United Kingdom, the 
second largest seizing country). As with resin, averages of 
multi-kilogram herbal seizures were previously common in 
Turkey but the size of the cases has declined since 2009 
and is now just over 1 kg (2011 average). This remains large 
compared with other countries and points to bulk trafficking, 
probably of herbal material of domestic origin.
(43)  The large proportion of seizures made at user level in the United Kingdom may be, at least partially, attributed to the increasing use of police warnings for 
cannabis possession (Mulchandani et al., 2010).
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that Vietnamese criminals in several countries may be 
connected, while similarities in equipment and growing and 
distribution methods suggest the existence of a criminal 
franchise system. Chinese nationals have also been reported 
to grow cannabis commercially in countries including Ireland 
and the United Kingdom.
OCGs in the Western Balkans, in particular Albanian-
speaking groups, play a significant role in supplying cannabis 
to the EU market. Cannabis grown in Albania and the Kosovo 
region is trafficked for the most part overland to Greece or by 
sea to Italy, but also via Slovenia and Hungary.
Moroccan OCGs control an important part of the cannabis 
resin trade to the EU. Moroccan and EU criminals including 
Spanish, Dutch and British groups control the flows through 
the main entry points, Spain and Portugal, and thence 
overland to North-West Europe, Germany, Italy and the 
Nordic countries. Occasionally, EU-based groups have the 
leading role in the trade. Bulk quantities of cannabis are 
imported, usually by go-fast boats from Africa to Europe. 
OCGs use global positioning system (GPS) or radio-
controlled devices to recover packages of resin from the 
water. Recent intelligence shows that, as with other drugs, 
container shipments are increasingly used.
There has been an increase in cases of importation of 
cannabis resin by air couriers to the Nordic countries. Spanish 
and Moroccan OCGs cooperating with Nordic criminals 
organise shipments from Morocco or Spain. The networks of 
couriers, including nationals of Morocco, Spain and Central 
and North European countries, are very well organised. They 
transport the resin as swallowed pellets—traditionally not a 
common modus operandi for trafficking of this drug.
Wide-ranging investigations have revealed that some 
Moroccan groups strategically place their members in, or 
forge alliances with, criminal groups in Belgium, Germany, 
Spain, France, Italy and the Netherlands. This affords them 
a position from which to import cannabis resin into the 
largest markets in Europe. They have invested in businesses 
to facilitate resin smuggling between Morocco and Europe. 
Like other drug networks, they have developed a multi-crime 
approach and may use violent means, including murder, to 
protect their interests.
Afghanistan has become an important producer of cannabis 
resin. Some Turkish- or Albanian-speaking OCGs may have 
an advantage in the trade of Afghan cannabis resin 
because of their long-standing involvement in trafficking 
heroin from Afghanistan. Turkish OCGs are already known 
to be involved in the wholesale secondary distribution of 
cannabis resin in the EU, and this may also be true of 
Albanian-speaking OCGs.
Trends in organised crime involvement 
with cannabis in Europe
Cannabis production and trafficking has become 
increasingly attractive to organised crime in recent years, 
with various groups trying to capitalise on the largest drug 
market in Europe.
OCGs operate both large-scale plantations and, a more 
recent trend, a large range of small facilities in several 
countries, in an attempt to mitigate risk. Vulnerable people, 
such as the elderly, are often lured into becoming growers 
with the promise of high revenues, but end up being 
exploited.
OCGs need access to equipment and chemicals to set up 
profitable cannabis plantations. Several investigations have 
revealed that legal companies knowingly supply growing 
equipment to organised crime. The misuse of premises is 
also an important feature of cannabis cultivation: property 
rental agents and holiday parks often facilitate this activity, 
either knowingly or unknowingly, and false documents are 
used to fraudulently obtain mortgages to purchase premises. 
Criminals increasingly resort to publicly available 
communications technology to monitor crops.
Owing to their high levels of expertise, Dutch OCGs are 
important facilitators in the production of cannabis in the EU. 
They have extended their activities to neighbouring countries 
such as Belgium and Germany, possibly to benefit from 
lower running costs and because of increased pressure from 
Dutch law enforcement. They are also present in regions 
linked more with cannabis resin sourced in Morocco, 
particularly Spain, France, Italy and Portugal. Investigations 
show increased cooperation with OCGs from these 
countries for setting up plantations, often with Dutch 
nationals in management positions.
Some Dutch criminals have evolved from plantation 
administrator and small-scale trafficker to the more lucrative 
role of broker. They use existing trafficking networks to 
distribute cannabis from independent growers. They have 
also expanded their activities into cannabis resin trafficking, 
and production and distribution of synthetic drugs.
In recent years, Vietnamese OCGs have become prominent 
in the indoor cultivation of cannabis in many EU countries, 
particularly Belgium, the Czech Republic, Germany, Ireland, 
France, Hungary, the Netherlands, Poland, Slovakia and the 
United Kingdom. Closed and hierarchical in structure, these 
groups have expanded to incorporate specialist roles for 
electricians, plumbers and managers of cultivation facilities. 
Gardeners tending the plants are often illegal migrants 
working to pay off their passage. Investigations have shown 
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encouraging the use of the ENPI to implement measures on 
drug issues in the ENP action plans (see Chapter 1). As part 
of bilateral talks with Morocco, a major source country for 
cannabis resin, work was initiated on planning a rural 
development programme to reduce cannabis cultivation (EC, 
2010a).
A common approach to addressing the production of 
cannabis can be found among the Member States at EU 
level; however, there are still important national differences 
in how countries handle legal issues linked to cannabis. For 
example, the specific threshold quantities that have been set 
for possession of certain amounts of cannabis and the 
associated penalties vary among Member States (see also 
Chapter 2). The differences between selected countries, in 
this respect, are shown in Figure 14.
In the secondary distribution of cannabis products, the 
criminal landscape becomes more diverse, with more 
involvement of European groups. For example, Polish OCGs 
supply the markets in some Nordic countries and have links 
with OMCGs. OMCGs are known to supply both cannabis 
resin and herb in Northern Europe and they have 
established their own facilities to grow cannabis.
Responses to cannabis trafficking at 
European and international level
European policy initiatives
The EU addresses drug issues as a key part of its 
international cooperation efforts with both neighbouring 
countries and those further afield. Through this approach, 
the EU and its Member States engage with countries where 
the cultivation and trafficking of cannabis occur in a way 
that reflects the shared responsibility the EU has in this area 
and a balanced approach to drug problems. Consequently, 
different policy instruments support and implement aspects 
of the EU Drugs Strategy (2005–2012) and its action plans.
Several actions in the EU Drugs Action Plan (2009–2012) 
focus on activities that have an impact on the cultivation and 
trafficking of cannabis internationally. Action 62 aims at 
Twenty-five arrested in joint counterfeit euro and 
drug trafficking investigation 
On 13 December 2011, Spanish authorities, working with 
Europol, dismantled a criminal group involved in drug 
trafficking and distributing counterfeit currency with a face 
value of more than EUR 2 million in 20 EU countries. A total 
of 25 people were arrested.
In June 2011, Spanish authorities dismantled the first part of 
the network when they seized 1 tonne of cannabis and 
arrested 11 suspects. However, investigations continued, 
focusing on euro counterfeiting.
The main counterfeiter was the owner of a canned food 
distribution company, which was used as a cover for the 
illicit print shop, where EUR 50 notes were printed.
The criminal group also imported counterfeit EUR 20, 50 
and 100 notes from criminals in Italy, for further distribution 
around Europe. Fourteen suspects were arrested and 
counterfeit banknotes with a face value of EUR 1.5 million 
were seized together, with materials for producing more 
counterfeit notes. Machinery and tools to forge Spanish 
identification documents were also found.
Moving to a new phase in the development of 
Dutch coffee shops
The Netherlands is the only country in Europe with a 
nationwide system for regulated supply of cannabis, which 
is distributed in ‘coffee shops’ licensed by municipal 
authorities. Technically, the sale of small amounts of 
cannabis in these shops is an offence, but it is tolerated 
provided the operator adheres to a set of criteria issued by 
the prosecutor general:
•  No more than 5 g per person may be sold in any one 
transaction, and the coffee shop is not allowed to keep 
more than 500 g of cannabis in stock (1).
•  No hard drugs may be sold.
•  Drugs may not be advertised.
•  The coffee shop must not cause any nuisance.
•  Alcoholic beverages may not be sold.
•  No drugs may be sold to minors (under the age of 18), 
nor may minors be admitted to the premises.
Two new criteria were introduced in the three southern Dutch 
provinces in May 2012, to be implemented across the 
Netherlands from January 2013. Coffee shops will become 
closed clubs and allowed no more than 2 000 registered 
members, who must be Dutch residents (2). And from January 
2014 the minimum distance from schools will be 350 metres. 
The mayor may order a coffee shop to be closed if these 
criteria are disregarded (Article 13a of the Opium Act). The 
ultimate result may also be the prosecution of the offender, 
who may be the owner of the coffee shop, the client or both.
(1)  The supply of cannabis to coffee shops is illegal and subject to 
law enforcement; this issue is frequently referred to as the 
‘back-door’ issue.
(2)  The policy was modified by the Coalition Agreement of the new 
Government in late 2012, with registration no longer required.
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production sites, enabling the identification of matches 
between seized equipment and materials. The ELSC collates 
modus operandi, photographic and basic forensic information 
on significant seizures or seized equipment. This is used to 
initiate information exchange, further investigations and 
forensic profiling for the targeting of criminal networks.
Following the establishment of Project Cannabis in March 
2010, the European Expert Group on Cannabis (EEGC) was 
formed to provide additional input. The creation of the 
Expert Group supports Action 44 of the EU Drugs Action 
Plan (2009–2012). Europol works closely with this group, 
which is a multidisciplinary joint unit consisting of law 
enforcement experts from different EU countries.
International initiatives
The CCP, a joint initiative between the UNODC and WCO (see 
Chapter 1), has yielded promising results in intercepting 
cannabis shipments. In the year ending December 2011, three 
exceptional cases involving three containers resulted in the 
seizure of 13.4 tonnes of cannabis (UNODC and WCO, 2012).
Operational initiatives
Europol plays an important role in countering cannabis 
production and trafficking internationally. It provides support 
for the OAPs concerned with the Western Balkans and 
container shipments that translate into action the EU crime 
priorities B and E of the EU policy cycle 2011–2013 (see 
Chapter 1).
A dedicated focal point on cannabis has been created 
within the AWF on serious and organised crime. This assists 
in revealing links between different cases, and may result in 
the identification of new criminal targets. The data collected 
are used to enhance information exchange between law 
enforcement agencies responding to cannabis production, 
covering the equipment used and wholesale trafficking of 
the drug.
Project Cannabis includes the Europol Cannabis Cultivation 
site Comparison System (ECCCS) and the Europol Logo 
System on Cannabis (ELSC). The ECCCS gathers detailed 
photographic and technical information on cannabis 
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Figure 14:  Prescribed penalty ranges for supplying cannabis in some European countries
Note:  This graph is based on estimates, with some penalty ranges calculated using an assumed potency or street price. In some cases, the quantities chosen 
span two different penalty ranges in a country. The penalty ranges do not take into account all aggravating or mitigating circumstances or judicial 
discretion, and they are nominal sentences. They are those to be awarded by the judge according to the legal framework; regardless of the actual 
sentences awarded and executed. In Ireland, the prescribed penalty range extends to life imprisonment.
Source: EMCDDA/Legal Correspondents Network.
For conclusions and recommendations relating to the cannabis market, please refer to pages 133–134 in Chapter 10.
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cocaine, and the second most widely used drug after 
cannabis. Importantly, the European amphetamine market 
(2 million Europeans are estimated to have used the drug in 
the last year) represents highly profitable ‘business 
opportunities’ for criminal actors. Although some 
amphetamine is produced in ‘kitchen-type’ laboratories, it is 
likely that the vast majority is manufactured in middling to 
large facilities by OCGs, some of which are able to operate 
throughout Europe. In addition, amphetamine is also 
produced in South-East Europe for export to the Middle East, 
where it is sold under the name ‘captagon’.
Global overview
Since the 1990s, an increasing number of countries 
around the world have reported amphetamine 
manufacture (UNODC, 2011h). Lack of data on production 
and consumption means that estimating the amounts 
available for consumption is a challenge. The number of 
past year users of amphetamines worldwide (44) was 
estimated at between 14 and 56 million in 2009 
(UNODC, 2011a), and potential global manufacture at 
between 160 and 600 tonnes in 2008 (UNODC, 2010a). 
One-third of this potentially manufactured amount could 
be amphetamine.
Amphetamine still seems to be produced mainly in Europe. 
Large-scale production is found principally in the North-
Western parts of the continent, whereas small- to middle-
scale production predominates in Central and Eastern 
Europe (Europol, 2007b; EMCDDA–Europol, 2011) (45). In 
2009, all of the amphetamine production facilities 
dismantled worldwide and reported to the UNODC 
(2011a) were in Western and Central Europe (UNODC, 
2011a), although, more recently, laboratories have also 
been dismantled elsewhere in the world.
Introduction
Amphetamine was first synthesised in Germany in 1887 by 
a Romanian chemist (Edeleano, 1887). It is a synthetic 
stimulant of the central nervous system, closely related to 
methamphetamine. Although amphetamine has occasional 
therapeutic uses, most is manufactured in clandestine 
facilities in Europe. The most common amphetamine salt is 
the sulphate—a white or off-white powder soluble in 
water. Illicit products mostly consist of powders. 
Amphetamine may be ingested, snorted or, less commonly, 
injected. Unlike the hydrochloride salt of 
methamphetamine, amphetamine sulphate is insufficiently 
volatile to be smoked.
Although, worldwide, methamphetamine is probably the 
most widely used synthetic stimulant, in Europe it is 
amphetamine, mostly as sulphate salt, that has historically 
been the most heavily produced, trafficked and used 
synthetic stimulant. Amphetamine, therefore, may be viewed 
as a ‘European drug’.
For a considerable time amphetamine was the most 
commonly available stimulant drug in Europe. This situation 
changed when 3,4-methylenedioxy-methamphetamine 
(MDMA) use became widespread in the 1990s, and 
significant volumes of cocaine entered the European market 
in the 2000s. Nevertheless, in most European countries 
amphetamine use remains an important element in patterns 
of stimulant use found today, including problem use. In 
contrast to the global picture, methamphetamine is far less 
commonly seen in Europe, although it may be important in 
some countries (see Chapter 6).
Overall, amphetamine has stabilised as the second most 
widely used stimulant drug in Europe today after cocaine. 
But in many countries, especially in the North and East of 
Europe, it is the most consumed stimulant, far ahead of 
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(44)  When this report refers to amphetamines in the plural, this includes amphetamine, methamphetamine and related substances such as fenethylline, 
methylphenidate, cathinone, etc., but not ecstasy or its relatives. The two groups together—amphetamines and the ecstasy family—are sometimes referred 
to as amphetamine-type stimulants (ATS).
(45)  Methamphetamine predominates in the Czech Republic and, to some extent, in neighbouring countries, although recent reports note its possible spread 
outside this traditional area of production and consumption and towards countries with shores on the Baltic Sea (see Chapter 6).
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Globally, amphetamine seizures increased 10-fold from 
2000 (3.1 tonnes) to 2009 (33 tonnes), but fell sharply to 
19 tonnes in 2010. The proportion of total amphetamine-type 
stimulants (ATS) seized accounted for by amphetamine also 
decreased in 2010, and for the first time since 2006 more 
methamphetamine than amphetamine was seized worldwide. 
These decreases are largely attributable to large drops in 
seizures reported by a few countries in the Near and Middle 
East and South-West Asia. This region accounted for almost 
three-quarters of total amphetamine seized worldwide in 
2009, with the remainder, 27 %, seized in Europe, mostly 
Western Europe (UNODC, 2006b, 2012a).
The chemical 1-phenyl-2-propanone (P2P; also known as 
benzyl methyl ketone (BMK)) is a precursor predominantly 
During the last 30 years, consumption of amphetamine 
tablets with a ‘captagon’ logo (46), a counterfeit 
pharmaceutical product, has spread from South-East Europe 
to the Middle East, especially the Arabian Peninsula, where 
the drug has been popular since the beginning of the 1980s 
(UNODC, 2009a). Captagon was originally the registered 
trademark of a medicinal product. The limited forensic data 
available show that seized captagon tablets contain mainly 
amphetamine sulphate and caffeine (Interpol, 2009). 
Captagon seizures in the Middle East, which dominate 
global amphetamine seizures, amount to 24.7 tonnes (75 % 
of global seizures) in 2009 (UNODC, 2011h). However, 
comparatively little information is available on the 
organisation of illicit production of captagon and the 
precursor chemicals used.
Table 4: Amphetamine in Europe at a glance
Age group  
(years)
Estimated number 
of users (million)
% of European population 
(range between countries)
Consumption (1)
Lifetime 
15–64 13 3.8 (0.1–11.6)
15–34 7 5.5 (0.1–12.9)
Last year 
15–64 2 0.6 (0.0–1.1)
15–34 1.5 1.2 (0.0–2.5)
Number (% of all drug admissions)
Drug treatment (2010) (2)
All admissions 23 163 (6 %)
First admissions 9 199 (6 %)
Number (% of all drug offences)
Drug offences (2011)
All drug offences 74 026 (6 %)
Offences involving use or possession 54 144 (5 %)
Offences of drug supply 15 653 (8 %)
Seizures (3) (2011)
Quantities (tonnes) EU (including Croatia, Norway and Turkey) 5.7 (6.1)
Number EU (including Croatia, Norway and Turkey) 34 000 (37 300)
Mean retail price (2011) (EUR per gram) Range (IQR) (4) 8–28 (8.6–20.7)
Mean purity (2011) (%) Range (IQR) (4) 5–30 (9.5–22.3)
Notes
(1)  European estimates are computed from national estimates weighted by the population of the relevant age group in each country. They are based 
on surveys conducted between 2004 and 2010/11 (mainly 2007–2010) and therefore do not refer to a single year. 
(2)  Information is available on about 470 000 drug users entering specialist treatment in Europe (EU, Norway, Croatia, Turkey). Data include 
methamphetamine treatment admissions. Units coverage may vary between countries.
(3)  The 2011 figures should be considered as estimates; where 2011 data were not available (United Kingdom), 2010 data were used in their place. 
Amphetamine tablets are included, assuming a weight of 250 mg per tablet.
(4)  IQR: interquartile range, or range of the middle half of the reported data.
Sources: EMCDDA/Reitox national focal points, EMCDDA (2012a).
(46)  The composition of captagon tablets remains unclear; however, laboratory analyses indicate that it no longer contains fenethylline (as opposed to the 
legitimately marketed captagon tablets that initially shaped the ATS market in the region), but rather amphetamine in combination with caffeine and other 
substances (UNODC, 2008c).
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BMK trafficking issues
The illicit production of key amphetamine precursors was 
rare in Europe until 2010. But supply problems due to 
increasingly effective international control measures seem to 
have led to the illicit manufacture of precursors within 
Europe using so-called ‘pre-precursors’ such as phenylacetic 
acid (47), benzaldehyde or a-phenylacetoacetonitrile 
(APAAN, also known as 2-phenylacetoacetonitrile), most of 
which are not placed under international control. As a result, 
Europol suggests that at present the majority of the BMK 
used by criminal groups is self-produced in Europe. Fairly 
large quantities of APAAN, a non-controlled chemical, have 
been seized in Belgium, Poland and the Netherlands. These 
countries are also the first to report dismantling of BMK 
used to manufacture amphetamine in Europe, but which may 
also be used to make methamphetamine. International trade in 
BMK is relatively small and restricted to a few countries. Thus, 
between 2005 and 2010, a total of 128 transactions between 
10 exporting and 26 importing countries involving 98 000 
litres of BMK were notified to the INCB (INCB, 2012a).
Global seizures of illicit BMK shipments increased from 
4 900 litres in 2009 to 26 000 litres in 2010, the largest 
total since 2004. As a result of a large haul of 5 000 litres 
of BMK in Belgium, seizures of BMK in Europe doubled in 
2010 compared with 2009 and 2008. However, it seems 
that in 2011 and the first half of 2012, no significant BMK 
seizures were reported in Europe. In 2010, three countries, 
Mexico, Canada and Belgium, confiscated 95 % of the BMK 
seized worldwide (INCB, 2012a).
Global seizures of phenylacetic acid, a precursor of BMK 
(see below), also reached record levels in 2010, with a total 
of about 183.5 tonnes confiscated, almost four times the 
previous record in 2005. The three countries seizing the 
most phenylacetic acid in 2010 were the United States, 
Mexico and China. Phenylacetic acid seizures in Europe in 
2010 totalled 2 kg (INCB, 2012a).
Production and precursor issues
The production of amphetamine sulphate is a multistep 
chemical process involving a precursor chemical and a 
range of reagents and solvents. The main amphetamine 
precursor is BMK. In theory, 1 litre of BMK yields about 
1.4 kg of amphetamine sulphate, but actual yields in 
clandestine facilities have tended to be well under 1 kg. 
Several methods can be used to manufacture amphetamine, 
but the most common in Europe is the so-called ‘Leuckart’ 
synthesis using BMK. Despite its low yield, this is arguably 
the easiest method (Europol, 2010).
The illicit facilities synthesising amphetamine dismantled in 
Europe vary in size from small ‘kitchen’ laboratories to 
extensive ‘online’ production facilities. A range of equipment 
is needed for production, and in the case of large-scale 
production, mostly occurring in the Netherlands and 
Belgium, it is increasingly common to find ‘custom-made’ 
and industrial equipment, such as stainless-steel reaction 
vessels, permitting much higher production levels. In Poland, 
the capacity of clandestine amphetamine manufacturing 
facilities is also reported to have increased in recent years 
(Krawczyk et al., 2009).
(47)  The INCB (2012a) reports that a range of non-scheduled derivatives and esters of phenylacetic acid, such as ethyl phenylacetate, are also used as BMK 
‘pre-precurors’ by criminal actors. However, the evidence available suggests that this is essentially the case for the manufacture of methamphetamine in 
Mexico and Central America.
Threats and risks posed by illicit 
amphetamine laboratories
Clandestine amphetamine laboratories may pose significant 
risk of fire, explosion and toxic fumes to those operating 
them and those nearby, and to law enforcement personnel 
when they enter them. There are also environmental threats 
linked to the chemical waste products generated during the 
production process, which have been estimated to range 
between 18 and 24 kg of chemical waste per 1 kg of 
amphetamine manufactured (ACMD, 2005; NDLERF, 
2005).
Dumping site for waste products resulting from illicit 
amphetamine production found in Geldermalsen, the 
Netherlands, May 2012
Source: Dutch National Police—LFO via Europol.
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The available data appear to reflect two main types of user: 
those who may be considered problem users, possibly 
injecting the drug, and eventually seeking treatment; and 
casual users, who can be further subdivided into 
recreational users (e.g. to enhance a night out) and those 
who use to improve task efficiency. 
According to estimates of drug prevalence, about 13 million 
Europeans aged 15 to 64 (3.8 %) have tried amphetamines 
in their lifetime. Focusing on the 15–34 years age group, the 
age group in which drug use is most common, an estimated 
1.5 million Europeans (1 %) have used the drug at least 
once in the past 12 months. Between 2005 and 2010, last 
year amphetamines use remained relatively low and stable 
among the 15–34 years age group in most European 
countries, with prevalence levels of less than 3 % in all 
reporting countries (see Figure 15a).
Despite prevalence of amphetamines in the young adult 
population being at a maximum of 2.8 %, treatment data for 
amphetamines suggest the existence of substantial problem 
use within a subset of countries. Amongst the countries 
where prevalence is lowest, Greece, France, Italy and 
Portugal, there is little evidence of problem use, all reporting 
very few first-time entrants to treatment with amphetamines 
as their primary drug (0.2 %). However, in countries where 
prevalence is higher, there is more variation. Belgium, 
Denmark, Germany, Estonia, Latvia, Hungary, Poland, 
Finland and Sweden all report proportions of between 10 % 
and 25 %. In the Czech Republic and Slovakia, where 
methamphetamine predominates, figures are reported of 
almost 70 % and just over 40 % respectively. In addition, 
Estonia, Czech Republic, Lithuania, Finland, Latvia and 
Sweden report that between 50 % and 80 % of these clients 
were injecting the drug, thus increasing the risk of infection 
(see Figure 15b).
Trends over time in the proportion of new entrants to 
treatment for amphetamines provide an insight into problem 
use. Trends amongst the higher prevalence countries differ. 
Between 2005 and 2010, the proportion of first-time clients 
in Finland and Sweden citing amphetamines as their primary 
drug showed a marked decline (from 27.6 % to 12.3 % and 
from 32.7 % to 19.2 %, respectively), whereas there was a 
marked increase in Latvia (from 22.6 % to 29.6 %) and rates 
in Denmark and Germany remained relatively stable (at 
10.2–11.5 % and 9.7–12.6 % respectively). Data for Estonia 
are available only for the period between 2007 and 2010, 
over which period the proportion more than doubled from 
4.5 % to 10.8 %. Some caution should be exercised when 
interpreting these changes as reflecting changes in the 
market as they could also incorporate changes in reporting 
patterns or provision of treatment.
laboratories (which convert APAAN into BMK). In all cases, 
the pre-precursors were shipped from China. Significant 
seizures of APAAN include 1 tonne seized in Belgium in 
2010, 700 kg in Poland in April 2011 and 1.1 tonnes in the 
Netherlands in June 2012.
Despite production of BMK in Europe from ‘pre-precursors’, 
BMK continues to be smuggled into Europe, notably from 
China but also from non-EU European countries. This is 
illustrated by recent seizures of 5 000 litres of BMK in 
Belgium (sourced from China) in 2010 (INCB, 2012a), and 
600 litres discovered in Lithuania in August 2011. 
Available intelligence indicates that the precursors in the 
last seizure were sourced from an Eastern European 
country outside the EU.
Although APAAN appears to be the pre-precursor most 
frequently used in Europe, law enforcement operations have 
shown that phenylacetic acid may also be used to produce 
BMK and then amphetamine or methamphetamine in 
Europe. For instance, in Poland, three clandestine facilities 
manufacturing BMK from phenylacetic acid for sale to 
amphetamine manufacturers have been dismantled since the 
early 2000s (Krawczyk et al., 2009). Recently, the INCB 
has reported the dismantling of clandestine amphetamine 
production sites using phenylacetic acid in Germany and 
Spain in 2010 (INCB, 2011). Owing to concerns over an 
increase in global seizures since 2006, phenylacetic acid 
was rescheduled in January 2011 from Table II to Table I of 
the 1988 United Nations Convention.
Consumer markets for amphetamine 
in Europe
Distinguishing between amphetamine and methamphetamine 
is difficult both for users and for observers of use. The drugs 
share the effects of enhancing alertness, suppressing hunger 
and providing feelings of well-being and euphoria. At 
present, it is not possible to distinguish between the two 
drugs in most of the quantitative data on consumption 
collected at the European level. Given that both drugs may 
be available but indistinguishable in some markets, this 
section largely discusses the broader family of 
amphetamines, including methamphetamine. However, for 
some countries the distinction is justified. The Czech Republic 
is historically a country where methamphetamine has 
dominated the market, and more recently a similar situation 
is being reported in Slovakia; discussion of these countries 
will be deferred to the next chapter. Methamphetamine also 
appears to be prevalent, along with amphetamine, in 
Finland, Sweden, Norway, Latvia, Estonia and Lithuania 
(EMCDDA–Europol, 2009, 2011).
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mainly in Turkey, increased from 1.1 million seized in 2001 
to an all-time record of over 20 million in 2006; it then 
declined to 1.4 million in 2010 and 1.3 in 2011—almost the 
level reported 10 years ago. While this last development 
could be linked to the displacement of amphetamine 
production out of Southern Europe, the general decline in 
seizures of amphetamine powder is more difficult to explain 
and may result from a combination of factors (e.g. changes 
in traffickers’ modus operandi, in intelligence accessed by 
law enforcement, or in their targeting).
Trafficking areas
Amphetamine seizures and production sites dismantled over 
the last five years (Figure 17) suggest that amphetamine 
production and trafficking in Europe can be broadly thought 
of as concentrated in four geographical areas.
The ‘North-West area’
European and international sources indicate that the 
North-West area is the main source of the amphetamine 
consumed in most West European countries, including 
Belgium, Germany, Spain, the Netherlands and the United 
Trends in amphetamine production 
and trafficking in Europe
Seizures
Amphetamine produced in the EU is trafficked extensively 
within Europe, and some is exported abroad, but in 
quantities that remain difficult to determine.
The number of amphetamine seizures in Europe has been 
fluctuating for the last decade around an annual average 
of 36 000. However, this analysis is limited by the fact 
that two major seizing and producing countries—the 
Netherlands and Poland—do not report the number of 
seizures made.
Of the total amounts of amphetamine products seized in 
Europe (Figure 16), most is in powder form, the remainder 
being tablets. Quantities of amphetamine powder recovered 
in Europe doubled between 2001 and 2007, when they 
stabilised around 8 tonnes per year, but then sharply 
decreased in 2010 to 5 tonnes, due to a major decline in 
amounts intercepted in the Netherlands, the United Kingdom 
and Turkey. The number of amphetamine tablets intercepted, 
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Figure 15:  (a) Last year use of amphetamines (b) Clients entering treatment for primary amphetamine use
Note:  Data in (a) refer to young adults (aged 15–34 years). Data in (b) refer to clients entering treatment for the first time. The figures show the most recent 
data available in each country. Owing to high levels of methamphetamine use in the Czech Republic, Latvia, Slovakia, Finland and Sweden, it is likely 
that percentages represent clients seeking treatment not for amphetamine but for methamphetamine use.
Source: EMCDDA/Reitox national focal points, EMCDDA (2012a).
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and the Netherlands are also often used to produce MDMA 
(ecstasy). High production capacity appears to be a 
characteristic feature of the North-West hub as the facilities 
dismantled elsewhere in Europe have tended to be smaller.
The North-West area is also where the largest quantities of 
amphetamine are confiscated, and is among the largest 
for number of seizures. It is probably also the region of 
Europe where the largest quantities of amphetamine are 
consumed; at least, it includes what is probably Europe’s 
largest national consumer market for the drug, the United 
Kingdom (UNODC, 2008c). The largest amounts of 
amphetamine powder in Europe are recovered in the 
Kingdom (48), which have large to middling consumer 
amphetamine markets. Amphetamine from the North-West 
hub is also exported to Denmark, Sweden and Norway, and 
is reported to be found in Central and Southern European 
markets such as in Greece, Italy, Hungary, Austria and 
Croatia.
Amphetamine synthesis and tableting facilities in the 
North-West area would seem to be concentrated in the 
Netherlands and, to a lesser extent, Belgium. Most of the 
large amphetamine production sites seized in the region 
featured sophisticated equipment. The facilities and 
equipment used to manufacture amphetamine in Belgium 
Quantity seized by Turkey
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Quantity seized by United Kingdom
Quantity seized by other countries
Number of seizures in Europe
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Figure 16:  Seizures of amphetamine in Europe, 2001–2011
Note:  All 30 European countries are included, except the Netherlands and Poland where Number of seizures data are not available. In the absence of 2011 
data for the United Kingdom, 2010 data were used for 2011. The total amounts represent the sum of the quantities of amphetamine seized under 
different forms, including powder, tablet (one tablet is assumed to weigh 250 mg), liquid (1 litre is assumed to weigh 1 kg) and paste.
Sources: EMCDDA/Reitox national focal points, EMCDDA (2012a).
(48)  Several large seizures of amphetamine were made in France in recent years, but Europol information indicates that most of these large shipments were in 
fact intended for the United Kingdom market and, to a lesser extent, the Spanish market.
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The consumer market for amphetamine in the Nordic 
countries is a significant one, since it accounts for most of 
the problem drug use in Europe. However, since population 
sizes are small, it is probably more limited than other 
markets. It is partly supplied by amphetamine produced in 
the North-West area and partly by that produced in the 
North-East area (discussed below). Trafficking in 
amphetamine is likely to be intense, with seizures in 
Sweden totalling 0.9 tonnes over 2009–2011 and in 
Norway 0.4 tonnes. The relatively low average size of 
cases in these two countries (60 g and 50 g respectively) 
would suggest that the quantities smuggled are relatively 
small compared with other consumer markets such as the 
United Kingdom, or, alternatively, that law enforcement 
targets the lower segments of the supply chain. In 
comparison, seizures in Denmark (totalling 0.6 tonnes over 
2009–2011) are of slightly larger size (around 120 g in 
average), pointing to its possible role as a transit country 
Netherlands, where a total of 4 tonnes was seized in the 
2009–2011 period, followed closely by Germany with just 
under 4 tonnes.
With an average seizure size of around 0.5 kg (over 
2006–2008), France, where amphetamine production has 
not been detected and where prevalence of use is low, 
appears to be a transit country for amphetamine destined 
for larger consumer markets such as Spain and the United 
Kingdom. France would seem to make the largest seizures, 
on average, of amphetamine in Western Europe (49). The 
lower average seizure size in the United Kingdom (200 g 
over 2008–2010) is likely to reflect a mixture of street-level 
deals and mid-level to wholesale trafficking. In Belgium, 
where amphetamine manufacture also occurs, but where 
total quantities intercepted over 2009–2011 are 
comparatively small (about 0.5 tonnes) (50), the average 
seizure size is low, under 100 g.
(49) It is possible that the situation has changed since 2008 when France reported its latest available data on number of seizures.
(50) This compares with nearly 1.5 tonnes of amphetamine seized in France over 2009–2011 and over 5 tonnes in the United Kingdom over 2008–2010.
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Figure 17:  Dismantled amphetamine production, storage and tableting sites, as reported to Europol, 2007–2011
Source: Europol.
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(170 g over 2009–2011), pointing to the important role of 
the country both as a producer of amphetamine and as a 
transit area for amphetamine destined for Finland.
Production and trafficking in Central Europe
Production and trafficking of synthetic stimulants also takes 
place in Central Europe, albeit on a smaller scale. Judging 
from data on seizures of clandestine facilities, production in 
Central Europe is centred on Germany, especially southern 
Germany, although facilities are occasionally found 
elsewhere, for instance in Hungary in 2009. Illicit 
amphetamine and methamphetamine production is a fairly 
long-standing phenomenon in Germany, dating back to the 
1970s at least. A total of eight illicit amphetamine 
production facilities were seized in the country in 2009 and 
2010 (BKA, 2009, 2010). Most of the amphetamine (and 
methamphetamine) facilities dismantled in Germany seem to 
be ‘kitchen-type’ laboratories. The main reason for this fairly 
limited amphetamine production is probably that the 
German consumer market is largely supplied with 
amphetamine manufactured elsewhere, first and foremost the 
Netherlands. Germany is also likely to be a transit territory 
for amphetamine produced in the North-West and the 
North-East areas and smuggled to Nordic countries (Nilsson 
and Kegö, 2009).
Germany is intercepting increasingly large amounts of 
amphetamine powder every year, ranking just after the 
Netherlands in the last three years. The comparatively high 
average size of amphetamine seizures (160 g over 
2009–2011) probably reflects both the intensity of 
trafficking activities in the country (Germany is 
simultaneously an amphetamine producer, transit and 
importer country) and the extent of the domestic 
amphetamine consumer market, which is characterised by 
medium to high levels of use in young adults. However, 
since 2001, the average size of amphetamine seizures has 
been generally on the increase, pointing to a possible 
refocusing of drug law enforcement activities towards 
amphetamine and increased targeting of higher segments 
in the supply chain. This is likely to be supported by the 
increase in the quantities intercepted in Germany over the 
10-year period, making it the largest seizing country in 
Europe in 2010 and 2011.
Although neither Hungary nor Austria ranks among Europe’s 
10 largest amphetamine-seizing countries, relatively high 
cumulative totals of amphetamine—168 kg and 81 400 
tablets in Hungary and 99 kg in Austria—seized in the 
2009–2011 period suggest that both countries are fairly 
significant players in Central Europe. Slovenia is also 
thought to produce principally amphetamine, although 
for amphetamine originating elsewhere in mainland 
Europe.
The North-West area’s links to Spain have traditionally 
involved the supply of tablets, large numbers of which are 
seized every year, with record numbers of over 300 000 in 
2006 and 2010, close to 100 000 in 2009 and just under 
200 000 in 2011. Although comparatively small, indicating 
interceptions close to the consumer market, the average size 
of seizures in Spain (usually under 100 g) has generally 
increased over the last 10 years (from 5 g on average in 
2001 to 100 g in 2011).
The ‘North-East area’
Significant production and trafficking of amphetamines 
occurs in the North-East area, especially in Poland and, 
apparently to a lesser extent, in Lithuania and Estonia, while 
recent intelligence indicates a possible renewal of 
amphetamine production in Latvia. Sporadic, limited 
production has also been detected in the past in Finland and 
Sweden (UNODC, 2008c). It would appear that the 
quantities produced in the North-East hub are smaller than 
in the North-West area, but larger than in Central Europe.
Poland seems to be the North-East area country where the 
largest quantities of amphetamine are manufactured. About 
150 amphetamine production facilities were dismantled in 
Poland between 1995 and 2009. The general pattern for 
some years in the North-East area has been that 
amphetamine, and increasingly methamphetamine (see 
Chapter 6), is produced for local consumption, which is 
increasing, and for export to Finland, Sweden and Norway, 
and possibly Denmark, Germany and Hungary. Some 
trafficking networks seem to link specific producer countries 
to specific consumer countries. For instance, amphetamine 
produced in Poland seems to be exported mostly to Sweden, 
whereas the primary export market for the amphetamine 
manufactured in Estonia appears to be Finland.
It should be noted that in Estonia, and to a greater extent 
Lithuania, though not in Poland, the production of 
methamphetamine now seems higher than that of 
amphetamine (UNODC, 2008c; EMCDDA, 2009a; 
Krawczyk et al., 2009; Nilsson and Kegö, 2009; Pullat, 
2009; Finland: Reitox, 2009).
Poland is also the country in the North-East area reporting 
the largest quantities of amphetamine powder intercepted, 
which totalled 1.4 tonnes over 2009–2011. At a much lower 
level, with around 150 kg seized over the three-year period, 
quantities recovered in Estonia have always been much 
larger than in the other two Baltic States, and the size of 
seizures there would seem also to be larger on average 
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2011, more than three-quarters were seized in Turkey (1.1 
million captagon tablets). Turkey has long been the principal 
country seizing amphetamine tablets in Europe, with several 
million captagon tablets intercepted every year since 2002, 
and a record 20 million in 2006. It should be noted that 
captagon tablets are mostly not intended for consumption in 
the EU. The sharp reduction, compared with previous years, 
in the numbers recovered in Turkey since 2008 would 
support the thesis that the manufacture of captagon tablets 
has been relocated outside South-Eastern Europe. A similar 
reduction, although less steep and going back further in 
time, can also be seen in quantities intercepted in Bulgaria, 
which have decreased from an all-time peak of 1.4 tonnes 
in 2005 to around 0.2 tonnes recovered annually since 
2008; there is, however, insufficient evidence to offer any 
valid explanation of this trend.
The seizures made in Turkey and Bulgaria have always 
stood out among EMCDDA reporting countries by virtue of 
their extremely large size, of the order of kilograms—
averaging 17 kg and 5 kg, respectively, in the period 
2009–2011. This suggests a strong predominance of 
wholesale trafficking of amphetamine in these two countries, 
and probably reflects the fact that South-East Europe has 
been used as an area of amphetamine production and 
transit, especially of captagon, with a number of shipments 
being intercepted during both export and import.
Trends in organised crime involvement 
with amphetamine and other synthetic 
drugs in Europe
This section discusses the involvement of organised crime 
in the production and trafficking not only of amphetamine 
but also of methamphetamine (discussed in Chapter 6) 
and ecstasy (Chapter 7). OCGs are involved in a 
significant proportion of illicit synthetic drugs production 
and trafficking in Europe. The production of synthetic 
drugs is lucrative: they can be produced almost anywhere 
at low cost. The international dimension of organised 
crime is linked primarily to sourcing precursors and 
exporting drugs from the EU to other markets, mostly 
MDMA and amphetamines. EU criminal groups cooperate 
with Chinese, Russian-speaking, Turkish or Latin American 
OCGs.
Past examples have proven that OCGs adapt to changes, 
and are able to respond to the market, producing and 
distributing several types of synthetic drugs—and finding 
new precursor solutions. Organised crime involvement in the 
synthetic drugs market is very collaborative. Dutch, Belgian, 
British, Lithuanian, Polish and Icelandic OCGs work together 
to meet market demand. Such alliances enable OCGs to 
amounts seized are much smaller (7 kg and 8 400 tablets in 
2009–2011). Both Interpol (2009) and the INCB (2011) 
have reported dismantling of amphetamine production 
facilities in Slovenia in recent years.
Captagon in the ‘South-East area’
Bulgaria and, to a lesser extent, Turkey are believed to be 
significant producers of ‘captagon’, although it is likely that 
captagon manufacture also occurs elsewhere but goes 
undetected. Between 2001 and 2007 Bulgaria seized 18, 
many large-scale, amphetamine production facilities 
associated with the manufacture of captagon tablets 
(UNODC, 2008c). In 2008, it was reported that some 
amphetamine production had been moved out of Bulgaria, 
although exports from Bulgaria to the Middle East continued. 
A further eight amphetamine manufacturing sites were 
dismantled in Bulgaria between 2009 and 2011 (Bulgaria: 
Reitox, 2008, 2010, 2011).
Following the dismantling of 12 captagon production 
facilities in 2006, Turkey may now be primarily a transit 
country for captagon manufactured in East European 
countries, Syria and Armenia, and bound mainly for the 
Arabian Peninsula (Turkey: Reitox, 2011). However, 
captagon facilities have been detected in Turkey since 
2006. For instance, 473 kg of amphetamine was seized at 
a captagon manufacturing facility in September 2009 
(KCM, 2009). Clandestine laboratories have also been 
seized in non-EU Balkan countries (INCB, 2011).
Trafficking in amphetamine has long been an important 
drug supply issue in South-East Europe, with Turkey and 
Bulgaria seizing considerable amounts of the drug. Of the 
1.3 million amphetamine tablets intercepted in Europe in 
Amphetamine purity
Amphetamine seems to be the illicit drug whose purity 
shows the highest variation. Analyses of samples across 
Europe—most of which are from seizures at different levels 
of the market—reveal extreme values between 0 % and 
100 %, making purity very unpredictable. Samples of very 
high purity, over 95 %, were found in a number of countries 
in 2011, in particular those with higher levels of 
consumption—Sweden, the United Kingdom and Norway. 
Although mean purity varies across countries between 5 % 
and 30 %, the highest purity (20–30%) is found in countries 
where production is documented (Belgium, Latvia, Lithuania 
and the Netherlands) or where consumption is relatively 
high (Finland, Sweden and Norway).
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waste dumping and wholesale distribution. Division of tasks 
combined with increased use of mobile laboratories, 
conveniently placed in border areas, makes it difficult for law 
enforcement agencies to identify the criminal hierarchy, 
thereby enhancing the criminal organisation’s security.
Dutch and Belgian OCGs continue to play an important role 
in the large-scale production of synthetic drugs in the EU. 
Investigations have shown that prominent criminal groups 
are involved in the production of several drugs: typically 
MDMA, amphetamine and, to a lesser extent, 
methamphetamine. These groups have a historical 
advantage with regard to logistics, expertise, technology, 
advanced methodology and production capacity. Their 
prominent position is unlikely to be significantly challenged 
at EU level, at least in the short to medium term.
Until recently, there were limited indications of organised 
crime involvement in methamphetamine trafficking in the EU. 
Available information indicates that Lithuanian criminal 
groups play an important role in methamphetamine 
production in the Baltic countries and trafficking to the 
Scandinavian market. Although both Scandinavian and 
Lithuanian groups control methamphetamine trafficking to 
Nordic countries, it is generally Lithuanian nationals who 
carry out the actual smuggling, by car. Methamphetamine is 
usually concealed in custom-made hiding places or in 
vehicle cavities and trafficked by regular ferry lines from 
Lithuanian, Latvian or Estonian ports via the Baltic Sea.
In May 2009, the Lithuanian authorities seized a mid-scale 
methamphetamine production site, together with 
approximately 100 kg of high-purity methamphetamine. 
Lithuania-sourced methamphetamine is synthesised from 
BMK, of which Lithuanian crime groups have been important 
suppliers to the EU market.
Polish OCGs are also active in the small- to mid-scale 
production of amphetamine destined for the Scandinavian 
market. However, intelligence suggests that more 
sophisticated industrial and custom-made equipment is also 
used by Polish and Lithuanian OCGs. Investigations have 
also revealed attempts by Icelandic OCGs to establish 
large-scale production laboratories.
The role of Bulgarian criminal groups in large-scale 
amphetamine production and trafficking for the Middle East 
market has increased. Several large-scale production 
facilities managed by Bulgarians have been uncovered in 
recent years, and significant quantities of amphetamine, 
various equipment and chemicals were found. Production 
facilities have also been established in the Western Balkans, 
the Near East and the Caucasus, with EU nationals recruited 
as managers in some cases.
control the entire flow of illicit drugs, from sourcing the 
precursors to distribution of the final product. These groups 
have acquired significant financial power and influence over 
the illegal market. Violence is sometimes used to secure their 
position in the trade.
European synthetic drugs production is reliant on the 
cooperation of specialists in the field of organic synthesis 
and facilitators for equipment. There are indications that the 
services of some chemists and facilitators may be shared by 
multiple OCGs on a transnational basis, thus creating a 
specialist support service for organised crime. Within the 
EU, the exploitation of legitimate trade is used to obtain 
sophisticated glassware, industrial and custom-made 
equipment such as distillation machines, heating mantles, 
tableting machines and punches.
Illegal production of synthetic drugs is often characterised by 
a division of labour. Different members of OCGs may carry 
out different operations such as precursor and essential 
chemical acquisition, equipment and material supply, storage, 
Synthetic drugs network broken up
An international organised crime network, responsible for 
the large-scale production and trafficking of synthetic 
drugs, was broken up in 2012 following an extensive 
investigation by European law enforcement authorities. The 
operation resulted in the arrest of the key members of the 
criminal network, the discovery of three illegal drug 
production facilities and seizure of drugs and arms.
The investigation began when Swedish authorities identified 
that large quantities of amphetamine were being trafficked 
in Sweden. When preliminary investigations confirmed that 
an international criminal network was involved, a joint 
initiative with Europol and other EU Member States was 
launched. As a result, in March 2011, Europol initiated 
Operation Fire, which involved cooperation with several 
European law enforcement agencies.
During the operational phase of the investigation, 30 kg of 
amphetamine was seized in Sweden and three suspects 
were arrested, as well as two in Germany and one in the 
Netherlands. In addition, cooperation with Bulgarian 
authorities led to the arrest of three members of the 
organised crime network and the dismantling of three illegal 
synthetic drugs production facilities. The Bulgarian authorities 
seized approximately 75 litres of amphetamine base 
(enough to produce around 120 kg of pure amphetamine), 
15 kg of amphetamine and 1 400 litres of various chemicals. 
Equipment was also seized, including two tableting 
machines, together with five firearms, ammunition and 
6.4 kg of trinitrotoluene (TNT, an explosive).
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Portugal. Intelligence suggests the growing prominence of 
Polish and Lithuanian OCGs in trafficking drugs obtained in 
the Netherlands to various Nordic and Baltic States, Ireland 
and the United Kingdom, as well as the United States and 
the Russian Federation (EMCDDA–Europol, 2011).
Lithuanian OCGs are brokers for numerous illicit 
commodities in Northern and Western Europe and East 
European non-EU countries. They have connections with 
Russian-speaking OCGs. Their influence extends to other 
Baltic countries, the Nordic countries, Spain (for the sourcing 
of cocaine) and the Russian Federation and Ukraine (for the 
sourcing of precursors for synthetic drugs production) 
(Europol, 2011a).
Chinese OCGs in the Netherlands facilitate the supply of 
synthetic drugs to other parts of the EU via Chinese 
communities in destination markets. Emerging trends include 
a greater prominence of suspects of Moroccan origin in 
production and distribution. Demand in the Middle East has 
resulted in the Balkan routes being used to traffic 
amphetamine and MDMA produced in Europe. Turkish 
OCGs are involved, and it is believed that synthetics are 
often exchanged for heroin.
MDMA shipments from the EU to South America have also 
been observed. Moreover, intelligence confirms that, on 
several occasions, European and Latin American OCGs 
exchanged ecstasy for cocaine. West African criminal 
networks use major EU airports to traffic methamphetamines 
produced in Africa to the Asian market, especially Japan. 
For this purpose they recruit couriers from the EU. Member 
States report increased methamphetamine seizures in 
airports, linked to flights from Africa to Japan, via Europe.
Major synthetic drugs production and trafficking in the EU 
requires the diversion of precursors and the trafficking of 
other chemicals and equipment. Involvement of organised 
crime in the precursors trade follows the legal flow, in terms 
of the existence of legal manufacturing, availability, regular 
trade routes and feasibility of initial diversion. Organised 
crime has an important interest in non-scheduled pre-
precursors and other essential chemicals (e.g. BMK and 
piperonyl methyl ketone (PMK) derivatives or analogous 
substances). This enables them to avoid legislative 
constraints and better camouflage their activities. The 
long-term storage of chemicals in multiple locations is 
another common tactic, the aim being that, even if some 
storage facilities are detected, supply is uninterrupted.
Large-scale producers of synthetic drugs in North-West 
Europe source chemicals from legitimate industry within their 
own countries or, as a result of enforcement measures, from 
other countries. To facilitate production, front companies are 
established to ‘legitimise’ the acquisition of or trade in 
chemicals and equipment and thus conceal from the 
authorities their subsequent diversion for illicit use. For 
example, Dutch and Belgian OCGs or their partners establish 
companies for this purpose in other EU countries. Lithuanian 
and Polish OCGs supply them with precursors in exchange 
for a proportion of the product. Investigations have revealed 
that some groups initially investigated for trafficking precursor 
chemicals are involved in other forms of crime. Available 
intelligence suggests that initial importation of chemicals is 
centred on Central and South-Western European countries.
Dutch OCGs have been cooperating with Chinese OCGs in 
the supply of precursors. Both PMK and BMK, the precursors 
of MDMA and amphetamine, respectively, have traditionally 
been sourced predominantly from China. Until 2005, large 
quantities of BMK were imported into major European ports, 
but between 2005 and 2009 there were no major seizures of 
Chinese-sourced precursors in the EU. MDMA production has 
continued, most likely using PMK diverted via unidentified 
sources and/or new routes and new methods. Forensic 
analysis has confirmed that the PMK identified in MDMA in 
the EU (seized at production sites and in tablets) came from 
China. Intelligence suggests that Chinese OCGs continue to 
supply the EU with chemicals, precursors and pre-precursors, 
disguised as non-scheduled substances or transported by 
using complex routing, often via small companies they control.
The intra-European trafficking of synthetic drugs is closely 
connected with OCGs active in North-West Europe, working 
with groups from the distribution areas, such as Northern 
Europe. Dutch, British and Belgian OCGs seem to control 
large consignments of amphetamine or MDMA to the United 
Kingdom but also to other countries, such as Spain and 
Operation De-Bads in Belgium and the 
Netherlands
In 2011, Belgian police started an investigation into a 
Belgian–Dutch criminal group very active in producing and 
trafficking synthetic drugs, but also cannabis and cocaine. 
After police seized 62 kg of amphetamine in Belgium, it 
became clear that those drugs were destined for a local 
organised crime motorcycle gang. As a result of the 
cooperation between Belgian and Dutch police, 12 arrests 
were made. House searches in Belgium resulted in the 
dismantling and seizure of two cannabis nurseries, 37 kg of 
amphetamine, 100 ecstasy tablets and 5 litres of 
amphetamine oil. Dutch police seized half a kilogram of 
cocaine, 30 kg of ecstasy tablets (150 000 tablets), 5 kg of 
ecstasy powder and 720 litres of chemicals for the 
production of ecstasy tablets.
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challenges these issues represent have been addressed in 
key structural instruments, including the Treaty on the 
Functioning of the European Union (Lisbon Treaty) and the 
Stockholm Programme. At another level, the basis for shared 
and coordinated action between the EU and its Member 
States has been set out in strategic documents that lay the 
foundation for the implementation of policies against illicit 
drugs and the associated health and security challenges. 
Among these are the Internal Security Strategy for the 
European Union, adopted in 2010 by the Council of the 
European Union, and the EU Drugs Strategy (2005–2012) 
and its action plans (see Chapter 1).
The Polish Presidency of the Council of the European Union 
in the second half of 2011 made the reduction of synthetic 
drugs in Europe one of its priorities. An important initiative 
was the development and adoption of the European pact 
against synthetic drugs in October 2011 (Council of the 
European Union, 2011a), established under the EU Drugs 
Strategy (2005–2012) and the EU Drugs Action Plan 
(2009–2012). It also functions as a practical application of 
the Stockholm Programme and the Internal Security Strategy 
Poly-drug trafficking has become more common, especially 
in the European redistribution phase. Many major seizures 
have been part of so-called cocktail loads, including 
substantial quantities of cannabis, cocaine and heroin.
Responses to synthetic drugs trafficking 
at European and international level 
There are inevitably similarities and overlaps in the policy 
responses to related families of drugs, and this section, like 
the previous one, considers not only amphetamine, but also 
methamphetamine and ecstasy, covered in Chapters 6 and 
7, respectively.
European policy initiatives
Synthetic drugs are the second most commonly consumed 
group of illicit substances in Europe, after cannabis, and 
Europol’s OCTA for 2011 clearly identified the role of 
organised crime in the production and trafficking of synthetic 
drugs (Council of the European Union, 2011a). The 
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Figure 18: Prescribed penalty ranges for supplying amphetamine in some European countries
Note:  This graph is based on estimates, with some penalty ranges calculated using an assumed purity or street price. In some cases, the quantities chosen 
span two different penalty ranges in a country. The penalty ranges do not take into account all aggravating or mitigating circumstances or judicial 
discretion, and they are nominal sentences. They are those to be awarded by the judge according to the legal framework, regardless of the actual 
sentences awarded and executed. In Ireland, the prescribed penalty range extends to life imprisonment.
Source: EMCDDA/Legal Correspondents Network.
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information available within and outside the Member States. 
This facilitates the discovery of links between different cases, 
the identification of new criminal targets and target groups 
in addition to initiating, supporting and coordinating the 
intelligence aspects of investigations. At the same time, it 
enhances information exchange, knowledge and experience 
in the area of synthetic drugs, related precursors and 
equipment. The focal point forms part of the AWF on serious 
and organised crime (52). The purpose of the AWF on 
serious and organised crime is to support the competent 
authorities of the Member States as well as third-party 
experts associated with the activities of the analysis groups 
in preventing and combating organised crime and other 
forms of serious crime.
Project Synergy also includes the Europol Illicit Laboratory 
Comparison System (EILCS) and the Europol Ecstasy Logo 
System (EELS), the latter incorporated within the general 
Europol Synthetic Drug System (ESDS). The EILCS collates 
detailed photographic and technical information on 
synthetic drugs production, storage and dump sites. This 
for the European Union (Council of the European Union, 
2011a). Within the Council of the European Union, the 
Horizontal Working Party on Drugs (HDG) and the Standing 
Committee on Operational Coordination on Internal Security 
(COSI) address synthetic drug issues in a complementary 
manner. In developing the pact, the Polish Presidency was 
responding to the EU policy cycle for organised and serious 
international crime and the call for action on synthetic drugs 
raised in the pact on cocaine and heroin (see Chapter 1) 
(Council of the European Union, 2010b, 2011a).
As part of the policy cycle, eight priorities were adopted, the 
fourth of which (crime priority D) aimed to reduce the 
production and distribution of synthetic drugs in the EU, 
including new psychoactive substances (Council of the 
European Union, 2011c). An OAP was designed to implement 
the strategic goals for this crime priority. The OAP provides 
the different policy actors responsible for delivering it with a 
coordination overview of the actions to be achieved. 
Specifically, it focuses on activities designed to have a rapid 
impact on organised criminals, the criminal activities in which 
they are engaged and their commodities. While COSI has the 
overall responsibility for coordinating the implementation of 
the OAP, Poland is the main driver, tasked with the plan’s 
management. Within the plan, each action has an assigned 
leader, responsible for the task’s progress, while the driver 
(Poland) ensures continuous contact among the leaders. In 
order to deliver joint actions, the EMPACT (see Chapter 1) 
framework is utilised as the law enforcement cooperation 
platform for undertaking the work (Council of the European 
Union, 2011e).
The EU and its Member States undertake a range of 
coordinated actions against the production and trafficking of 
synthetic drugs and new psychoactive substances. However, 
differences exist between countries on key issues such as 
penalty levels. One area in which this can be seen is in the 
variation among countries on the threshold quantities and 
sentencing ranges related to these drugs. Figure 18 looks at 
this issue in a selection of countries.
Operational initiatives
Europol plays an important role in the implementation of the 
OAP addressing EU crime priority D, which targets the 
production and trafficking of synthetic drugs (51). One way in 
which Europol does this is through its Project Synergy and its 
dedicated focal point, which gathers and exploits relevant 
(51)  Other EU-level operational law enforcement resources used in the response to the production and trafficking of synthetic drugs include JITs and joint 
customs operations (JCOs) (European Commission, 2011a).
(52)  In line with the new AWF concept endorsed by the Europol Management Board, the Europol Director opened a new AWF on serious and organised crime 
on 15 June 2012. All former AWFs were transformed into focal points.
Training on dismantling illicit synthetic drugs 
laboratories
The manufacture of synthetic drugs by organised crime 
groups within the EU presents a set of challenges for 
authorities. These include the environmental risks of 
unregulated chemical processing and dumping of waste 
products and the dangers faced by law enforcement 
personnel involved in detecting, targeting and dismantling 
illegal laboratories. Therefore, Europol and CEPOL (the 
European Police College), with the assistance of different 
experts from Member States, are organising training 
courses for law enforcement and forensic personnel. Those 
courses provide participants with access to the different 
types of equipment that can be used in clandestine 
laboratories generally, as well as in specific areas, such as 
Eastern Europe. This allows officers to gain experience of 
working with reconstructed facilities for the manufacture of 
synthetic drugs, those used to convert precursors, as well as 
indoor marijuana cultivation set-ups. Three training centres 
are available in Europe: the International Centre for 
Combating Clandestine Laboratories (Poland), Campus 
Vesta—Clan Lab Training Facility (Belgium) and the Fire 
Brigade Facility (the Netherlands).
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programme aims to assist United Nations Member States in 
generating, analysing and using information on the patterns 
of trafficking and use of synthetic drugs in order to design 
effective policies and interventions. It supports countries to 
better monitor trends, including detecting and reporting on 
new trends, while improving methods for exchanging 
comparable information (UNODC, 2008d). Several 
countries, including Australia, Canada, Japan, New 
Zealand, South Korea, Thailand and the United States, help 
fund the programme (UNODC, 2012c). The EMCDDA is a 
member of the programme’s steering group and Europol 
closely cooperates with the programme.
The INCB has developed platforms to monitor the trade in 
licit precursor chemicals that can be used to produce illicit 
drugs. Project Prism focuses on precursors such as P2P (BMK) 
and phenylacetic acid, which can be used to manufacture 
both amphetamine and methamphetamine, as well as the 
methamphetamine precursors ephedrine and 
pseudoephedrine. Under the auspices of Project Prism, a 
series of operations have been undertaken, generating 
information about the changing activities of criminals 
engaged in the trafficking of precursor chemicals. The Project 
Prism Task Force launched Operation PAAD (Phenylacetic 
Acid and its Derivatives), which ran between 31 March 2011 
and 31 August 2011, with 63 countries participating. 
Alongside offline notifications, Operation PAAD utilised the 
PEN system, which was launched in 2006, allowing 
governments to monitor precursor shipments. In total, the Task 
Force received 24 notifications in relation to chemical 
seizures in storage locations and production sites amounting 
to 610 tonnes (INCB, 2012a). The Operation revealed a 
decrease in seizures of ephedrine and pseudoephedrine 
reflecting a switch by traffickers to phenylacetic acid and 
other non-scheduled substances (INCB, 2012b).
enables the matching of seized equipment, materials and 
chemicals, leading to information exchange, backtracking 
investigations and forensic examination with the aim of 
identifying facilitators and criminal groups. The ESDS 
collates modus operandi, photographic and basic forensic 
information on significant seizures. This again enables 
matching of seizures or seized punches, promoting 
information exchange, further investigations and forensic 
profiling targeting criminal groups. In addition, Europol 
specialists provide ‘on-the-spot’ assistance in the dismantling 
of illicit synthetic drugs production sites.
Project Synergy supports and is supported by EU initiatives 
on the forensic profiling of synthetic drugs and related 
precursors for law enforcement purposes, particularly the 
European Drug Profiling System (EDPS) project, whereby 
significant seizures may be forensically matched, leading to 
or supporting ongoing intelligence analysis. The EDPS 
project began in February 2010 and is primarily focused on 
the continued profiling of amphetamine, profiling of MDMA 
and undertaking a feasibility study on the profiling of both 
heroin and cocaine. This activity will contribute to reducing 
the involvement of organised crime in producing and 
trafficking illicit drugs by making forensic profiling part of 
intelligence-led law enforcement operations. Coordinated by 
the Netherlands, eight national law enforcement agencies 
and Europol are involved in the project.
International initiatives
Synthetic drugs and chemical precursors are targeted by 
United Nations initiatives, as described in Chapter 1. In 
September 2008, the Global Synthetics Monitoring: 
Analyses, Reporting and Trends (SMART) programme was 
launched in Bangkok, Thailand, by the UNODC. The 
For conclusions and recommendations relating to the synthetic drugs market, please refer to pages 136–138 in Chapter 10.
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Introduction
Methamphetamine is a synthetic substance that acts as a 
stimulant of the central nervous system, and is closely related 
to amphetamine. The most common salt is the hydrochloride, 
which occurs as a white or off-white powder or as water-
soluble crystals. Illicit products are mostly powders, but the 
pure crystalline hydrochloride, sometimes referred to as ‘ice’, 
may also be found. Since its initial synthesis from ephedrine 
in Japan in 1919, methamphetamine use has evolved over 
the years. Originally it was a legal, experimental substance 
used as a medicine. It was then used as a stimulant by 
fighters in the Second World War before becoming a 
widely prescribed medication. Since the 1970s it has been 
an illicitly used and produced drug, and its popularity has 
increased dramatically in some parts of the world since the 
1990s (EMCDDA–Europol, 2009).
Methamphetamine is probably the most widely consumed 
and manufactured synthetic stimulant in the world 
(UNODC, 2011a, h). In many countries across the globe it 
is reported as the second most prevalent illicit drug after 
cannabis. Today, methamphetamine is associated with 
significant public health, social and security problems 
throughout the world. These are especially apparent in 
North America and Asia. Moreover, the use of the drug is 
also spreading to new areas, notably in the southern 
hemisphere, and to some developing and transitional 
countries. By contrast, in Europe, the production of 
methamphetamine is limited and concentrated in some 
Baltic countries, especially Lithuania, and in the Czech 
Republic and neighbouring countries such as Slovakia and 
Germany.
Although methamphetamine use remains limited in Europe 
as a whole, especially in comparison with the use of other 
stimulants such as cocaine and amphetamine, it is the cause 
of significant harm in some Member States. In the Czech 
Republic, it is the most used illicit drug after cannabis. Since 
the late 1990s, methamphetamine problems have also 
grown in Slovakia. There is also evidence of spread to other 
countries, especially in Eastern and Central Europe, 
including Germany. Moreover, large seizures in recent years 
in the Nordic and neighbouring countries suggest that 
methamphetamine is increasingly available in these 
countries and may to some extent be replacing 
amphetamine in the stimulant market. This, combined with 
the relative ease with which the drug can be produced, and 
some evidence of growing methamphetamine production 
outside the areas in which it has traditionally been found, 
raises concerns that future supply-driven diffusion cannot be 
ruled out. 
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Table 5: Methamphetamine in Europe at a glance
Seizures (2011)
Quantities (kg) (1) EU (including Norway and Turkey) 528 (1 043)
Number EU (including Norway and Turkey) 5 100 (9 500)
Mean retail price (2011) (EUR per gram) Range 8–79
Mean purity (2011) (%) Range (IQR) (2) 16–82 (28.7–67.6)
Notes
(1)  All reporting countries, except four where methamphetamine seizures are not recorded (Spain, Malta, the United Kingdom and Croatia), are 
included in European totals. Methamphetamine tablets are included, assuming a weight of 250 mg per tablet.
(2)  IQR: interquartile range, or range of the middle half of the reported data.
Source: EMCDDA/Reitox national focal points.
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•  Hydriodic acid/red phosphorus: red phosphorus, 
hydriodic acid, solvents and hydrochloric acid are added 
(Europol, 2007c–e).
The hypophosphorous acid/iodine and hydriodic acid/red 
phosphorus methods are most frequently used for the illicit 
manufacture of Pervitin in the Czech Republic. In the two 
remaining methods, the Leuckart method and the reductive 
amination method, methamphetamine is synthesised from 
1-phenyl-2-propanone (BMK).
All of these methamphetamine production methods depend 
heavily on the availability of the precursors and the know-
how of the producers. However, note that, while the 
production methods using ephedrine or pseudoephedrine 
are mainly found in Germany, the Czech Republic, the 
Netherlands and Slovakia, methamphetamine seized from 
Lithuanian OCGs is produced using BMK.
The production of methamphetamine in Europe appears to 
be limited compared with other regions of the world. 
However, information on production facilities in Europe is 
not standardised, and as a result it is difficult to form a clear 
picture of trends in production. For instance, whereas the 
EMCDDA and the UNODC receive reports on all production 
facilities dismantled at national level, Europol mostly collects 
data on larger-scale production facilities.
Global overview
The UNODC estimates that there were between 14 million 
and 56 million users of amphetamines (53) worldwide in 
2009, a significant proportion of whom live in Asia, where 
the synthetic stimulant most used is, overwhelmingly, 
methamphetamine (UNODC, 2011a).
Global seizures of methamphetamine increased markedly in 
2010, totalling 45 tonnes compared with 31 tonnes in 2009 
and 22 tonnes in 2008. This was mostly due to large 
increases in seizures in East and South-East Asia, where 
20 tonnes, or almost 50 % of the global total, was seized in 
2010, and in North America, especially Mexico, where 
seizures doubled to reach about 13 tonnes (UNODC, 
2012a). In a European context, seizures totalled about 
630 kg in 2010 (EMCDDA, 2012a). Asia, North America 
and Oceania have been the main world regions for 
production and consumption of methamphetamine for about 
15 years. Illicit methamphetamine is predominantly 
produced near its main consumer markets in East and 
South-East Asia, North America and Oceania. Nevertheless, 
since the mid-2000s methamphetamine production and use 
have spread to new countries, including Iran, South Africa 
and Nigeria.
Importantly, in the same period a trend towards the 
transcontinental trafficking of the drug from Nigeria and Iran 
to Asia has emerged. Nigerian and Iranian couriers are 
frequently arrested in possession of significant amounts of 
methamphetamine at airports in countries such as Indonesia, 
Japan, Korea, Malaysia and the Philippines (UNODC, 
2011h), as well as Turkey (KOM Department, 2012).
Production and precursor issues
There are five known methamphetamine production methods 
in Europe. The three most common are the lithium/ammonia, 
hypophosphorous acid/iodine and hydriodic acid/red 
phosphorus methods. All three are simple, one-step reactions 
of ephedrine or pseudoephedrine carried out using glass or 
stainless-steel equipment. In addition to the precursor 
(pseudo)ephedrine, the following chemicals are used:
•  Lithium/ammonia: lithium or sodium metal, ammonia, 
solvents and hydrochloric acid are needed.
•  Hypophosphorous acid/iodine: iodine, hypophosphorous 
acid, solvents and hydrochloric acid are added.
(53)  When this report refers to amphetamines in the plural, this includes amphetamine, methamphetamine and related substances such as fenethylline, 
methylphenidate, cathinone, etc. but not ecstasy or its relatives. The two groups together—amphetamines and the ecstasy family—are sometimes referred 
to as amphetamine-type stimulants (ATS).
The basics of methamphetamine production
The production of methamphetamine (and of synthetic 
drugs generally) is not labour intensive, it is easily 
concealed and protection requirements are much lower 
than for plant-based drugs. The methamphetamine 
manufacturing process is flexible, as it is not very difficult to 
synthesise the drug from a range of precursors and other 
chemicals through a variety of basic, often one-step, 
chemical processes. If one chemical is unavailable, another 
can be used instead. The scale of production is also 
flexible, as the drug can be manufactured in facilities 
ranging from ‘kitchen labs’ using rudimentary know-how 
and technology and operated by the users themselves, to 
industrial premises equipped with the latest technology and 
run by organised criminal gangs. A final factor is that 
methamphetamine laboratories can be set up rapidly to 
supply a specific order and taken apart equally quickly to 
avoid detection. The equipment can be stored in a car, van 
or lorry and set up at another location.
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Pervitin in the Czech Republic
In the Czech Republic, the illegal production and use of 
methamphetamine has been an important element in the 
country’s drug problem since the 1970s. At that time, a 
simple formula for producing methamphetamine, known 
locally as Pervitin, was rediscovered. Production was 
probably based initially in Prague but quickly spread to the 
Czech—but not the Slovak—parts of Czechoslovakia. 
Production was usually carried out by small groups of 
user-producers and was facilitated by the existence of the 
VUAB factory, which was an important manufacturer of 
ephedrine for the global licit market. Some of this output 
was diverted to the illicit market. Other pharmaceuticals 
that contain ephedrine or pseudoephedrine, such as 
Solutan (later Modafen and Paralen Plus), were widely 
available and were used in the production of 
methamphetamine using the ‘reduction method’, together 
with other freely available chemicals. Although the VUAB 
factory closed down production in 2003 (Griffiths et al., 
2008), illicit (but usually small-scale) methamphetamine 
production is still common in the Czech Republic.
Figure 19:  Methamphetamine production installation dismantled 
in Schiedam, the Netherlands, June 2011
Source: Dutch National Police — LFO via Europol.
Table 6:  Dismantled methamphetamine  
production facilities reported to the 
EMCDDA and UNODC, 2010
Country UNODC Reitox national reports
Austria   5 —
Bulgaria   2   2
Czech Republic 307 307
Germany  13    16 (1) 
Hungary   1   1
Netherlands —   2
Note
(1)  The German Reitox report states: ‘detected production sites were 
mainly small laboratories that produced methamphetamine’. In 
addition, most of the production facilities dismantled in the 
Czech Republic are likely to be small-scale ‘kitchen-type’ 
facilities where small amounts of drugs are produced.
Sources: UNODC (2012d), Reitox (2011).
In 2010, the EMCDDA received 328 reports of dismantled 
methamphetamine production sites from five Member 
States (see Table 6). Information on dismantled 
methamphetamine facilities in 2011 and 2012 is available 
only from Europol, and will refer mostly to large-scale 
production. Germany seized 10 methamphetamine 
facilities in 2011 while Bulgaria seized four, the 
Netherlands two and the United Kingdom one. One facility 
was seized in Ireland in 2012.
Intelligence available to Europol suggests that the largest 
quantities of methamphetamine are produced in mid-scale 
laboratories located in Baltic countries, such as Lithuania, in 
order to supply some Scandinavian markets and the United 
Kingdom. No methamphetamine production facilities were 
dismantled in Lithuania, Latvia or Estonia in 2010 or 2011, 
but in 2009 an illegal methamphetamine laboratory of 
medium capacity was dismantled in Lithuania (Lithuania: 
Reitox, 2010). Production in the Czech Republic and 
neighbouring countries such as Germany and Slovakia is 
usually on a smaller scale, occurring mainly in ‘kitchen-size’ 
laboratories, and is destined to be consumed in the region 
where it is produced. Europol information also indicates that 
methamphetamine is produced in the Netherlands, Poland 
and the United Kingdom. Whereas most of the 
methamphetamine produced in Poland and the United 
Kingdom is probably for domestic use, that made in the 
Netherlands seems to be destined for export to 
Scandinavian countries.
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and pseudoephedrine have been seized since 2005 
(INCB, 2012a). This is in line with the fact that these regions 
are also those where most methamphetamine is 
manufactured and consumed in the world. The INCB also 
notes that seized amounts of ephedrine and 
pseudoephedrine have dropped drastically at world level 
over the past 10 years. Although this may reflect increased 
efficiency of the international control system for precursor 
chemicals, it may also reflect challenges in controlling 
diversion of medical preparations and changes in precursor 
trafficking methods, methamphetamine manufacturing 
methods (increased reliance on BMK and less on ephedrine 
and pseudoephedrine) and trafficking routes, for instance 
via Africa, Central Asia and the Balkans. In addition, 
Vietnam and Taiwan have been identified as significant 
sources of ephedrine and pseudoephedrine shipments 
diverted in 2011.
Importantly, it is also likely that countries traditionally 
associated with the heroin trade, such as Afghanistan, Iran, 
Iraq, Jordan, Pakistan, Syria and Turkey, which report 
legitimate requirements for ephedrine or pseudoephedrine 
(or both) much higher than the international per country 
average, are sources and/or destinations for diverted 
ephedrine and pseudoephedrine (INCB, 2012a).
It is difficult to report accurately on seizures of ephedrine and 
pseudoephedrine in Europe in recent years as sources diverge 
considerably in the amounts reported seized (Table 7).
However, Europol indicates that some ephedrine is diverted 
within the EU or obtained from regions outside the EU, in 
Eastern Europe and the Western Balkans. In addition, 
pseudoephedrine is extracted from over-the-counter 
pharmaceutical preparations available in a number of EU 
Member States. In the absence of harmonised controls, illicit 
synthetic drug producers in Member States where sales of 
Precursors
Globally, illicit methamphetamine is frequently synthesised 
from the precursors ephedrine and pseudoephedrine, which 
are currently produced by extraction from the ephedra plant, 
or by chemical synthesis. It may also be manufactured from 
1-phenyl-2-propanone (P2P), also known as BMK, and 
phenylacetone, although in Europe BMK is more commonly 
used to manufacture amphetamine (54). Ephedrine, 
pseudoephedrine and BMK in bulk form are under 
international control and listed in Table I of the 1988 United 
Nations Convention. However, the control regime applied to 
pharmaceutical preparations containing ephedrine and 
pseudoephedrine (e.g. cold remedies in tablet form) is not 
as strict (UNODC, 2008c).
BMK, ephedrine and pseudoephedrine are produced and 
traded globally for legitimate purposes. However, the global 
legitimate trade of ephedrine and pseudoephedrine is much 
larger than that of BMK, since BMK has few legitimate 
applications. For instance, the INCB (2012a) has reported 
that global trade in BMK amounted to a total of 17 700 
litres in 26 shipments in 2011. In contrast, there were 3 965 
shipments of ephedrine and pseudoephedrine in bulk and 
pharmaceutical preparations in 2011, which amounted to 
1 130 tonnes and 1.4 million tablets of pseudoephedrine 
and 137 tonnes of ephedrine. As a result, it is more difficult 
to prevent diversion of ephedrine and pseudoephedrine to 
illicit uses.
In 2011, a total of 26.8 tonnes of ephedrine and 
pseudoephedrine in bulk and pharmaceutical preparations 
was seized globally. Four countries, China, India, Mexico 
and the United States, accounted for nearly 85 % of this 
total, while large amounts were also seized in Australia 
and New Zealand. East and South-East Asia and North 
America are the regions where most quantities of ephedrine 
Table 7:  Seizures of ephedrine and pseudoephedrine in the EU, 2009–2011
INCB European Commission
2009 2010 2011 2009 2010 2011
Ephedrine (bulk) 245 kg 527 kg 563 kg 685 kg 1 206 kg N/A
Ephedrine (preparations) 814 kg 33 kg   2 kg  10 kg    12 kg N/A
Pseudoephedrine (bulk) 503 kg 67 kg  36 kg 186 kg 1 054 kg N/A
Pseudoephedrine (preparations) 775 kg 439 kg + 326 941 units (CZ)+ 462 units (DE) + 336 units (SK)  94 kg 517 kg   110 kg N/A
Sources: INCB (2012a), European Commission (2011a).
(54) Issues relating to BMK and phenylacetic acid are reviewed in greater detail in Chapter 5 of this report.
88
EU drug markets report: a strategic analysis
Within Europe methamphetamine has historically been 
associated with the Czech Republic. Explaining the 
popularity of the drug within the country, Zábranský (2007) 
points to stringent border controls during the communist 
period, meaning that any illicit drugs had to be produced 
locally. The ready availability of the precursors, a relatively 
simple production process and the development of 
cooperative groups (squads) with the skills to ‘cook’ the drug 
resulted in a local supply of methamphetamine from the 
early 1970s onward. Distribution of the drug is said to have 
remained largely within the squads until the fall of 
communism in 1989, following which the now established 
drug could reach a broader market.
Based on the most recent survey in 2010, some 1.4 % of 
the population of the Czech Republic aged 15–64, or just 
over 100 000 individuals, have tried methamphetamine in 
their lifetime. Amongst people aged 15–34 (the age group 
most associated with drug use), 0.8 %, or just over 
24 000 individuals, are estimated to have used the drug 
in the last 12 months. Complementing the data on low 
levels of prevalence, treatment data provide some 
indication of the scale of problem use: in 2010, almost 
68 % of clients entering treatment for the first time were 
reported as citing Pervitin (methamphetamine) as their 
primary drug.
In Slovakia, a 2006 survey estimated that 1.2 % of the 
population aged 15–64, or just over 47 000 individuals, 
had tried the drug at least once, and 0.7 % of 15- to 
34-year-olds, or approximately 12 000, had used the drug 
within the last 12 months. Since 2000, the proportion of 
first-time entrants to treatment citing Pervitin as their primary 
drug has increased steadily, reaching 41 % of a total 
number of 1 018 clients in 2010. This was matched by a 
steady decline in opioid treatments, and for the first time 
methamphetamine now accounts for the largest number of 
clients entering treatment in Slovakia.
Information from Sweden and Norway specifically on 
methamphetamine is available from studies targeting 
specific groups. These suggest that methamphetamine has a 
presence in the user market in these countries, along with 
the more traditional amphetamine. For example, on the basis 
of analysis of samples taken from persons detained by the 
police for minor drug offences between 2005 and 2009, 
the Swedish national focal point suggests that 
‘methamphetamine is relatively common in the Swedish drug 
scene although mainly cut with amphetamine’ (Sweden: 
Reitox, 2011).
this medication are restricted travel to neighbouring 
countries in order to source supply (Europol, 2011a). Bulk 
shipments of ephedra extracts, ephedrine and 
pseudoephedrine may also pass through the EU on their 
way to other regions, for instance North America. Some 
cases of exchange of ephedrine or pseudoephedrine for 
cocaine by criminal groups have been detected in past 
years (Europol, 2008).
Consumer markets for methamphetamine 
in Europe
The user market for methamphetamine in Europe is largely 
restricted to a group of small, geographically close, 
countries. Within these countries, however, the drug has a 
significant impact; and there are some small signs that it is 
entering new markets elsewhere.
Central to understanding the methamphetamine user market 
is distinguishing this drug from its close relative, 
amphetamine. Unfortunately, in many cases, the available 
data do not allow this. Consequently, this section draws 
primarily on specific country reports that distinguish between 
the two drugs, supplemented by monitoring data on 
prevalence and treatment.
As with stimulants generally, there is evidence of 
recreational use within specific population groups and of 
more problematic use as reflected in treatment data. Of 
concern with methamphetamine is the potential for 
increased problems resulting from a move from the powder 
format traditionally found in Europe to the higher purity 
crystalline format evident in the United States and Australia, 
which is smokable (55). However, to date there is little 
evidence of smoking of methamphetamine in Europe, and 
any change would be noteworthy.
There are two countries where methamphetamine dominates 
the stimulant market: the Czech Republic, with a history of 
local production and use stretching back to the early 1970s, 
and more recently Slovakia, where the drug has increased 
in importance since the turn of the century. In these two 
countries use of amphetamines is taken to mean 
methamphetamine use. There is evidence of 
methamphetamine in the stimulant markets in Norway and 
the countries around the Baltic Sea, particularly those with a 
history of amphetamine use and injection. In these countries 
amphetamine is still the dominant stimulant. In addition, 
there is concern that the drug may be gaining in importance 
in new, potentially large, markets, such as Germany.
(55) Yielding a faster ‘hit’ than snorting and thus presenting greater risks of dependence.
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2011). It is not certain that what is referred to as crystal 
methamphetamine is the same product known as ‘ice’ in 
other countries such as the United States and Australia. In 
late 2011, drug users in Athens were reporting the 
availability of limited amounts of methamphetamine in its 
crystalline format, known locally as ‘sisa’. Further data are 
required to judge the extent or permanence of this 
phenomenon. All the indicators start from low baselines, and 
the drug is still of relatively low importance, although, 
clearly, the potential for a growth in popularity is cause for 
some concern.
Overall, the group of countries where methamphetamine 
predominates or shares the stimulant market with 
amphetamine accounts for less than 10 % of the 15- to 
64-year-old population in Europe. However, the drug 
dominates the user market for amphetamines in the Czech 
Republic and Slovakia, and is more apparent in Estonia, 
Latvia, Lithuania, Finland, Sweden and Norway than in the 
past. The user market is diverse, with some recreational use, 
but on the basis of the treatment data there is a suggestion 
of substantial injecting and problematic use in this group of 
countries.
Trends in methamphetamine production 
and trafficking in Europe
Seizures
Based on seizure data, trafficking in methamphetamine 
would appear to be limited in Europe. The maximum seized 
in one year was 1 tonne (involving 9 500 cases) in 2011. 
The overall increase in both number of cases and quantity 
of methamphetamine recovered in the last decade (Figure 
20) may suggest a general expansion of trafficking in 
methamphetamine, but identification and reporting of the 
substance has also increased during the period, making 
interpretation of the trend difficult. The quantities 
intercepted have increased sixfold since 2006 (when data 
first became available for most countries) while the number 
of cases has nearly tripled over the same period. Rather 
than a general increase in the size of the shipments 
intercepted at European level, this reflects a few large 
operations across the region. Most of the increase in 
quantities intercepted in Europe in 2011 is due to 
exceptional seizures in Lithuania and Turkey.
In 2010, the Norwegian national focal point reported that in 
2009, for the first time, methamphetamine was the second 
most prevalent substance after alcohol in samples taken from 
drivers (32 %; equivalent to 1 480 samples) (Norway: 
Reitox, 2010). Although reported as representing a fourfold 
increase since 2001, caution was advised in that, ‘It is still 
reasonable to believe that amphetamine and 
methamphetamine are used interchangeably, depending on 
what is available on the market. There are no clear 
indications of a particular demand for methamphetamine.’ In 
the following year methamphetamine was found in 30 % of 
samples, making it the fourth most common substance in 
drivers’ blood samples, after alcohol, amphetamine (32 %) 
and cannabis (31 %), indicating a change in the ranking of 
drugs but the continued high prevalence of 
methamphetamine (Norway: Reitox, 2011). Interpreting 
findings from these surveys is complicated by the fact that 
with time methamphetamine may convert to amphetamine 
within the body. Nevertheless, in both Sweden and Norway 
targeted studies provide an indication of the drug’s place in 
the market.
In Finland, Latvia, Lithuania and Estonia, the main evidence 
of methamphetamine presence on the market comes from 
seizures data, where amphetamine is also in evidence. In 
the absence of any clear indication to the contrary, it would 
seem that amphetamine continues to dominate the user 
markets.
Returning to treatment data for amphetamines (both 
methamphetamine and amphetamine), in the countries 
where methamphetamine use is reported, it is notable that a 
high proportion of clients entering treatment for the first time 
and citing amphetamines as their primary drug report 
injection of the drug. No data are available for Norway, but 
in the Czech Republic, Estonia, Latvia, Lithuania, Finland 
and Sweden this proportion ranges from 50 % to 79 %. 
Only in Slovakia is it substantially lower, at 28 %. There 
appears to be an association of high proportions of injecting 
amphetamines and the presence of methamphetamine in the 
market.
Evidence of methamphetamine use in other countries is 
sporadic, although in 2011 Germany reported an increase 
in methamphetamine users known to the police and in the 
number of methamphetamine laboratories dismantled, as 
well as an almost fourfold increase in the amount of ‘crystal 
methamphetamine’ seized in the country (Germany: Reitox, 
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(56) Four countries—Spain, Malta, the United Kingdom and Croatia—do not report methamphetamine seizure data.
in these countries never amounted to more than a few 
kilograms a year until 2010, when the total quantity 
recovered rose to 21 kg in the Czech Republic and 27 kg in 
Germany, followed in 2011 by seizures of 20 kg and 40 kg 
respectively. The average size of seizures in the Czech 
Republic and Germany, commonly between 15 and 50 g 
over the last decade, is larger than in Slovakia (between 1 
and 6 g), which may confirm recent media reports about the 
existence of frequent methamphetamine trafficking activities 
between Germany and the Czech Republic.
Baltic and Nordic area
The other route reportedly carries larger quantities of the 
drug. It links the Baltic States predominantly to the Nordic 
area (see Chapter 5, section ‘Trends in organised crime 
Trafficking areas
Europol has identified two main intra-European 
methamphetamine trafficking routes.
Central Europe
On the first route, methamphetamine produced in the Czech 
Republic is exported by car to bordering countries, 
especially Germany (mainly Bavaria and Saxony) and 
Slovakia, where the drug is also produced in small-scale 
units, destined mainly for the domestic market.
These three countries have a similar profile, reporting a 
large number of very small seizures of methamphetamine, 
probably resulting from the dismantling of small production 
units and interceptions at retail level. Quantities intercepted 
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Figure 20: Seizures of methamphetamine in Europe, 2001–2011 (56)
Note:  All 26 European countries reporting methamphetamine seizures are included, except the Netherlands and Poland where Number of seizures data are 
not available. The total amounts represent the sum of the quantities of methamphetamine seized under different forms; for calculation purposes, tablets 
were assumed to weigh 250 mg.
Source: EMCDDA/Reitox national focal points, EMCDDA (2012a).
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followed at a distance by Finland, with annual quantities of 
between 15 and 40 kg. However, data on the average size 
of interceptions show that the large quantities recovered 
every year in Norway result from thousands of very small 
seizures (50 g on average in 2009–2011), while in the other 
two countries seizure cases are usually larger (150–170 g 
on average in 2009–2011). These may suggest a higher 
targeting of the lower segments of the distribution chain in 
Norway, as compared with Sweden and Finland.
Outside these two main trafficking hotspots in Northern and 
Central Europe, recent developments suggest that some 
methamphetamine may also be produced in Western 
Europe. Substantial amounts of methamphetamine have 
recently been seized in the Netherlands (10 kg in 2007, 
45 kg in 2010 and 35 kg in 2011) and in Belgium (39 kg in 
2010). It is too early to talk about a new trend there since 
there were no reports of interceptions in these two countries 
in other years.
Europe: an emerging transhipment methamphetamine 
area?
A new trend in trafficking in methamphetamine produced in 
West Africa has recently been discerned. Major EU airports 
are used in transit to the Asian market, mainly Japan. 
Member States report an increased number of such seizures, 
with EU and African citizens commonly involved as couriers.
A similar situation has been observed in Turkey, where 
quantities seized tripled between 2009 and 2011, to 350 kg 
(see Figure 20). The drug, mostly originating in Iran, transits 
Turkey destined for Asian-Pacific countries such as Malaysia, 
Thailand, Japan, Indonesia and Australia. It is mainly 
smuggled via air couriers (80 % of whom are of Iranian 
origin) and cargo deliveries (KOM Department, 2012).
In addition, South-East Europe may also become a source of 
methamphetamine as seizures of methamphetamine 
manufacturing facilities have occurred in Bulgaria in recent 
years (see Table 6).
involvement in amphetamine and other synthetic drugs in 
Europe’). Currently, the majority is transported by car from 
the Baltic States and Poland via Germany to Denmark and 
then Sweden and Norway.
Seizure data appear to confirm that the traffic in 
methamphetamine across the Baltic Sea involves larger 
amounts than the cross-border trafficking of Czech-
manufactured Pervitin. Of the three Baltic States, Lithuania is 
clearly intercepting the largest quantities of 
methamphetamine each year, commonly between 15 and 
50 kg, compared with annual seizures in the range of 
5–15 kg in Latvia and small amounts, commonly less than a 
kilogram, in Estonia. However, record quantities of 
methamphetamine have recently been intercepted in the 
three countries (52 kg and 134 kg in Latvia and Lithuania, 
respectively, in 2011 and 38 kg in Estonia in 2008), 
confirming that the area is the site of smuggling of relatively 
large consignments of the drug. The comparatively large 
size of cases in Lithuania since 2006 may suggest the major 
role of the country as an exporter of methamphetamine 
since then, with seizures averaging around 500 g in the 
period 2009–2011, 10 (or more) times larger than average 
seizures in the other two Baltic countries.
The Nordic countries have long been identified as major 
amphetamine markets with respect to problematic drug use; 
however, it would seem that methamphetamine could be 
gaining ground there. It is likely that methamphetamine has 
always been present, albeit less consumed than today, but 
the distinction between the two products has become more 
frequent in recent years, thus increasing the visibility of 
methamphetamine on the market. The methamphetamine 
used in these countries is reportedly manufactured mainly 
from BMK, as is amphetamine, suggesting a likely blurring, 
in some cases, of the boundaries between the two 
production and trafficking chains. Norway has for some 
time been the main seizing country in Europe for 
methamphetamine, with a total of 540 kg seized during the 
period 2009–2011. Sweden is the second largest seizing 
country with 370 kg intercepted over the same period, 
For conclusions and recommendations relating to the synthetic drugs market, please refer to pages 136–138 in Chapter 10.
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Introduction
MDMA was first synthesised in 1912 by a German 
pharmaceutical company trying to develop haemostatic 
(anti-bleeding) medication (Freudenmann et al., 2006). 
MDMA remained relatively unused and out of the public 
eye until 1978, when the first reports of its 
psychopharmacological effects in humans were published 
in the United States (Benzenhöefer and Passie, 2010).
In the late 1970s, MDMA was used by some 
psychotherapists as an aid for enhancing communication 
and emotional expression, and increasing empathy and 
pro-social feelings. By the early 1980s, MDMA had reached 
recreational markets and, still being legal, it was sold and 
distributed in US nightclubs, initially in Texas (Shulgin, 
1990).
MDMA emerged on the European market in the mid-1980s, 
originally smuggled from the United States. It soon gained 
popularity, becoming embedded, in particular, within the 
electronic dance and rave movements of Spain and the 
United Kingdom. The late 1980s and early 1990s saw the 
phenomenon of rave/dance parties exported back to the 
United States and spreading globally, taking with it the use 
of MDMA in a dance context. The use of MDMA across the 
globe began to increase although manufacture of the 
substance appeared to remain primarily with Europe. The 
popularity of ecstasy has ebbed and flowed over the last 
decade, and production is now global.
Global overview
Somewhere between 10 and 28 million people worldwide 
may have used ecstasy in the past year (0.2–0.6 % of the 
general population aged 15–64). Consumption appears to 
be on the decline in Oceania, typically the highest use 
region; however, there is some evidence of a resurgence in 
both the US and European markets (UNODC, 2012a).
Although MDMA first became established as a 
recreational drug in the United States in the early 1980s, 
Europe soon took over as the world’s leading source of the 
drug. In particular, Belgium and the Netherlands were 
noted as major global producers of MDMA with industrial-
scale manufacturing capacity and high levels of 
organisation, sophistication and professionalism (UNODC, 
2003b). Production of ecstasy is now global, with North 
America, Asia and Oceania all reporting large-scale 
production.
The reported global number of dismantled laboratories 
producing ecstasy declined from 52 in 2009 to 44 in 
2010, but an increase in the size and production capacity 
of dismantled facilities was noted in some countries. Most 
of the seized laboratories were situated in Australia (17), 
Canada (13) and Indonesia (12). Compared with 2009, 
laboratory seizures fell in Indonesia but remained relatively 
stable in both Australia and Canada. In addition to the 12 
laboratories dismantled in Indonesia in 2010, three 
tableting facilities were detected, leading to speculation 
that the country may be taking over from the Netherlands 
as the main source of ecstasy in Asia (UNODC, 2011a, 
2012a).
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Ecstasy
Ecstasy refers to synthetic substances that are chemically 
related to amphetamines, but which differ to some extent 
in their effects. The best-known member of the ecstasy 
group of drugs is 3,4-methylenedioxy-methamphetamine 
(MDMA), but analogues are also sometimes found in 
ecstasy tablets (MDA, MDEA) (1). MDMA is mainly 
produced in tablet form and with a ‘logo’ imprint. Since 
1999, when Europol started identifying tablets and their 
logos, some 560 primary logos have been recorded, with 
around 1 860 variations. Since 2005, tablets that are 
marketed as MDMA or have a logo associated with 
‘ecstasy’ have increasingly been shown to include other 
illicit substances and synthetic new psychoactive 
substances.
(1)  In this chapter we use the term ecstasy in a broad sense, to 
refer to substances that contain MDMA or its analogue drugs 
or to substances that are presented as ecstasy. We use the term 
MDMA only for findings specific to MDMA.
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suspicious since June 2010. In addition, between 2010 and 
mid-2011, Mexico recorded large seizures of methylamine (a 
non-scheduled substance used to manufacture MDMA) 
arriving from China and totalling 154 000 litres (INCB, 2011).
Overall, ecstasy supply appears to have experienced a 
significant decline since 2008, owing mainly to dramatic 
drops in Europe. This may have been a result both of 
successful enforcement activities targeting precursor 
chemicals and of a subsequent displacement of ecstasy from 
some markets by new psychoactive drugs. There are, 
however, indications that the global market for ecstasy is 
undergoing a resurgence, with large increases in seizures 
observed in East and South-East Asia, and increases in 
seizures in Oceania as well as increases in availability and 
use of ecstasy in the United States (UNODC, 2012a).
After a peak in world seizures in 2007, at 16.6 tonnes, 
global ecstasy seizures experienced a dramatic drop in 
Detected production of ecstasy appears to occur relatively 
close to the consumer markets in East and South-East Asia, 
North America and Oceania. Canada appears to be the 
primary source of ecstasy for the United States, with seizures 
of tablets at border entry points reaching a record high of 
3.9 million in 2010, with the average size of seizures also 
increasing (UNODC, 2012a). Seizures of ecstasy tablets 
both within Canada and identified as coming from Canada 
rose from 405 kg in 2009 to 529 kg in 2010; the majority 
was destined for the United States, and some for Australia, 
Malaysia and Peru. The increase in Canadian ecstasy 
production appears to have occurred in parallel with a 
decrease in European production levels (INCB, 2011), 
suggesting that Canada is emerging as a global producer 
and exporter of ecstasy.
Mexico may also be emerging as an ecstasy producer, with 
2 500 litres of safrole (an MDMA precursor) seized at an 
airport in 2011, and three shipments of safrole reported as 
Table 8: Ecstasy in Europe at a glance
Age group  
(years)
Estimated number 
of users (million)
% of European population 
(range between countries)
Consumption (1)
Lifetime
15–64 11.5 3.4 (0.4–8.3)
15–34 7.5 5.7 (0.6–12.4)
Last year
15–64 2 0.6 (0.1–1.6)
15–34 1.5 1.3 (0.2 – 3.1)
Number (% of all drug admissions)
Drug treatment (2) (2010)
All admissions 951 (0.2 %)
First admissions 485 (0.3 %)
Number (% of all drug offences)
Drug law offences (2011)
All offences 13 489 (1.1)
Offences for drug use/possession for use 10 477 (1.0)
Offences for drug supply 3 017 (1.5)
Seizures (3) (2011)
Quantities (tablets) EU (including Croatia, Norway and Turkey) 4 million (5.4 million)
Number EU (including Croatia, Norway and Turkey) 9 600 (12 500)
Mean retail price (2011) (EUR per tablet) Range (IQR) (4) 4–17 (5.0–9.0)
Mean MDMA content (2011) (mg per tablet) Range (IQR) (4) 43–133 (64.2–89.6)
Notes
(1)  European estimates are computed from national estimates weighted by the population of the relevant age group in each country. They are based 
on surveys conducted between 2004 and 2010/11 (mainly 2007–2010) and therefore do not refer to a single year.
(2)  Information is available on about 470 000 drug users entering specialist treatment in Europe (EU, Norway, Croatia, Turkey). Units coverage may 
vary between countries.
(3)  The 2011 figures should be considered as estimates; where 2011 data were not available (United Kingdom), 2010 data were used in their place. 
Ecstasy seizures in other forms (liquid, powder) are not included.
(4)  IQR: interquartile range, or range of the middle half of the reported data.
Sources: EMCDDA/Reitox national focal points, EMCDDA (2012a).
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Precursor seizures
In 2010, world seizures of PMK amounted to 2 litres, down 
from 40 litres in 2009, while seizures of safrole fell from 
1 048 litres in 2009 to 168 litres in 2010. In the EU, no 
PMK was seized in 2010, suggesting that it is no longer 
used as the main precursor for the manufacture of ecstasy. It 
appears that safrole has taken over, despite only four 
seizures being made, totalling 85 litres, all of which 
occurred in the Netherlands. In 2008, Estonia reported a 
large seizure of 1 841 litres of safrole, and in 2009 
Lithuania reported the seizure of 929 litres, potentially 
indicating domestic production (INCB, 2011). The size of the 
ecstasy market far outweighs the size of the precursor 
seizures, indicating that a large portion of the precursor 
illicit trade remains undetected.
Developments in precursors
One of the outcomes of strengthened controls and targeted 
seizures of the main MDMA precursor chemical PMK has 
been an increase in the use of non-scheduled chemicals, the 
so-called ‘masked precursors’ (57), in the manufacture of 
MDMA. One such example is methyl-3-[3’4’-
(methylenedioxy)phenyl]-2-methyl glycidate (MMDMG), also 
known as PMK glycidate. MMDMG is a synthesised 
derivative of piperonal and, as yet, is not a controlled 
substance. It was first detected in Australia in 2004 
(UNODC, 2012b). Evidence of its use emerged in Europe in 
2010, when about half a kilogram of the substance was 
seized in an MDMA and methamphetamine production site 
in the Netherlands, along with possible instructions for how 
to convert it into PMK.
The use of this masked precursor in the manufacture of 
ecstasy appears to be increasing throughout Western and 
Central Europe, apparently replacing PMK. In the 
Netherlands, Europe’s main producer of ecstasy, 1.2 tonnes 
of MMDMG was seized in 2010, 1 tonne of which was 
intercepted in a single case detected as a result of a 
mis-declared airfreight shipment arriving from China. Also in 
2010, Slovakia reported to Europol a seizure of 700 litres of 
MMDMG. In March 2011, Denmark seized 800 kg of 
MMDMG via air cargo that was reportedly one in a series 
of shipments destined for the Netherlands and which had 
originated in China (INCB, 2011). MMDMG has also 
reportedly appeared in Belgium, Estonia and Poland 
(UNODC, 2012b).
2008, to nearly 6 tonnes, and further declined to under 
4 tonnes in 2010 (UNODC, 2012a). North America is 
currently the largest seizing region, accounting for 20 % of 
global seizures (13 % in the United States and 7 % in 
Canada), while West and Central Europe represent the 
second largest seizing region, with 13 % of global seizures.
Production and precursor issues
The Netherlands probably emerged as the main European 
ecstasy centre at the end of the 1980s by virtue of its pre-
existing expertise in synthesising drugs and its well-established 
trafficking routes. Until then, MDMA had been imported in 
tablet form from Spain and in powder form from the United 
States, to be locally tableted. Ecstasy was also reported to be 
manufactured by a German pharmaceutical company until it 
was prohibited. Originally manufactured by people involved 
in the drug scene and in the rave culture, by the early 1990s 
organised crime had established its hold on the production of 
ecstasy in the Netherlands (Blickmann, 2004).
Precursors
The majority of the precursors and pre-precursors used to 
manufacture MDMA are sourced from Asia, with 
suggestions that OCGs are responsible for managing the 
development of large-scale production and marketing in 
Europe, including the importation of precursors.
The main precursor chemical associated with the 
manufacture of MDMA is 3,4-methylenedioxyphenyl-2-
propanone (3,4-MDP-2-P), also known as PMK. In addition, 
sassafras oil, safrole, isosafrole and piperonal can be used 
to manufacture either PMK or MDMA. All of these 
substances are under international control, but also have 
legitimate uses for the cosmetic and mosquito repellent 
industries (INCB, 2011).
Although Europe has previously been viewed as a major 
global source of MDMA, its dominance of global ecstasy 
supply has declined steadily since 2004. In particular, no 
notable seizures of PMK have been reported since 2007. 
However, underlying this finding may be some retooling of 
operations, with OCGs making use of alternative chemicals 
and also developing and using pre-precursors to PMK. In 
2009, the EU signed agreements with China relating to 
precursor control and in particular the importation of PMK, 
which is likely to have been a factor in the decline of PMK 
availability for illicit use in Europe.
(57)  Precursors temporarily converted into other non-controlled substances are called ‘masked precursors’. They are converted back into essential precursors 
through the use of easily available chemicals.
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manufacture of MDMA. It uses pressure reaction vessels in 
combination with hydrogen gas and a catalyst (often 
platinum oxide) to synthesise PMK.
Seizures of production facilities
There has been a decline in the numbers of ecstasy 
laboratories dismantled annually in Europe, from over 20 in 
2002 to five or fewer from 2009 onwards (Figure 22). 
Ecstasy manufacture in Europe may have peaked in 2000, 
Production
The scale of ecstasy production can vary widely, ranging 
from low-level production in small, kitchen-like laboratories 
to industrial-scale production in factories, as has typically 
been observed in Western Europe. The first step is synthesis 
from the precursor chemicals, following which the crude 
MDMA oil is separated from the other components by 
distillation. Next, a salting process is used to convert the 
liquid to a solid. Vacuum suction is then employed to further 
extract unwanted residue chemicals, followed by drying. 
Once the solid MDMA has been dried, it is granulated and 
mixed, and colour can also be added at this step. Finally, 
tableting—often with the addition of a logo imprint—and 
vacuum packaging (for consistency and dryness) finish off 
the whole process (Europol, 2010).
A variety of production methods can be used, and as a 
result the equipment used for production may vary. The most 
common production process which has been encountered in 
large-scale production sites is reductive amination. This 
involves converting PMK into an intermediate, which is 
subsequently converted into MDMA by introducing different 
catalysts (reductive substances) to cause the desired 
chemical reaction. Depending upon the reductive substance 
used, the production method may vary, but the pressure 
reaction method is the most commonly used in large-scale 
Figure 21:  Amphetamine and ecstasy production equipment, Belgium, 2010
Source: Europol.
Large-scale illicit drug production site 
detected in Belgium
In May 2010, the Hasselt Federal Police, in close 
cooperation with Europol, dismantled a large sophisticated 
illicit drug laboratory, which had the potential to produce 
hundreds of kilograms of synthetic drugs, in this case 
amphetamines and MDMA. The set-up of this illicit drug 
laboratory was unique, with a yearly production capacity 
of an estimated European street value of several million 
euros. Six suspects were arrested in Belgium. The 
investigation lasted several months and also involved 
cooperation with the Netherlands and Germany. 
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when 50 laboratories were reported to have been 
dismantled to the UNODC (2011h).
The Netherlands appears to be the main source of ecstasy in 
Europe, reporting much higher numbers of dismantled 
laboratories since 2002 than other countries. Between 2002 
and 2004, for example, the number of laboratories seized 
annually in the Netherlands ranged between 10 and 18, 
whereas, to date, no other European country has reported 
double-digit figures in any year. In Belgium, laboratories were 
also dismantled every year in the last decade, except in 2007 
and 2010, although the number is always smaller than in the 
Netherlands. Production in other countries does occur; this 
was more dispersed throughout Europe before 2003–2004, 
although most of the dismantled laboratories were located in 
Central and Northern Europe (Germany, Estonia, Spain, 
France, Lithuania, Austria, Poland, Portugal and the United 
Kingdom). Seizures of ecstasy laboratories in recent years 
suggest that production levels across Europe have dropped, 
and that manufacture now would be taking place largely in 
the Netherlands. In 2010, two laboratories were dismantled 
in the Netherlands and one in Bulgaria; in 2011 four were 
dismantled in the Netherlands and one in Belgium; and in the 
first half of 2012 only one was found in the Netherlands.
A recent development noted in the Netherlands has been 
the strategic change in ecstasy production since around 
2008, when individual production stages (e.g. synthesis, 
tableting) were no longer performed at a single location, but 
were spread over several facilities (both static and mobile), 
to avoid detection (UNODC, 2011h).
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Figure 22: Number of ecstasy laboratories dismantled in Europe, 2002–2012
Note:  As the number of laboratories dismantled in Europe differs between sources, the horizontal line within each bar represents the lowest reported number 
and the top of the bar the highest one. 2010–2012 data were provided from one source only, Europol.
Sources: UNODC World drug reports (2002–2012), UNODC Global ATS assessment (2005–2009); Europol Intelligence (2002–2012).
Monitoring dismantled ecstasy production 
facilities
Examining trends in production can be challenging. Some 
information can be gleaned from data on the dismantling 
of production facilities, although inferences about levels 
and trends in production should be made with care: as with 
seizures of illicit drugs in general, the data can reflect law 
enforcement resources and priorities as much as drug 
production itself.
Leaving this problem aside, data on the number of 
dismantled ecstasy production laboratories in Europe are 
poor. The most obvious reason is the differences between 
the data reported by the sources available (Europol, 
EMCDDA/Reitox national focal points, UNODC). The 
lack of shared definitions of the terms ‘production facility’ 
and ‘laboratory’ is likely to account for some of the 
discrepancies between reporting systems. Ecstasy, for 
example, is often manufactured in the same facilities as 
amphetamine; but a facility may be reported as 
producing only one of the two drugs. In addition, the 
different stages of production and manufacture now tend 
to occur at different locations, with facilities used for 
synthesising the substance, others for tableting the drug, 
and others as storage space, the reporting of which may 
differ between countries. These issues also stand true for 
the reporting of other synthetic drugs production 
laboratories.
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(aged 15–34) (with a European average of 1.3 %), with 
males generally reporting levels of use higher than females 
in all countries. For comparison, last year use of the drug 
among young adults in the United States is estimated at 
3.1 %.
Targeted surveys provide an insight into levels of ecstasy use 
reported by young adults attending clubs and other nightlife 
venues in Europe. Recent studies of these groups in the 
Czech Republic and the Netherlands showed levels of last 
year use of ecstasy of 42 % and 33 % respectively (Czech 
Republic and Netherlands: Reitox, 2011). Ecstasy use was 
more common than amphetamines use in both samples. 
Data from this type of study design, however, must be 
interpreted with caution as samples may not be 
representative of the overall population of clubbers, and 
even less representative of the general population.
Overall, in the European countries with the highest 
estimates of last year use among young adults (Czech 
Republic, Estonia, Spain, Slovakia, United Kingdom), use 
peaked in the early 2000s. Subsequently, in some Member 
States (Denmark, France and the United Kingdom), the 
prevalence of cocaine overtook that of ecstasy and, in 
some cases, amphetamines (Figure 23). During the period 
2005–2010, a stabilising or downwards trend was 
observed in these countries, mimicking the trends observed 
in the ecstasy supply indicators (seizures, price and purity). 
Consumer markets for ecstasy in Europe
Historically linked with the dance music scene, ecstasy is 
one of the most used illicit stimulants in Europe, along with 
amphetamines. In recent years, there has been some decline 
in the use and availability of ecstasy, but recent data 
suggest that the market may be experiencing a revival.
Ecstasy is usually taken orally (as a tablet) or, less often, 
snorted (in powder form). The number of ecstasy users is 
similar to the number of amphetamines users, but remains 
lower than the number of cocaine users. Use among the 
general population is low and has been stable over time. By 
contrast, prevalence levels amongst young people are far 
higher—especially amongst those going to clubs and dance 
events and heavy drinkers. There are frequent reports of the 
combined use of ecstasy with other substances, including 
alcohol (EMCDDA, 2009d).
Based on data from the most recent population surveys, it is 
estimated that about 11.5 million Europeans have tried 
ecstasy (58) (average of 3.4 % of the adult population), and 
about 2 million have used the drug during the last year (of 
whom 1.5 million are aged 15–34), with the highest 
estimates being reported by Latvia, Slovakia, the 
Netherlands and the United Kingdom (these four countries 
accounting for 40 % of the estimated 2 million users). Use of 
the drug in the last year is concentrated among young adults 
(58)  In this context, the section refers to drug tablets that users commonly refer to as ‘ecstasy’. Available data do not distinguish, within the ecstasy group, 
between tablets containing MDMA and other drug tablets that contain other scheduled and non-scheduled psychoactive substances.
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2
1992 1995 1999 2000 2002 2005 2010
%
Cocaine
Amphetamines
Ecstasy
a) France
0
1
2
3
4
5
6
7
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
%
Cocaine
Amphetamines
Ecstasy
b) United Kingdom
Figure 23:  Trends in use of amphetamines, ecstasy and cocaine among young adults in a) France and b) the United Kingdom
Note:  The figures show the last 12 months prevalence of use among young adults aged 15–34.
Source: EMCDDA/Reitox national focal points, EMCDDA (2012a).
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was mentioned as the primary drug by 1 % or less of 
reported treatment entrants in all European countries (fewer 
than 1 000 clients in total); these individuals often reported 
concomitant use of other substances, including alcohol, 
cocaine and, to a lesser extent, cannabis and 
amphetamines.
Trends in ecstasy trafficking in Europe
MDMA content in ecstasy tablets
There has been a substantial change in the content of 
‘ecstasy’ tablets available on European markets in the last 
decade. In the first half of the new millennium, most tablets 
contained MDMA or analogues such as MDEA or MDA as 
the only psychoactive substance; in 2005, MDMA-like 
substances accounted for 70 % or more of the tablets 
analysed in 17 out of 23 reporting countries. Since then, 
there has been a diversification of the market, with a number 
of other controlled and non-controlled psychoactive 
substances being found in ecstasy tablets and a decrease in 
their MDMA content. This shift was most pronounced in 
2009, when only three countries reported that MDMA-like 
In other countries where repeated surveys have been 
carried out, ecstasy use is relatively low and, in most cases, 
stable.
During this period, there was a reported increase in many 
European countries in the number of detected new 
substances under the umbrella of the ‘legal highs’ 
phenomenon, some of which are designed to mimic the 
effects produced by ecstasy (e.g. mephedrone). In 
combination, the increased availability of ‘legal highs’ and 
decreased availability of ecstasy (EMCDDA, 2011b) may 
have had the effect of stabilising or reducing ecstasy use 
over this period. Although no direct link has yet been 
confirmed, recent data suggest that some form of substance 
replacement may have occurred in the consumer market. For 
example, the 2010/11 British Crime Survey found that the 
last year prevalence of mephedrone use was at a similar 
level to that of ecstasy among the general population 
(16–59 years) in England and Wales (Smith and Flatley, 
2011)—although the 2011/12 survey showed a fall in 
mephedrone use.
Treatment data suggest that very few drug users enter 
treatment for problems relating to ecstasy. In 2010, ecstasy 
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Figure 24: Content of ecstasy tablets analysed in the Netherlands, 1997–2011
Note:  MDMA includes MDMA and analogues. Meth(amphetamine) includes amphetamine and/or methamphetamine. Others includes all other scheduled 
psychoactive substances. Miscellaneous includes non-scheduled psychoactive substances and non-psychoactive substances.
Source: Reitox national focal point in the Netherlands.
101
Chapter 7 | Ecstasy
This partial restoration of the market may possibly result from 
the emerging use of new pre-precursors in the manufacture 
of MDMA in Europe. In the Netherlands, although mCPP 
and mephedrone were found in high proportions of ecstasy 
tablets in 2008 and 2009, compensating for the lack of 
MDMA (Figure 24), they now seem to have nearly 
disappeared from the Dutch market, accounting, in the first 
half of 2011, for only 4 % and 0.3 %, respectively, of the 
ecstasy tablets analysed and suggesting a recovery of the 
Dutch ecstasy market (Brunt et al., 2011; Netherlands: 
Reitox, 2011).
Analysis of amnesty bins suggests that ecstasy re-emerged in 
the United Kingdom in 2011 in a number of forms, including 
powders, capsules of crystal MDMA and tablets containing 
crystal MDMA (Figure 25).
Seizures and trafficking
Overall, both the number of ecstasy seizures (59) and 
quantities intercepted in Europe peaked at the turn of the 
century, with a fourfold decrease in number of seizures and 
a fivefold decrease in quantity observed since then. In 2010, 
seizures were at levels similar to or lower than those 
recorded in 1995. While the initial decline in the first half of 
the new millennium may be linked to the decreasing 
predominance of Europe as a producer for non-European 
markets, the more recent decline since 2008 confirms the 
reduced availability of MDMA in Europe discussed above. 
The total number of ecstasy tablets seized in Europe in 2011 
reached the level in 2008, confirming the partial recovery of 
the market suggested above (Figure 26).
Ecstasy is primarily sourced from within Europe. The 
Netherlands remains the country most identified as a source 
of ecstasy within Europe, with 10 European countries clearly 
reporting the Netherlands as a source in 2010. Intraregional 
trafficking appears to be common, with several countries 
reporting trafficking from neighbouring countries. Some 
countries note their role as transit areas to other markets; for 
example, ecstasy passes through Germany to reach 
Bulgaria, Romania, Ireland and Switzerland and through the 
Baltic States en route to the Nordic countries, Ukraine, 
Belarus and Russia (Reitox, 2011).
Historically, most of the ecstasy seized in Europe has been 
intercepted in the western part of the continent. The United 
Kingdom, followed by the Netherlands, have usually been 
the two countries seizing the largest quantities, several 
substances accounted for the largest proportion of the 
tablets analysed. In 2010, this number increased to eight 
and in 2011 to 10. However, in 2011, in 16 countries, most 
tablets analysed did not contain MDMA (or analogues). 
Amphetamines, sometimes in combination with MDMA-like 
substances, were relatively common in tablets analysed in 
Spain, Luxembourg and Turkey. Most of the reporting 
countries mentioned that piperazines, and in particular 
mCPP (1-(3-chlorophenyl)piperazine), were found, alone or 
in combination with other substances, in tablets analysed; 
these substances were found in around 20 % or more of 
tablets analysed in 2011 in Belgium, Denmark, the Czech 
Republic, Cyprus, Austria, Portugal, Finland, the United 
Kingdom and Croatia.
This decline in MDMA availability has occurred alongside a 
rise in popularity of new psychoactive substances often 
marketed as ‘legal highs’ (but also as ‘ecstasy’), such as BZP 
(1-benzylpiperazine), MDPV (methylenedioxypyrovalerone) 
and, particularly, mephedrone (which belongs to the 
cathinone group). These substances are designed to mimic 
the effects of stimulants such as ecstasy and may have 
become a replacement for it. The finding of piperazines in 
place of MDMA in ecstasy tablets has increased since 
2005, while cathinones started to appear from 2008 
(EMCDDA, 2010). An increase in the MDMA contents in 
ecstasy tablets analysed in some European countries points 
to a resurgence of the ecstasy market after the drought of 
2009, although the levels have not quite returned to those 
seen in the first half of the last decade.
(59)  Tablets seized and reported as ‘ecstasy’ may vary largely in terms of content. While some countries perform systematic analysis to determine whether they 
contain MDMA substances, others may record under this heading all tablets sold as ‘ecstasy’ regardless of the actual content, and other ones also list 
tablets containing non-controlled psychoactive substances.
Figure 25:  Ecstasy capsule containing visible crystal MDMA, 
North-West England, 2011
Source: Simon D. Brandt, Liverpool John Moores University.
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Turkey has recently emerged as a major ecstasy seizing 
country, with quantities intercepted slowly increasing over 
the last decade, reaching a peak of 1.7 million ecstasy 
tablets in 2005. Although, as in other countries, the 
subsequent decline led to a low in 2009, Turkey has become 
one of the largest seizing countries in Europe, reporting 1.4 
million tablets in 2011. The size of ecstasy seizures in Turkey 
has remained comparatively large over the last decade, with 
more than 1 000 tablets on average in most years since 
2001, and around 600 in the period 2009–2011, 
suggesting wholesale trafficking of the drug (reportedly 
sourced in Belgium and the Netherlands) destined 
apparently for the Turkish domestic market.
In contrast, the average seizure size in the United Kingdom 
has remained relatively small, around 100 tablets during 
2008–2010, lending support to the theory that the United 
Kingdom is a destination market for the drug and suggesting 
million ecstasy tablets every year, accounting for over half of 
the total amount recovered in Europe until 2007. In the early 
2000s, production in Germany was noted, and exceptional 
seizures of several million tablets were reported there in 
2001 and 2002. Since the mid-2000s, reported seizures in 
Germany have been on a par with those in France, the next 
largest seizing country at around 1–2 million tablets 
recovered annually since 2000, ahead of Spain, reporting 
seizures of 500 000 to 1 million tablets a year. This 
situation changed suddenly in 2008, with a sharp decrease 
in quantities seized in all five countries, to a record low in 
2009 and a slight increase in 2010. During this period, 
seized quantities reported in these countries have fallen 
below 1 million tablets and, in some cases, below 500 000. 
In 2011, there were suggestions of a partial recovery of the 
ecstasy market, particularly in France and the Netherlands, 
where seizures increased to 1.5 and 1.1 million tablets 
respectively.
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Figure 26: Seizures of ecstasy tablets in Europe, 2001–2011
Note:  All 30 European countries are included, except the Netherlands and Poland where Number of seizures data are not available. In the absence of 2011 
data for the United Kingdom, 2010 data were used in their place.
Source: EMCDDA/Reitox national focal points, EMCDDA (2012a).
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Interceptions in Poland have become comparatively large 
since 2005, placing the country in seventh position in terms 
of the total number of ecstasy tablets seized in the period 
2009–2011. Poland, already a major production area for 
amphetamine, may also be manufacturing ecstasy; in 2008 
a production facility was dismantled in Poland, and the 
country has been mentioned as a source of some of the 
ecstasy used in the Czech Republic, where consumption 
among young adults is amongst the highest in Europe.
a large number of seizures in middle to lower segments of 
the supply chain.
Belgium, also identified as a producer of ecstasy, although 
to a lesser extent than the Netherlands, is not amongst the 
largest seizing countries in Europe, except in 2005, when a 
record number of 2.5 million tablets were intercepted. The 
average size of Belgian seizures is comparatively low, at 50 
tablets in 2009–2011, suggesting a large number of 
interceptions at user level.
For conclusions and recommendations relating to the synthetic drugs market, please refer to pages 136–138 in Chapter 10.
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designed to better understand the complex signalling 
pathways in our bodies, while others have been studied as 
potential medicines. However, a common feature is that 
there is usually limited information about the effects of 
these drugs in humans and the harms that they may cause. 
Nonetheless, it appears that those involved in supplying 
new substances are increasingly searching this literature 
for potential new drugs. Some of these are then sold 
directly on the illicit market, while others, the so-called 
‘legal highs’, are sold more openly. A further development 
to this phenomenon is the detection of non-controlled 
psychoactive medicines on the market. The way in which 
some of these new drugs are marketed and distributed is 
also becoming more sophisticated. This includes their 
advertisement and sale on the open market, such as 
through the Internet (with delivery via courier and postal 
services), as well as sale in ‘bricks and mortar’ head 
shops (60).
Introduction
New psychoactive substances (new drugs) comprise a broad 
range of substances that are not controlled under 
international drug laws. Often they are intended to mimic 
the effects of existing controlled drugs. This is reflected in the 
fact that many are chemically similar to controlled drugs, 
but, at the same time, sufficiently different that they fall 
outside of the scope of drug laws. In addition, a growing 
number of new substances from entirely different chemical 
families, including stimulants and substances that mimic the 
effects of cannabis or opioids, have also recently been 
detected.
The term ‘new’ refers to the fact that these substances are 
new to the drug market or newly misused. Many new 
drugs have previously been described in the scientific and 
patent literature as part of legitimate research and 
development. Some have been used in experiments 
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(60) A shop that sells drug-related literature, paraphernalia and ‘legal highs’. They may also be called ‘smart shops’.
New drugs in Europe at a glance
The EU early warning system (EWS) operated by the EMCDDA 
and Europol currently monitors more than 250 new 
psychoactive substances.
From 1 January to 31 December 2012, a total of 73 new 
psychoactive substances were officially notified for the first time 
in the EU through the EWS, up from 49 in 2011, 41 in 2010 
and 24 in 2009.
Since 1997, 12 substances have been risk assessed under the 
EU system. Of these, eight (4-MTA, PMMA, 2C-I, 2C-T-2, 
2-C-T-7, TMA-2, BZP and 4-MMC) are now controlled across the 
EU and one (GHB) is controlled at international level.
The main groups of substances monitored by the EWS are the 
phenethylamines (with stimulant, entactogenic or hallucinogenic 
effects, such as PMMA and 2C-I), tryptamines (which have 
predominantly hallucinogenic effects, such as AMT and 
5MeO-DALT), piperazines (which exhibit predominantly 
stimulant effects, such as mCPP and BZP), cathinones (such as 
mephedrone, methylone and MDPV, which exhibit stimulant 
effects), synthetic cannabinoids (which can have hallucinogenic 
and depressant effects), as well as a broad group of plant-
derived and synthetic substances that do not strictly belong to 
any of the previous groups.
Data from EMCDDA monitoring show that the number of online 
shops offering new psychoactive substances/‘legal highs’ for 
sale to consumers in the EU continues to grow, with 693 shops 
identified in January 2012, up from 314 in January 2011 and 
170 in January 2010.
A recent Eurobarometer survey in those aged 15–24 across the 
EU found that while lifetime use of ‘legal highs’ in most Member 
States was 5 % or less, use in the United Kingdom, Latvia, 
Poland and Ireland was 8 %, 9 %, 9 % and 16 % respectively.
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While the appearance of new drugs is not a new 
phenomenon (Baum, 1985), over the past few years there 
has been an unprecedented growth in their number, type 
and availability (EMCDDA, 2011a; EMCDDA–Europol, 
2012a). That said, at least initially, many new drugs do not 
spread beyond small groups of users. In some cases they 
may be sold only as a short-term response to the reduced 
availability of controlled drugs (such as MDMA) that is often 
a result of enforcement measures. In addition, the effects of 
new drugs may not be acceptable to users, helping limit 
their spread. This may include serious acute toxicity that 
requires a particularly rapid response by practitioners, 
professionals, regulators and decision-makers. Those drugs 
that do gain a foothold can pose significant health and 
social harms. Recent examples include gamma-
hydroxybutyrate (GHB, a central nervous system depressant) 
(EMCDDA, 2002) and mephedrone (a synthetic cathinone 
with stimulant effects) (EMCDDA, 2011b). The potential for 
harm may be magnified by the fact that some new drugs are 
found in increasingly complex mixtures with other new 
drugs, and, sometimes, controlled drugs. In addition, in 
some settings, established injecting drug users are also using 
new substances (such as mephedrone and MDPV as 
replacements for heroin).
A growing number of new drugs are now controlled in 
Member States. However, their availability, coupled to the 
fact that there are limited data on their effects and harms, 
continues to pose serious challenges to drug policy and 
practice in Europe and, increasingly, elsewhere. This is 
compounded by the speed at which they appear as well as 
differences in national drug laws. Since the mid-1990s the 
EU has been proactive in its response to the new drug 
phenomenon, with a mechanism for information exchange 
(known as the early warning system, EWS), risk assessment 
and, where necessary, control of new substances across the 
Member States (Council of the European Union, 2005) 
(Figure 27).
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Figure 27:  Timeline of major developments and number of new psychoactive substances notified since Council Decision 2005/387/JHA 
came into effect in May 2005
Note:  BZP, 1-benzylpiperazine; NPS, new psychoactive substances; 4-MMC, 4-methylmethcathinone (mephedrone). Internet shops identified by EMCDDA 
monitoring offered NPS/’legal highs’ for sale and delivery to at least one EU Member State.
Source: EMCDDA.
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4-Methylamphetamine: new drug by accident  
or design?
4-Methylamphetamine is a derivative of amphetamine that 
was first notified to the EMCDDA in December 2009. It is 
usually found in combination with amphetamine and 
caffeine. It is unclear why 4-methylamphetamine has 
appeared on the market. (Notably, the drug was previously 
detected in the United States during the 1970s and the 
United Kingdom in the 1980s.) Information provided to 
Europol and the EMCDDA suggests that there is no distinct 
difference between 4-methylamphetamine and 
amphetamine in terms of the involvement of OCGs, 
production and trading methods and users. Unlike the 
precursor used to manufacture amphetamine, the precursor 
known to be used for the manufacture of 
4-methylamphetamine, 4-methyl-BMK, is not under 
international control and appears to be commercially 
available. It is possible that this led to the deliberate 
production of 4-MA, or 4-methyl-BMK could have been 
used accidentally instead of the precursor commonly used 
to manufacture amphetamine. Whatever the reason, a new 
drug appeared on the market for which limited information 
on their psychoactive and harmful effects is available. 
Since October 2011, 21 deaths linked to 
4-methylamphetamine have been reported to the EMCDDA. 
Although there is no evidence to suggest a specific demand 
for 4-methylamphetamine, it is sold as amphetamine, and 
so a large population of drug users may be at risk of 
exposure to it (see Chapter 5) (EMCDDA–Europol, 2012b).
Another group of new psychoactive substances—the 
so-called ‘legal highs’—are legally sourced and sold as 
replacements for controlled drugs on the open market by 
exploiting existing laws. This group includes a wide range of 
synthetic and plant-derived substances that are often sold as 
branded products. They are also sometimes sold in 
combination with other new substances. This may be an 
attempt to better mimic the effects of controlled drugs, or to 
achieve novel psychoactive effects, or as a result of 
accidental contamination or deliberate substitution. These 
so-called ‘legal highs’ are usually sold through the Internet 
and in ‘bricks and mortar’ head shops (in countries where 
there are few head shops, the Internet may play a key role 
in direct sales to consumers). They may also be sold by 
street-level drug dealers. Mostly they are advertised with 
aggressive and innovative marketing strategies. Often, in 
order to disguise the fact that they are psychoactive drugs, 
and circumvent ‘grey areas’ in consumer protection and 
marketing regulations, they are sold under various product 
labels, including ‘research chemicals’, ‘bath salts’ and ‘plant 
food’, and usually with an accompanying disclaimer that 
Production, marketing and supply of   
new drugs
The way in which new drugs are produced, marketed and 
supplied can differ significantly. Some are sold directly on the 
illicit drug market. Here they may be produced from chemical 
precursors in clandestine laboratories of varying size and 
sophistication. In the past these have typically been referred 
to as ‘designer drugs’ (Baum, 1985). Examples include PMMA 
(para-methoxyamphetamine) (EMCDDA, 2003) and 2C-I 
(2,5-dimethoxy-4-iodophenethylamine) (EMCDDA, 2004), 
which are now controlled across the EU because of the risk of 
harm they pose. More recently, 4-methylamphetamine, usually 
sold as amphetamine, has been detected in 15 Member 
States (see box) (EMCDDA–Europol, 2012b). New drugs sold 
on this market may also be tableted or otherwise packaged 
from bulk substances that are bought from legitimate sources; 
these include mCPP and BZP (Europol–EMCDDA, 2005; 
EMCDDA, 2009b). Both precursors and substances have 
been sourced from third countries and from within Europe. 
This market is dynamic, with source countries changing over 
time and place. While the source countries for precursors is 
often unclear, in some cases, the precursor, such as that 
required to manufacture 4-methylamphetamine, is offered for 
sale on the Internet by chemical suppliers that appear to be 
based in China (EMCDDA–Europol, 2012b).
Overall, these new drugs are believed to be largely used 
surreptitiously by producers as replacements for established 
controlled drugs which may be in short supply, such as 
MDMA (ecstasy). This supposition is supported by the 
finding that many of them are found as tablets that use the 
same logos as ecstasy tablets. In some cases, new drugs 
may also be found in combination with controlled drugs, 
possibly in an attempt to ‘bulk up’ the drug and thereby 
reduce the amount of controlled drug. An example of both 
uses is the identification in 2004 of the piperazine derivative 
mCPP in tablets sold as ecstasy. One possible reason for the 
emergence of mCPP was the decreased availability of the 
chemical precursors used in the synthesis of MDMA. This, 
coupled with the fact that mCPP appears to mimic some of 
the subjective effects of MDMA and that it could be legally 
sourced in Europe and elsewhere, may have made it an 
attractive substitute to producers (Europol–EMCDDA, 2005; 
Bossong et al., 2010). Similarly, although BZP came to 
prominence as ‘party pills’, and was commonly sold on the 
open market as such, some of the tablets that were seized 
on the illicit market were clearly intended to be sold as 
ecstasy, bearing typical ecstasy logos. It is also important to 
note that some of these new substances are also sold as 
drugs in their own right (e.g. 2C-B, also known as ‘Nexus’, 
which is now under international control) or as a ‘special 
type’ of ecstasy (such as mCPP).
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multi-kilogram quantities, from China and, to a lesser 
degree, India. Moreover, facilities for the processing and 
packaging of these substances have also been seized 
within the EU. One such example was the discovery in 
2010 by Belgian police of both a processing and 
packaging facility and large quantities of mephedrone, 
synthetic cannabinoids and acetone that had been 
imported from China. At this facility the synthetic 
cannabinoids were mixed with acetone, sprayed on to plant 
material and then packaged as smoking mixtures. Later, in 
2011, an investigation in the Netherlands led to the seizure 
of 150 kg of synthetic cannabinoids as well as 20 000 
packages of finished products. It is believed that this 
production facility had taken over the activities from the 
facility dismantled by the Belgian police.
As part of the marketing strategy to offer a replacement for 
controlled drugs, distributors and retailers use names for 
‘legal high’ products that allude to, or sound like, 
controlled drugs: ‘Snow blow’ for cocaine or ‘Xtacy’ and 
‘Doves Red’ (61) for MDMA. Common street names of 
controlled drugs are also used (e.g. calling products 
‘Charlie’, which is also a street name for cocaine). There 
have also been attempts to deceive consumers by 
marketing synthetic drugs as ‘natural’ herbal products, such 
as in the case of ‘Spice’ products that contained synthetic 
cannabinoids (EMCDDA, 2009c) (see box on p. 110). 
In the majority of such cases the substances are not listed 
on the product packaging.
It is also clear that retailers are exploiting the Internet as a 
vehicle for the marketing and sale of ‘legal highs’. Data from 
the EMCDDA’s Internet monitoring show that the number of 
online shops selling ‘legal highs’ continues to grow, with 693 
shops identified in January 2012. This was twice the number 
identified in January 2011 and a more than threefold 
increase from January 2010. Sales practices in this area 
also appear to have become more sophisticated, with more 
evidence of measures taken to conceal the identity of buyers 
and sellers (EMCDDA 2011a). Importantly, some online 
shops sell not only retail products but also bulk quantities of 
substances, presumably for resale.
In order to raise the profile of their products, Internet retailers 
use a range of marketing techniques. Many focus around 
selling the idea that ‘legal highs’ are good replacements for 
controlled drugs. Social media are also used a marketing 
tool. This includes posting videos on YouTube of ‘real 
people’ using the drugs and reviewing their effects. Some of 
these are set at music festivals, where traditionally the use of 
they are not intended for human consumption. However, 
describing these substances as ‘legal’ may not be strictly 
correct, as some may be regulated by medicines, food 
safety or other consumer protection laws; some may even 
contain controlled drugs.
Information from border seizures and law enforcement 
investigations in the Member States indicate that substances 
sold as ‘legal highs’ are typically imported, sometimes in 
(61) ‘Doves’ is a street name for ecstasy.
Product sold as a ‘legal high’
Use of this product (Annihilation) has been linked to 
hospitalisations in Europe. Chemical analyses of samples of 
the product were found to contain various combinations of 
synthetic cannabinoids, some of which are controlled 
drugs. Note that the product packaging does not list 
synthetic cannabinoids as an ingredient and the product is 
labelled as an incense and potpourri.
Source: Simon D. Brandt, Liverpool John Moores University.
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The drivers of new drugs
Essential to the recent developments in the new drug market 
are globalisation and innovation. This includes an increased 
capacity in chemical synthesis in emerging economies such 
as China and India that allows new drugs, their precursors 
and cutting agents (62) to be sourced cheaply. The Internet, 
too, plays a pivotal role, allowing entrepreneurs to search 
the scientific and patent literature for ideas for new drugs, to 
order them (or their precursors) from manufacturers, and in 
some cases to advertise and sell them to both consumers 
and dealers. At the same time, cheap air freight and courier 
services allow drugs to be delivered rapidly to wholesalers, 
retailers and consumers.
Many diverse factors drive the availability of new drugs. 
These form a complex web that makes it difficult to unravel 
the exact role they play and their importance. The simple 
fact that there are few, if any, restrictions on the 
manufacture, transport, importation, sale and possession of 
the drugs is clearly important as the risks to manufacturers 
and distributors are reduced. This can increase the 
availability throughout the supply chain, reducing costs. 
Several additional factors may also make new drugs more 
attractive and socially acceptable to consumers, driving 
demand. This includes the (mis)perception that ‘legal highs’ 
are of higher quality than controlled drugs and that they are 
less harmful, perceptions that may be reinforced by positive 
ratings by friends and other social contacts. In some cases 
new drugs may also emerge as a result of the poor technical 
knowledge of producers or from using the wrong chemical 
precursors (63). As noted, the marketing of many new drugs 
has also become increasingly innovative. This has allowed 
them to reach larger numbers of prospective consumers 
outside the traditional recreational user groups. These 
include consumers who typically do not use controlled 
drugs, as well as those who use new drugs for lifestyle 
reasons (such as to lose weight) or as a form of self-
medication.
While online networks are playing a growing role in how 
consumers learn about new drugs, buy them and, 
subsequently, share their experiences, traditional ‘offline’ 
social networks are likely to continue to be of great 
importance. For example, studies have shown that many 
users source some ‘legal highs’ from friends or street-level 
drug dealers (Gallup Organisation 2011; Dargan et al., 
2010). Although the interactions between these two types of 
networks are poorly studied, it is likely that there is a great 
deal of interplay.
illicit drugs is common. In some cases, these videos are shot 
as ‘before’ and ‘after’ reviews to emphasise the effects of the 
drugs. Similarly, it appears that the results of search engines 
are manipulated (known as ‘spamdexing’; Gyöngyi and 
Garcia-Molina 2005) so that substances, product names 
and retailers are artificially ranked in the top results of 
search engines. This form of manipulation is important for 
distributors and retailers as consumers tend to trust and 
select links that are highly ranked in search engines (Pan et 
al., 2007). At the same time official websites providing 
health information on new drugs may be ranked lower, 
meaning that users may be less likely to come into contact 
with unbiased information. Retailers also accept a range of 
payment methods, such as credit and debit cards, Internet 
payment accounts, electronic bank transfers and even cash 
payment into banks. Payment in cash, whether in ‘bricks and 
mortar’ head shops or for Internet purchases, is likely to 
extend the customer base for ‘legal highs’ to young or 
marginalised people who do not have access to payment 
cards.
A further dimension of the new drug phenomenon is the 
growing number of psychoactive medicines that are being 
misused. Some of these are authorised as medicinal 
products within the EU (such as pregabalin) and are either 
diverted from the regulated market or imported from third 
countries. They may also include substances and products 
that are not licensed within the EU, such as phenazepam 
and etizolam (benzodiazepines) (EMCDDA–Europol, 
2012a).
(62) These may be added to ‘bulk out’ and/or ‘dilute’ the drugs or as binding agents in the production of tablets or ‘pellets’.
(63) Which may be accidental or deliberate.
The synthetic cannabinoids AKB48 and 2NE1: 
novel marketing?
Synthetic cannabinoids were first detected on the EU market 
in 2008 as potent drugs hidden in smokable herbal 
products sold as ‘Spice’ (EMCDDA, 2009c). Recently, two 
other synthetic cannabinoids, with the code names AKB48 
and 2NE1, have been notified to the EMCDDA; these code 
names are not thought to be described in the literature. 
Interestingly, these are also the names of popular pop 
bands in Japan and South Korea. One possible reason for 
using these code names for marketing on the Internet may 
be an attempt to draw on the popularity of the bands 
through their high ranking in search engine results. It is also 
possible that the use of these names is an attempt to target 
the fan base of the bands concerned.
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market to one that increasingly involves organised crime. As 
noted above, synthetic cathinone derivatives such as the 
former ‘legal high’ mephedrone have also appeared on the 
illicit market. This suggests that OCGs have become involved 
in their distribution, as do stockpiles of the drugs in 
neighbouring countries. Indeed, when mephedrone first 
emerged on the market it was legally sourced from countries 
outside the EU; however, more recently, Polish police have 
dismantled a mephedrone production site, seizing 5 kg of the 
drug in the process. According to intelligence in this case, 
there were links to organised crime as well as trafficking of 
50 kg of mephedrone within Poland and to other Member 
States. Intelligence also indicates that criminal groups are 
involved in the distribution of herbal smoking mixtures that 
contain synthetic cannabinoids. In light of the readiness of 
such groups to exploit gaps in drug control legislation, and 
the speed with which markets develop for non-controlled 
drugs, criminal interest in new drugs is likely to grow. This is 
likely to be especially the case as criminal organisations 
recognise the potential of drugs that can be bought legally 
and cheaply in large quantities, or can be synthesised 
relatively easily, and which are attractive alternatives to 
controlled drugs. Crucially, as the Internet plays a key role in 
procuring, marketing and selling new drugs, its transnational 
nature will limit law enforcement activities.
Consumer markets
The consumer market for new drugs is complex and, for the 
most part, poorly studied. Prevalence data are limited and 
often suffer from methodological limitations. In the case of 
new drugs that are sold directly on the illicit market, the user 
groups will reflect, to some degree, the existing markets for 
controlled drugs such as amphetamine or ecstasy. In the 
case of ‘legal highs’, most surveys have examined use in 
targeted groups (such as dance music fans and night club 
patrons), which tend to comprise larger numbers of ‘early 
adopters’ of new drugs. These findings are not 
representative outside the survey population. However, the 
use of new drugs in these populations can be very high and 
may provide both insights into the harms a drug may have 
as well as an indication of substances that may be attractive 
to other users and which could become more widespread.
More recently, representative surveys have been undertaken 
in some Member States. For example, a national survey in 
Spain that examined use of ‘emerging drugs’ in students aged 
14–18 found overall lifetime use of ‘legal highs’ of 0.7 % 
(0.6 % in the last year and 0.5 % in the last month) (64) 
The interplay between the new drug 
market and illicit drug market
Much of the policy focus on new drugs has concerned 
their legal status; however, it is also important to see them 
in the context of the overall drug market. As an example, 
both law enforcement agencies and users report that some 
‘legal highs’, such as mephedrone (before it was 
controlled), can be purchased not only openly on the 
Internet, but also through the same illicit networks that are 
used to supply drugs such as ecstasy and cocaine. Indeed, 
mephedrone may have even become a drug of choice 
among certain groups, which may help sustain its market 
now that it is controlled across the EU (Wood et al., 2012). 
Moreover, as noted, new drugs may be tableted and sold 
as ecstasy on the illicit market. In 2009, for example, 
Dutch police seized more than 130 kg of mephedrone 
(260 000 tablets) from a tableting site and four related 
storage locations. Most were imprinted with a logo 
commonly used on ecstasy tablets.
Controlled drugs have also been detected in ‘legal high’ 
products. For example, in 2011, PMMA, which in 2002 
became a controlled substance in the EU because of the 
harms it poses, was detected in products sold as ‘legal 
highs’ along with the synthetic cathinone MDPBP 
(3’,4’-methylenedioxy-a-pyrrolidinobutyrophenone). At the 
same time, the drug was also detected on the illicit market in 
tablets sold as ecstasy and powders sold as ‘speed’ 
(amphetamine), in some cases in combination with MDPBP. 
This may suggest the involvement of organised crime. 
Alternatively, as PMMA is not under international control, it 
could have originated from a country where it is not 
controlled and deliberately sold as another substance. More 
recently, seizures of herbal cannabis have been reported to 
contain synthetic cannabinoids. Although this requires 
further study, possible reasons for using synthetic 
cannabinoids include increased profit by reducing the time 
from nursery to harvest or to increase the potency of ‘weak 
batches’ of herbal cannabis.
Predicting the extent to which new drugs will become a 
major part of Europe’s illicit drug market is difficult. However, 
OCGs recognise the potential profit to be made in new 
drugs, no doubt encouraged by the fact that there are few 
restrictions on their manufacture, distribution, sale and 
possession. That is not to say that well-conceived control 
measures will solve all the problems in this area, and there is 
a danger that they might even increase the momentum for an 
undesirable transition from a mostly online ‘legal highs’ 
(64)  The prevalence of use of ‘research chemicals’ was 0.4 % for lifetime use, 0.3 % in the last year and 0.2 % in the last month, while the prevalence of use of 
‘Spice’ products (which contain synthetic cannabinoids) was 1.1 % for lifetime use, 0.8 % in the last year and 0.4 % in the last month.
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standard drug tests do not currently detect all these 
substances.
Overall, in the case of most new psychoactive substances 
that have spread beyond relatively small groups of users, it 
is currently unclear if the new substances are displacing 
controlled substances, in either the short or long term, or are 
simply used in addition to the existing range of drugs.
Responding to new drugs in the EU
In the EU, the need for a rapid and effective response to 
new psychoactive substances and the harms they may 
cause has been recognised by decision-makers since the 
mid-1990s. Currently, it is the Council Decision 
2005/387/JHA that provides a legal basis for information 
exchange (EWS), risk assessment and, where necessary, 
control of new substances across the Member States 
(Council of the European Union, 2005). The EWS, 
operated by the EMCDDA and Europol in partnership with 
(Clinical Committee of the Government Delegation for the 
National Plan on Drugs, 2011). In addition, a recent 
Eurobarometer survey in those aged 15–24 found that while 
lifetime use of ‘legal highs’ in most Member States was 5 % or 
less, use in the United Kingdom, Latvia, Poland and Ireland 
was 8 %, 9 %, 9 % and 16 % respectively (Gallup 
Organisation, 2011).
In the case of some drugs, there is potential for a rapid 
increase in use among the broader population over a 
relatively short period of time. For example, although 
mephedrone was first detected on the UK market in mid-
2008, the 2010/11 British Crime Survey (covering England 
and Wales) found a prevalence of past year use of the drug 
among 16- to 24-year-olds of 4.4 %—similar to the rate for 
powdered cocaine and MDMA use (Smith and Flatley, 
2011). New drugs, particularly those sold as ‘legal highs’, 
may also be attractive to groups that are subject to drug 
testing, such as military personnel, those in drug treatment 
programmes and, more generally, vehicle drivers as many 
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awareness about new drugs among various professionals 
and a high level of interest in the phenomenon by decision-
makers at national level.
The Council Decision also provides for the assessment of the 
risks of new substances. This includes examining the 
physical, chemical, pharmaceutical and pharmacological 
characteristics of any new substance, as well as the health 
and social risks, the involvement of organised crime, 
whether it has been assessed under the UN drug control 
system, current control measures within the Member States, 
options for control and the possible consequences of these 
control measures (see box).
Responses by Member States
In response to the growing number of new drugs, some 
Member States have opted to schedule families of 
substances on the basis of their chemical make-up. This is 
known as ‘generic legislation’, and both Ireland and the 
United Kingdom have used this approach for some time. In 
other countries, in contrast, legislation covers a wider range 
of derivatives of controlled drugs with similar structures or 
effects (analogues) and can be applied to all substances 
controlled by drug laws (such as in Bulgaria and Norway), 
selected categories (Latvia, Malta) or just one small group 
(Luxembourg).
The rapid spread of new drugs is prompting some Member 
States to rethink their response to the problem. In some 
cases this includes defining proscribed drugs in functional 
terms rather than in terms of their chemistry. Examples can 
be found in Ireland and Poland. In 2010, both countries 
passed legislation to limit the open sale of new substances 
not controlled under drug laws. This required careful legal 
definitions of such substances. Briefly, the Irish law defines 
them as psychoactive substances not specifically controlled 
under existing legislation. The Polish law refers to ‘substitute 
drugs’, defined as a substance or plant used instead of, or 
for the same purposes as, a controlled drug, and whose 
manufacture or placing on the market is not regulated by 
separate provisions. It makes no specific reference to 
whether the drug is considered harmful.
The Irish law is enforced by the police. Senior police officers 
can serve a ‘prohibition notice’ on a seller; if the offender 
does not comply with this, the courts can issue a ‘prohibition 
order’. Selling or advertising drugs and non-compliance with 
a ‘prohibition order’ are punishable by up to five years in 
prison. By contrast, in Poland the law is enforced by the 
state public health inspectorate. The penalty for 
manufacturing or distributing substitute drugs is a large fine, 
while the penalty for advertising them is up to one year in 
their networks (including national early warning systems), 
is a real-time mechanism for the exchange of information 
on new drugs that may cause health and social harms. 
Multidisciplinary information sources are combined in 
order to detect, identify, track and understand new 
patterns of use, emerging trends and potential threats 
related to new drugs. The system is used extensively by 
health and law enforcement professionals, the forensic 
science community, researchers and decision makers 
throughout Europe.
From 1 January until 31 December 2012, a total of 73 new 
psychoactive substances were notified for the first time in 
the EU through the EWS (Figure 28), up from 49 in 2011, 
41 in 2010 and 24 in 2009 (EMCDDA–Europol 2012a). 
The marked increase in the number of notifications is taking 
place in the context of a continuous development of the 
‘legal highs’ phenomenon and probably reflects both the 
number of drugs available in the EU as well as the 
improved reporting capacities of national early warning 
systems. The latter is also likely to reflect increased 
Mephedrone: an example of how the EU 
responds to new drugs
Mephedrone is a synthetic cathinone with properties similar 
to stimulant drugs such as MDMA and cocaine. It appeared 
for the first time in Europe in 2007 and quickly gained 
popularity among young people in some countries, leading 
to a specific demand for the substance. In 2010, it became 
the first cathinone derivative to be risk assessed at EU level. 
At this time, seizures of mephedrone were reported by 22 
Member States. Some reported significant seizures, noting 
that production and export took place in Asia and in 
particular China. Mephedrone was readily available on the 
Internet, where it was sold usually as a powder in retail and 
bulk quantities as a legal alternative to cocaine or ecstasy. 
The substance was variously advertised as a ‘research 
chemical’, ‘bath salts’ or ‘plant food’. Although data were 
limited, the risk assessment found that mephedrone could 
be an attractive drug for those seeking stimulant effects for 
recreational purposes and that it had the potential to 
spread to other populations and countries, which may 
constitute a health and social threat. It was also found to 
have some of the same toxic features as MDMA and 
cocaine, causing acute problems similar to those seen with 
the use of illicit stimulants. Moreover, the available data 
suggested that the drug could produce dependence in 
users. However, the chronic health effects were virtually 
unknown. Based on this information the Council of the 
European Union decided that mephedrone should be 
controlled in all Member States (EMCDDA, 2011b).
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guidelines was piloted for the synthetic cannabinoid 
JWH-210. Similarly, in Hungary, substances that are 
reported by a formal notification will be ‘rapidly’ assessed 
by an expert group, which will subsequently decide whether 
they should be scheduled, and, if so, if they should be 
controlled as individual substances or as a family. In Finland, 
the possession of drugs formally notified by the EU EWS will 
be criminalised. Austria, Poland and Sweden are also 
examining tools to assess the harms posed by new drugs. In 
Romania, a project to assess the risks related to ‘legal highs’ 
has adopted the EMCDDA risk assessment guidelines.
Despite these approaches, the globalised nature of the new 
drugs market makes it particularly difficult to control and 
reduce supply. Producers and retailers have employed 
sophisticated strategies that exploit gaps in existing control 
and regulatory measures and allowed them to rapidly adapt 
to new measures. This is fuelled by differences in drug laws 
between both Member States and third countries, 
particularly those emerging economies where the substances 
are manufactured. Alongside this, insufficient control of 
freight and postal packages makes it easier to import and 
distribute new drugs into the EU. At the same time, while 
organised crime has long been a defining feature of the 
designer drug market, its growing involvement in the ‘legal 
highs’ and medicines market—where large profits and lower 
risks act as incentives—adds to the difficulties faced in 
developing effective and efficient responses aimed at 
reducing the supply of new drugs.
prison. Public health inspectors may prohibit trade of a 
‘substitute drug’ for up to 18 months in order to assess its 
safety, if there is a justified suspicion that it might pose a 
threat to health. If the drug is found to be harmful, the 
distributor is required to meet the costs of the assessment. 
The inspectors also have the right to close premises for up to 
three months. In both countries, no offence or punishment is 
set out for the users of these substances (EMCDDA, 2011c).
Several countries (Bulgaria, Latvia, Luxembourg, Romania 
and Slovakia) have introduced initiatives to improve and 
accelerate the legal response to threats posed by new drugs. 
They include introducing a temporary ban on any new drug 
that conforms to an agreed definition (Hungary, United 
Kingdom) and issuing a list of unregistered ‘quarantine’ 
substances, subject to specific control measures (Slovakia).
Penalties for selling substances that have psychoactive 
properties or present risks to health have also intensified (e.g. 
Germany, Hungary, Austria, Poland, Romania, Finland and 
Sweden). Swedish police and customs officers now have 
powers to seize unidentified substances, order a formal 
investigation of the health risks of a substance and destroy 
hazardous goods assumed to be used to achieve intoxication.
There are also national initiatives for assessing the risks 
posed by new drugs prior to introducing control measures. 
For example, Latvia has developed local risk assessment 
guidelines and an expert commission convenes twice a year 
to inform the control process. The use of these new 
For conclusions and recommendations relating to the new psychoactive substances market, please refer to pages 
138–140 in Chapter 10.
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Netherlands responsible for exacerbating France’s drug 
problems. Facing the negative impact of international drug 
tourism and increasing international pressure, the 
Netherlands re-oriented its drug policy in 1995 with a 
Ministerial Statement: ‘The Dutch drug policy. Continuity and 
change’. This introduced a more restrictive policy towards 
coffee shops and redefined guidelines for the detection and 
prosecution of illegal activities as defined in the Opium Act. 
In 1996, the Public Prosecution Service redefined the criteria 
for tolerated coffee shops (the so-called AHOJ-G criteria) (66). 
The tolerated transaction size per person was reduced from 
30 g to 5 g and local authorities were given new powers to 
take action against coffee shops. Local mayors could close 
down coffee shops temporarily or permanently if they 
ignored the AHOJ-G criteria.
The new policy sharply reduced the number of coffee shops, 
from over 1 300 in the early 1990s to 846 in 1999 and 666 
in 2009. Border municipalities strengthened their enforcement 
policies, by closing down coffee shops or moving them out of 
the city centre and towards the border. However, production 
capacity was not reduced, but was diverted to the non-
tolerated Dutch market, and to the export market.
Coffee shops or organised crime money makers
Proponents of the ‘market separation’ policy originally 
claimed that coffee shops were supplied almost entirely by 
small-scale indoor growers (Spapens et al., 2007). However, 
it became clear that there were close connections between 
the coffee shops and criminal organisations. The cannabis 
market in the Netherlands had become a money-making 
business. Korf (2003) estimated an annual turnover for the 
Dutch cannabis market of EUR 210 million in 2003. 
Bieleman and Snippe (2006) put the average annual 
turnover of a typical Dutch coffee shop at between 
EUR 280 000 and EUR 380 000, while others estimated 
Cross-border displacement of cannabis 
cultivation: a Belgian perspective
In the 1960s, the Netherlands developed what was generally 
seen as a liberal drug policy designed to achieve a 
separation of drug markets. The main aim was to curb the 
spread of ‘hard’ drugs, and heroin in particular, which was 
then cheap and widely available in Amsterdam. Cannabis 
was seen as presenting fewer risks to users, and the cannabis 
market was not expected to become highly commercialised, 
assumptions that seem—with the benefit of hindsight—
overoptimistic. In the 1970s and mid-1980s coffee shops sold 
cannabis resin, imported from producing countries such as 
Morocco, Lebanon, Nepal and Turkey. Until the beginning of 
the 1990s, domestic cultivation of cannabis was generally 
small scale and amateur; herbal cannabis was imported from 
Jamaica, Thailand and the African continent (65).
In contrast, American know-how in the indoor cultivation of 
cannabis herb had developed rapidly as a response to strict 
US cannabis controls (Jansen, 2002; Decorte, 2010). Given 
the Dutch market preference for resin, this technology was at 
first slow to take hold in the Netherlands. However, things 
changed in the early 1990s, with media reports of domestic 
indoor cultivation of strains of herbal cannabis with very 
high THC content (Niesink et al., 2007). This boosted the 
indoor cultivation of herbal cannabis, leading to what 
Jansen (2008) described as ‘The Green Avalanche’—an 
unprecedented growth of domestic cultivation.
Drug tourism and international pressure
From the early 1990s, municipalities near the Dutch border 
were visited by thousands of international coffee shop tourists 
every day, leading to diplomatic tensions between the 
Netherlands and neighbouring countries—and especially 
with the Chirac government in France, which held the 
Chapter 9 | Issues in focus
(65)  For fuller discussion of the evolution of Dutch drug markets and drugs policy, see Jansen (1989, 2008), Boekhout van Solinge (1996, 2004), Korf et al. 
(2001, 2005), De Ruyver (2006, 2011), van de Bunt (2006), van Ooyen-Houben (2006), Surmont (2007), Fijnaut and De Ruyver (2008) and Pakes and 
Silverstone (2012).
(66)  Coffee shops were not allowed to advertise (A), or sell hard drugs (H) and had to make sure there was no nuisance (O), no people younger than 18 were 
allowed in the shops (J) and the maximum transaction size was restricted to 5 g per person (G).
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complex, and different groups may be responsible for different 
levels in the distribution chain (68). Some networks are involved 
in both production and selling: buying, processing and selling 
cannabis on a large scale. Research has shown that the 
high-level players in these criminal networks are very well 
known in the world of serious and organised crime.
These networks are thought to use extreme violence against 
‘business associates’ and competitors—also called 
‘horizontal violence’ (Spapens et al., 2007)—linked to 
non-payment and ‘ripping off’ plantations. Especially in 
socially disadvantaged neighbourhoods, violence may also 
be used to coerce people into cannabis cultivation, or to 
ensure that they do not withdraw from doing so.
Grow shops now play a significant part in the organised 
production of cannabis. It appears that the majority of 
cannabis produced in the Netherlands (and presumably also 
in Belgium) is not destined for coffee shops, but is bought by 
grow shops (Spapens et al., 2007, 2011) for the non-
tolerated market. To this extent, grow shops can be seen as 
outposts of the criminal networks involved in organised 
cannabis cultivation.
Although coffee shops are primarily seen as the retail level 
of the (tolerated) chain of cannabis distribution, they may 
also play an important role in high-level distribution, serving 
as storage points for drugs in transit.
Recent developments
Recently, the Netherlands has made further significant 
changes to its tolerance policy: since January 2012, coffee 
shops have been allowed to sell cannabis only to Dutch 
residents and must also register their customers (the 
so-called Wietpas). A recent study claims that this has led 
to more nuisance, since dealers and networks are now 
focusing more on street sales to clients who are not willing 
to register with coffee shops and drug tourists who are not 
able to do so (Maalsté and Hebben, 2012). This may 
generate additional opportunities for the criminal networks 
in expanding their selling business to non-tolerated 
premises and the streets, especially in Belgium, avoiding 
local enforcement around the coffee shops (Fijnaut, 2012). 
In fact, Belgium’s main concern is not so much street sales, 
but the displacement of Dutch criminal networks to 
Belgium, to shorten the distance between supply and 
demand (especially from French drug tourists), which may 
result in a further increase in cannabis plantations in 
Belgium (Beckers, 2012).
that the Checkpoint coffee shop in the Dutch border 
municipality of Terneuzen had a weekly consumption of 
100 kg of cannabis, and an annual turnover of 
approximately EUR 40 million (Vanhove et al., 2012b).
Displacement into Belgium
The stricter enforcement of the laws against large-scale 
cannabis cultivation in the Netherlands resulted in a 
shift—or displacement—of cultivation to the Belgian border 
region, where the risk of detection was lower (67). Most of 
the plantations discovered by the Belgian police forces were 
run either by Dutch entrepreneurs or by individuals with 
strong connections with the Netherlands, taking advantage 
of Dutch know-how in growing cannabis; in addition, most 
of the cultivation equipment for the plantations originated 
from Dutch grow shops.
There was a steep rise in the number of plantations discovered 
in Belgium, as the experience and skills of Belgian police 
developed. In 2003, 35 plantations were discovered and in 
2010 this number was close to 1 000 (Figure 29), these being 
concentrated along the border with the Netherlands.
Figure 29:  Cannabis plantations discovered in Belgium, 
2003–2010
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Source: Belgian Federal Police, Desk Production DJP/Drugs.
Violence and grow shops
The organisation of cannabis distribution networks in the 
Netherlands and Belgium is known to be multilayered and 
(67) For more details, see Fijnaut and De Ruyver (2008), Van Camp (2012) and Vanhove et al. (2012b).
(68) For more details, see Bovenkerk and Hogewind (2003), Spapens (2011), Spapens et al. (2007) and Vanhove et al. (2012b).
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is not an online shop in itself, and in this respect is 
comparable to sites such as eBay. A recent study (Christin, 
2012) found that the vast majority of customer feedback is 
positive. This can be an important driver for recruiting new 
clients. Sellers have the possibility of working in a so-called 
‘stealth’ mode, which allows them to operate within a 
trusted customer environment and by invitation only, 
keeping their business even further out of reach of the 
authorities. Drugs can be delivered from/to any place in 
the world.
In line with the increase in new psychoactive substances, the 
results of an EMCDDA study suggest that the number of 
online shops selling new drugs/‘legal highs’ has continued 
to grow over the last few years. The number of shops 
identified in January 2012 was more than three times 
greater than in January 2010. At the same time, sales 
practices in this area appear to have become more 
complex, aimed at better restricting access and protecting 
the identity of buyers and sellers (see also Chapter 8).
The Internet is becoming a more important tool for 
promoting new drugs, but its role as a marketing tool also 
for ‘traditional’ drugs should not be disregarded. The 
Internet provides a secure and low-cost way for sellers to 
advertise these substances and build consumers’ interest. 
Sharing experiences, reviews and opinions in online 
communities raises the interest of potential clients. As with 
other drugs, the Internet has also made it easier for people 
to learn about ‘legal highs’, share their experiences of using 
them and provide advice and support to others.
Increased possibilities for recruitment 
Investigations show that social networking sites such as 
Facebook can be an efficient tool for recruiting EU citizens 
as couriers. OCGs have been known to use the social 
networks of their trusted couriers to recruit more people 
The Internet as a facilitator for drug 
trafficking
Internet technology increasingly facilitates a wide range of 
serious and organised crime activities, acting as a 
communication, research, logistics, marketing, recruitment, 
distribution and payment tool. In addition to high-tech 
cybercrime, payment card fraud, the distribution of child 
abuse material and audiovisual piracy, the Internet facilitates 
illicit drug synthesis, extraction and distribution, the 
recruitment of victims of human trafficking, the supply of 
counterfeit goods and many other criminal activities. It is 
also widely used as a money laundering tool by criminal 
groups (Europol, 2011a). In the near future the vast majority 
of investigations into transnational organised crime will 
necessitate some form of Internet investigation. The online 
investigation of criminal networks should be a commonly 
used tool (Europol, 2011b).
Drug distribution environment 
Internet technology has emerged as an important facilitator 
for drug markets, and is commonly used in the marketing 
and sale of new psychoactive substances (new drugs). 
Recently, it has become clear that practically any type of 
drug can be bought on the Internet. Consumers may feel 
more secure as they can avoid direct contact with drug 
dealers and benefit from anonymous communication. At the 
same time, drug dealers benefit from less exposure, 
reducing the chances of being detected.
Various reports note the existence of anonymous online 
markets selling conventional drugs and other illegal products 
such as weapons, forged documents or even child abuse 
material. These online markets provide a high level of 
secrecy, as they exist in the deep web, and in the so-called 
‘darknets’, which frustrates law enforcement owing to 
difficulties in identifying the sellers and their customers. 
Various methods of payment are used, including PayPal, 
prepaid payment cards and virtual currencies (or crypto-
currencies) such as bitcoin, which is commonly used and 
considered almost untraceable. An important factor in the 
success of such markets is the fact that buyers are able to 
rate sellers and review the products, enabling products and 
sellers to build a reputation.
Silk Road is one example of an anonymous online 
marketplace that has an international reach. Available 
information suggests that it is used in trafficking controlled 
drugs, including cannabis products, opiates and synthetic 
drugs. Like other anonymous markets, Silk Road offers a 
platform for transactions and its main focus is on reducing 
the possibility of identifying either the seller or the buyer. It 
Darknets
Darknets, in this context, are anonymising computer 
networks which allow for the hosting of services within 
them. Unlike the deep web, these services do not exist on 
the conventional worldwide web and require a user to 
download software to access them. The primary advantage 
of using a darknet is that it is very difficult to identify where 
a service is hosted in the real world and the IP addresses of 
those visiting these services are anonymised from external 
observers. The Onion Router (TOR) is by far the most 
commonly known darknet in use today.
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equipment. The Internet allows illegal entrepreneurs to 
search the scientific and patent literature for a range of 
substances that have psychoactive effects, in particular those 
that mimic the effects of controlled drugs that they can sell.
It also puts them in contact with chemical manufacturers and 
suppliers in emerging economies such as China and India, 
where large-scale synthesis is cheaper and less subject to 
scrutiny than in Europe. In turn, it also provides a low-cost 
way for manufacturers and wholesalers to sell these 
substances in bulk to customers. Investigations on new drugs 
have shown the important role of the Internet in providing 
access to the legal framework on controlled substances in 
EU Member States, allowing OCGs to relocate import and 
redistribution to countries with legislation gaps.
Internet applications also enable remote monitoring of 
production and storage sites. In addition, the availability of 
devices equipped with locating technology has resulted in a 
new modus operandi for drug collection in destination 
markets, specifically retrieval from caches using GPS and 
online maps (Europol, 2011a).
What makes the Internet a relevant facilitator for drug 
trafficking is the reach it can have. Available information 
suggests that drug trafficking organisations try to capitalise 
as much as possible on the advantages of the online 
environment. The EU comprises 7 % of the world’s 
population, but 16 % of the Internet users (360 million 
Internet users). Penetration of the Internet in the EU is more 
than twice the world average. There are 170 million 
Facebook accounts in the EU (69). In theory, Internet 
technology gives organised crime the ability to reach large 
audiences in terms of marketing, trade or recruitment, 
without geographical limitations and without any physical 
contact that would jeopardise their position.
into their criminal endeavours. The trips couriers have to 
undertake, especially to exotic destinations in Asia or 
South America, are positively presented to the network of 
friends as profitable holidays. The significance of 
trafficking drugs for organised crime is downsized to a 
minor, secondary, role.
The Internet can play an important role in attracting 
consumers, especially first-time users. The feeling of security 
is promoted by the lack of face-to-face contact and lack of 
proximity to organised crime elements, and probably has a 
bigger effect on younger users.
The preferred communication tool for organised 
crime networks
In recent years the Internet has become the preferred 
communication tool for organised crime as it offers a high 
degree of confidentiality. In particular, the perceived 
anonymity afforded by communications technologies such 
as web mail, secure instant messaging and Internet 
telephony has led to these being used increasingly by OCGs 
as a countermeasure to law enforcement detection and 
surveillance. Even groups regarded as more closely knit than 
technologically aware, such as Albanian-speaking groups, 
have recognised the value of platforms such as Skype. 
OMCGs also use social networking sites to communicate 
(Europol, 2011a).
Access to resources
The online environment provides access to a wide range of 
information on how to produce drugs, from growing 
cannabis to setting up laboratories to produce synthetic 
drugs, as well as opportunities to procure raw materials and 
(69) Internet World Stats—http://www.Internetworldstats.com (data to 31 December 2011, accessed 29 August 2012).
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terrorism. In May 2010, all five alleged key organisers were 
arrested simultaneously; two in Italy, two in the United 
Kingdom and one in France. In a related operation a few 
days earlier, French authorities arrested another six 
members of the same organisation (Eurojust, 2010).
Is the EU drug market financing terrorism?
The best-evidenced case of this in the EU were the Madrid 
bomb attacks in 2004, which were funded by money 
obtained from drug trafficking. The attack killed 191 people, 
wounded nearly 2 000 and caused millions of euros’ worth 
of damage to property. One of the terrorist cell members 
was a drug trafficker who was radicalised while serving 
time in prison in Morocco. He reportedly supported the 
Spanish terrorist cell financially by trafficking hashish and 
ecstasy. The drug-related activities were significant, 
considering that drugs worth over EUR 1 million were found 
by Spanish authorities. The explosives used in the attacks 
were obtained in exchange for large volumes of hashish.
There is information to suggest that EU-based separatist 
movements may be directly involved in drug trafficking, 
although some of them are also thought to control, or ‘tax’, 
local trafficking networks. Intelligence suggests connections 
between Somali OCGs trafficking khat (miraa) to the EU 
and the Al-Shabaab movement, which raises the possibility 
that the proceeds may fund terrorist activities (Europol, 
2011a). It should be noted here, however, that the legitimate 
khat trade is large in East Africa and therefore likely to be of 
interest to both criminal and terrorist organisations, and that 
this substance, which is not controlled under the international 
drug control conventions, is also shipped legitimately to 
some parts of the EU, where it is not currently prohibited.
The Kurdistan Workers’ Party (PKK), a Kurdish separatist 
movement, is involved in criminal activities in the EU, from 
which it is estimated to gather annual proceeds of around 
EUR 20 million. The PKK is often accused of being involved 
in drug trafficking. Although several known PKK members 
have been involved in drugs trafficking cases, establishing 
the financing of the organisation itself from this source is 
more challenging, owing to the difficulties of tracking the 
money outside EU borders. Nonetheless, the Turkish 
authorities strongly maintain that the PKK is involved in drug 
trafficking. Intelligence also suggests that the Tamil Tigers 
from Sri Lanka have also obtained some money from drug 
trafficking in Europe.
Considering that Europe is one of the world’s biggest 
markets for both cocaine and heroin, organisations such as 
the FARC (Revolutionary Armed Forces of Colombia) and the 
Taliban are likely to be financed to some extent—whether 
Drug trafficking and terrorism
This section examines some of the links between drug 
trafficking and terrorism. It is recognised that the concept of 
terrorism is a complex one. This chapter does not seek to 
explore definitional issues; rather, the focus here is on the links 
between the drug market, OCGs and terrorist groups. The 
need to fund terrorist activities, and the profits that can be 
obtained from drug trafficking, means that the line between 
terrorism and organised crime is becoming increasingly 
blurred. The areas in which terrorist groups operate also 
include drug-producing regions and/or countries attractive to 
drug traffickers because legal and political systems are 
fragile. Thus, it is clear that there are links between terrorism 
and organised crime, and there is evidence to suggest that at 
times ideologically motivated terrorist groups and profit-
motivated crime groups have used each other’s knowledge, 
expertise and capabilities for mutual benefit.
The illegal drug trade and finance for terrorism
Terrorist organisations cannot function without financial 
resources. In order to raise money they employ methods that 
are both legal, such as collecting donations from 
sympathisers or running their own legal businesses, and 
illicit, including traditional types of criminality as well as 
exploring new technologies and cyber criminality for the 
same purpose. Some terrorist organisations are known to 
have engaged in various types of criminality, including the 
abuse of social benefits, extortion, kidnapping, human 
trafficking, skimming schemes, credit card and cheque fraud, 
cigarette smuggling and insurance fraud (Europol, 2012).
There is a strong consensus among enforcement agencies 
that drug trafficking is used by terrorist organisations as a 
source of funding. Intelligence sources have often 
established the association between terrorism financing and 
drugs trafficking. Given the geographical location of many 
terrorist groups, and their need to obtain financing, the fact 
that they may be interested in the income obtained from the 
drug market is not surprising. The rationale for involvement 
clearly exists, even if obtaining strong judicially acceptable 
evidence of a direct link between the two is often difficult. 
These difficulties impact on prosecution for terrorism 
financing. As a result, few cases have been prosecuted in 
Europe.
Some illustrative examples do exist. In 2007, an investigation 
started in Italy into the activities of an OCG active in 
Afghanistan, Pakistan, Romania, Albania and Italy. The 
group had its headquarters in Rome and Milan, and was 
involved in facilitating illegal immigration and drug 
trafficking for the purpose of financing religiously motivated 
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Direct financing
Some organisations, such as the FARC and the Taliban, are 
involved in the different stages of cultivation, processing 
and smuggling of drugs. This is reportedly happening in 
the Afghan/Pakistan area, where the Taliban are suspected 
of having moved from taxing opium and heroin producers 
and traffickers to controlling the market. Various sources 
indicate that the Taliban and other anti-government forces 
in the region are largely financed by the heroin business. It 
has been estimated that the Taliban generated some USD 
155 million from the opiate trade in 2009 (UNODC, 
2011a). The FARC is involved in different stages of cocaine 
production and trafficking. Some observers have remarked 
that the FARC’s interest in drug trafficking has increased 
with time. Several prominent members of the FARC have 
been arrested and extradited to the United States, where 
they have been sentenced for trafficking large quantities of 
drugs.
Indirect financing
An indirect way to benefit from drug money is by levying 
taxes on the traffickers. There are indications that groups 
affiliated to Al Qaeda in the Islamic Maghreb (AQIM) are 
making profit from taxes levied on traffickers crossing its 
zone of influence. The Sahel region plays an increasingly 
important role as a transit area for drugs, especially 
cocaine, but also cannabis and heroin. Sources indicate that 
AQIM provides protection for traffickers and their cargo in 
exchange for money. Intelligence suggests an evolution 
towards a more direct involvement of AQIM in the drug 
trade and establishment of links with Latin American OCGs.
directly or indirectly—by the profits generated from drug 
trafficking in Europe. How much of this money ends up in 
the coffers of these organisations is difficult to assess. 
However, in very simple terms, even if a small proportion of 
the proceeds of drug trafficking supports the activities of 
terrorist organisations, the potential harm to society can be 
significant. In situations where groups engaged in terrorism 
have lost the support of states which previously financed 
their activities, drug trafficking may have become a more 
important way to raise money. The EU drug market is one of 
the most profitable in the world and big enough to 
accommodate new actors with such interests.
EU drug trafficking allows micro-financing of 
terrorist activities
Groups that engage in terrorist activities sometimes require 
substantial financial resources, but, for the most part, money 
is needed for purposes quite separate from the financing of 
attacks. Extensive funding can be required for propaganda, 
living expenses, training, logistics, websites, travel and other 
expenses. The costs of the actual terrorist attacks can be low 
enough to be financed by small-scale distribution of drugs 
(FATF, 2008). Expert opinion suggests that the costs of such 
attacks have decreased over time. This type of micro-
financing is difficult to identify and to link to terrorist 
organisations. The Madrid case is proof that a high-impact 
attack can be carried out with relatively small-scale 
resources. The main challenge for law enforcement in such 
cases is to be proactive, because the proceeds of the drug 
trade are outside legal financial flows, making detection 
almost impossible. Furthermore, links with the main 
organisations are difficult to make.
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years. The number of joint investigation teams (JITs) has also 
increased. Seven JITs on drug trafficking cases were initiated 
in 2011, compared with only three in 2010.
As to the geographic distribution of cases referred to Eurojust, 
the Member States most heavily involved in this type of crime 
(as measured by requesting and being asked for judicial 
cooperation) are Spain (164 cases) and the Netherlands 
(155), followed by France (110), Italy (107) and Germany (89) 
(Figure 31). An analysis of the crime type association confirms 
High-level drug trafficking through 
the lens of Eurojust casework
Eurojust is the EU judicial cooperation body, created in 
2002 to facilitate and coordinate cross-border serious crime 
cases. Accordingly, EU Member States refer cases to this 
body when requiring a high level of cross-border 
cooperation and coordination. Drug trafficking is one of the 
most common types of crime dealt with at Eurojust, and over 
the years a wealth of experience has been accumulated.
This section describes various aspects of Eurojust’s casework 
on drug trafficking from a quantitative and qualitative 
perspective. First, a statistical overview of casework is 
presented. This is followed by two examples on the sort of 
judicial cooperation required to deal with these cases. The 
final paragraph summarises proposals for improving 
Eurojust’s drug trafficking casework.
Statistical overview
Between September 2010 and August 2012, Eurojust 
registered 512 drug trafficking cases (compared with 450 in 
the previous two-year period) (Figure 30). The increase in 
complexity of the workload in this area can be seen from 
the type of assistance provided by Eurojust. Between 2010 
and 2012, Eurojust organised 105 coordination meetings 
with prosecutors and investigators in charge of high-level 
drug trafficking cases, double the figure for the previous two 
Case study 1: Drug trafficking by an Albanian 
organised group
Tackling drug trafficking originating in the Western Balkans 
has been identified as one of the seven EU priorities to 
combat organised crime, as the region is both a key transit 
and storage zone for illicit commodities destined for the EU 
and also a logistical centre for OCGs, including Albanian-
speaking OCGs.
The French authorities initiated a case at Eurojust involving 
Belgium, Italy and the Netherlands and supported by 
Europol. The target was an Albanian OCG trafficking 
heroin and cocaine.
Following meetings held at Eurojust to agree information 
exchange and coordination, a concerted plan of action 
was agreed. This led the investigators to detect an imminent 
trafficking operation involving drug transport from the 
Netherlands to France. In March 2012, a coordination 
centre was set up at Eurojust with on-the-spot analysis 
support by Europol focal point Copper in order to ensure 
smooth information exchange when the trafficking 
operation was intercepted.
The individuals transporting the drugs were arrested and 
the drug seized, which triggered 17 subsequent arrests, 
several house searches in France and the Netherlands and 
seizure of almost 12 kg of heroin in total. The Italian 
authorities, which had been targeting the same criminal 
network for approximately one year, in close cooperation 
with the French and Dutch police forces, launched in May 
2012 an operation in Italian territory resulting in the 
execution of 13 arrest warrants and the seizure of 15 kg of 
cocaine and 4 kg of heroin.
As mentioned above, coordinated action was agreed during 
meetings held at Eurojust. Because the criminal network was 
flexible and could adapt quickly to new developments, the 
investigative bodies in the countries involved had to 
exchange information intensively, including round-the-clock 
for a period of approximately two weeks leading up to the 
operation, all channelled through Eurojust.
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Figure 30:  Cases of drug trafficking handled by Eurojust, 
2004–2012
Note: 2012 data refer to the first half of 2012 only.
Source: Eurojust/Case Management System.
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Figure 31:  Distribution of requests for assistance on drug trafficking cases, 2010–2012
Note:  The map shows the geographical distribution of the national desks that requested assistance from Eurojust (requesting) and the desks that were 
requested by Eurojust to provide assistance on drug trafficking cases handled between 1 September 2010 and 31 August 2012.
Source: Eurojust/Case Management System.
that criminal organisation and money laundering are very 
often involved in the drug trafficking cases referred to Eurojust.
Case studies
The two case studies selected here illustrate the type of 
cooperation activities carried out when dealing with 
high-level drug trafficking cases at Eurojust. The first example 
refers to a ‘coordination centre’, a recently created tool that 
offers a central point for all parties on a specific day of joint 
action in several countries, with dedicated telephone 
contacts/e-mail addresses and people able to speak the 
languages needed to distribute and forward any information 
in real time. This tool is already popular with practitioners 
and will play an important role in the future.
The second example is of one of the JITs set up to disrupt 
international criminal networks. The financing of JITs by 
Eurojust is recognised by national authorities as a rapid and 
efficient way of establishing JITs at short notice. Aside from 
its role in funding JITs, Eurojust assists in other ways, such as 
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providing extensive advice and guidance on drafting, 
amending and extending JIT agreements and operational 
action plans.
Challenges for judicial cooperation
The complex activities required to coordinate high-level drug 
trafficking cases are described in detail in a recent analysis 
of Eurojust’s casework (Eurojust, 2012), which touches upon 
the various difficulties encountered in information exchange, 
JITs, controlled deliveries, execution of European arrest 
warrants, transfer of evidence or criminal proceedings, 
implementation of mutual legal assistance requests and 
international asset recovery.
On the basis of this analysis, Eurojust has formulated an 
action plan with recommendations to improve its casework 
(Eurojust, 2012). This is intended to improve coordination 
and communication between national authorities within the 
EU, and to promote participation of Europol and of third 
countries. It set out guidelines for dealing with jurisdictional 
conflicts, and encourages cross-border asset recovery.
Case study 2: Tokyo case (drug trafficking 
and JIT)
This case, opened at Eurojust in April 2011, concerns 
international drug trafficking from Brazil and some Central 
African countries to Japan via London using couriers 
recruited in Belgium and France. Two coordination meetings, 
in which Japanese representatives participated, were held to 
facilitate the exchange of information and the execution of 
letters of request. In July 2011, a JIT agreement was signed 
between Belgium, France and the United Kingdom, with the 
participation of Eurojust and Europol. In October 2011, a 
joint operation took place, with several arrests in Belgium 
and the United Kingdom. The investigation procedure was 
speeded up as a result of the coordination meetings and the 
JIT. In December 2011, two people were tried in Japan and 
found guilty: one was sentenced to eight years’ imprisonment 
and received a fine of EUR 3 780 and the other was sent to 
prison for six years and six months and received a fine of 
EUR 30 000. The financing through the Eurojust JIT funding 
project facilitated the successful execution of Belgian letters 
of request in Japan and Brazil.
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these key information needs are identified and discussed in 
the concluding section of this chapter.
Drivers of change for the modern 
European drug market
The changing faces of organised crime 
and drug trafficking
Historically, analysis of the drug market has tended to focus 
on specific drugs that are being trafficked along defined 
routes by OCGs which are, to some extent, specialised 
operators. This simplified geographical perspective is still 
valid and useful for targeting actions on high-priority areas. 
However, this picture now needs to be extended to take 
account of the more polymorphous, dynamic and fluid 
nature of the contemporary European drug market. OCGs 
are increasingly likely to take a multicommodity perspective 
and less likely to specialise in only one type of drug. At the 
same time, trafficking routes are also diversifying, in terms of 
both the types of drugs that are shipped along them and 
their geography, which is becoming increasingly 
heterogeneous and complex. Moreover, the growing 
exploitation of established commercial transport options 
means that, in many respects, thinking about discreet routes 
can be unhelpful simply because nowadays drugs may be 
moved through complex webs of interconnected channels.
Many examples of this diversity can be found in this report. 
For instance, heroin and cocaine may be trafficked through 
Africa and the Western Balkans and methamphetamine 
through Europe and possibly even South-West Asia. The 
implications of such developments for drug markets and 
existing supply reduction strategies can be profound, as is 
illustrated by the fact that significant cocaine seizures and 
imports are now reported in East European countries, or that 
methamphetamine now appears to be manufactured in Iran 
and Nigeria for export to East Asia via European airports.
There are a number of factors that are responsible for this 
growing market diversification. Globalisation is clearly 
important, with more countries now used as potential transit 
points, and the European drug market now having to be seen 
Introduction
This report has drawn together, for the first time, an 
unparalleled amount of information about the structure and 
operation of European drug markets and placed this 
information within the broader context of an understanding of 
the drugs phenomenon. This area has become an 
increasingly dynamic one, with new realities emerging to 
challenge long-held certainties in a way which only a few 
years ago would have been hard to imagine. The analysis 
reported here suggests that Europe is now entering an 
important new phase in respect to developments in the 
availability and use of drugs. This perspective is, however, of 
little value if it does not serve to inform future policies and 
actions. To facilitate this, this chapter analyses the data 
discussed in the body of the report to provide an overview 
and identify key conclusions and learning points. The 
operational implications of these are then developed in 
accompanying action points. The analysis provided is 
intentionally pragmatic and practically orientated, making the 
best use of the information available while acknowledging its 
limitations. The focus is on the European level, but it is 
recognised that the conclusions will also have relevance for 
policy considerations in individual Member States.
A top-level strategic summary and recommendations were 
provided at the beginning of this report. The basis for this 
can be found in the analysis provided in this chapter, which 
is structured in three parts. First, a number of linked factors 
that can be seen as drivers of contemporary developments 
in the European drug market are explored. These are not 
necessarily substance specific and generate 
recommendations for actions that are generally applicable. 
Next, conclusions that specifically pertain to the trafficking 
and marketing of individual drugs are considered in 
isolation in the second section of this chapter.
Finally, the information available to guide policies and 
actions in this area is considered. This report provides a 
comprehensive overview of the current European drug 
market. Nonetheless, it is clear from this analysis that data 
sources are underdeveloped in many areas, and this inhibits 
both an understanding of the problem and, critically, the 
development and targeting of effective responses. Reflecting 
Chapter 10 | Conclusions and recommendations
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patterns of drug use in Europe, and indeed globally, make 
OCGs more interested in the profit that can now be derived 
from synthetic and stimulant substances. Importantly, groups 
have to be adaptive if they are to continue to operate over 
the longer term. This requires the development of 
‘countermeasures’ with new approaches introduced to 
respond to successful supply reduction responses, such as 
the targeting of precursor chemicals, or known high-value 
trafficking routes and methods. This gives the drug market its 
dynamic and constantly evolving nature.
within the larger context of the changing international 
demand for drugs. This has been accompanied by the impact 
of open borders within the EU and a trend in Europe for drug 
production to take place close to its intended marketplace, 
with the rationale of minimising the risks associated with 
transportation and increasing potential profits.
The modern European drug market is also increasingly 
innovative and dynamic, which reflects, and exploits, the 
broader changes that have occurred in modern forms of 
communication and commerce. Additionally, changes in 
Action points
•   Strategic analysis: Strategic-level analysis with regular 
review is critically important to ensure that responses 
remain on target and meet the challenges posed by 
complex, faster moving and more interlinked drug 
markets.
•   Focus efforts on high-value targets: Targeted, 
coordinated and intelligence-led law enforcement 
actions against major OCGs, such as that provided by 
JITs supported by centralised analysis, must be 
regarded as a high priority.
•   Work more effectively through coordinated actions: EU 
Member States have the capacity for the rapid and 
secure sharing of information, and resources to support 
coordination are available. This should be exploited 
and EU agencies should be utilised to increase the 
effectiveness of cross-border and multilateral 
operations.
•   Keep track of moving targets: It is important to share 
intelligence on the geographical relocation of 
individuals with the expertise and motivation to exploit 
established infrastructure. Greater police and judicial 
cooperation is needed to track, target and disrupt the 
activities of high-value criminals and groups.
•   Follow the money: The investigation and prosecution of 
drug trafficking cases should be facilitated by 
multidisciplinary investigating teams that include 
specialist financial investigators and forensic 
accountants, with a focus on dismantling organised 
crime rings, developing prosecutable evidence, 
interrupting criminal money flows and money 
laundering and promoting international asset recovery, 
refining monitoring and detecting tools and drawing up 
typologies.
•   Address the legitimate commercial market: The growing 
challenge of intercepting drugs trafficked at high speed 
through complex routes using commercial channels is a 
major threat and requires the development of specific 
action plans targeting each of the sectors concerned. 
Partnership with industry and European-level 
cooperation and coordination will be essential for 
success.
Overview
•  Moving to a multi-commodity perspective: The 
European drug market is more polymorphous, dynamic 
and fluid. OCGs are more likely to be linked and take 
a multi-commodity perspective and are less likely to 
restrict their activities to a single drug type.
•   Diversification in trafficking: Trafficking routes are 
diversifying, in terms of both the types of drug that are 
shipped along them and of greater geographical 
heterogeneity and complexity.
•   Exploiting legitimate transportation opportunities: The 
exploitation of established commercial logistics, such as 
containers, aircraft, couriers and postal services, means 
that drugs may be moved through multiple transit points 
and complex channels. This dynamic and fluid 
operational model is more challenging to tackle than 
the one used for more linear and fixed geographical 
trafficking routes.
The changing face of organised crime
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difficult to discern. More recently, synthetic drug production 
has been noted in the region and drug flows through 
African countries have become more complicated and 
interrelated, with heroin, cocaine, cannabis and, now, 
synthetic drugs all playing a part.
The global dimension of the drug problem, together with the 
need to maintain a secure external border, makes it 
important for the EU to engage at all levels with non-EU 
countries and to take part in appropriate international and 
regional initiatives. There are many examples of the benefits 
that this kind of cooperation can bring. There are, however, 
some factors, such as a lack of respect for fundamental 
human rights and corrupt practices at senior levels that can 
inhibit fruitful or full collaboration between the EU and third 
countries. Furthermore, frustrations with domestic social and 
criminal problems associated with the drug market, together 
with broader political issues, can be noted in some Latin 
American countries. It remains unclear if this issue will have 
longer term implications for EU policy priorities to suppress 
production and trafficking from this region.
Any discussion of the more complex geographical nature of 
drug flows into and through Europe needs to bear in mind 
an important caveat, namely the importance of OCGs 
based in North-West European countries, which continue to 
play a key role in the intra-European distribution of almost 
all types of drugs. There are a number of reasons for this, 
including their proximity to major markets; the fact that this 
area is a hub for legitimate transportation; and the capacity 
that is provided by the existence of long-established drug 
redistribution networks.
It is also important to conclude any analysis of the global 
market by noting that the EU is also a drug-producing region 
for precursor chemicals of synthetic drugs and, increasingly, 
for cannabis. The importance of the EU in relative terms as 
an exporter of synthetic drugs seems to be declining as 
production in other parts of the world becomes more 
important. Nonetheless, continued efforts to disrupt the 
production of drugs intended for export, and measures to 
control the diversion of precursor chemicals, especially 
acetic anhydride, remains a priority. The EU is also a source 
of expertise and ‘know-how’ for the production of some 
synthetic drugs and intensive cannabis cultivation 
techniques. And increasingly it plays a leading role in the 
packaging, marketing and promotion of products containing 
new psychoactive substances, with some recent indications 
of export to non-EU countries.
Taken together, the factors driving developments in the drug 
market represent a major challenge for existing European 
drug control strategies. The problem is now more complex, 
faster moving and interlinked, and this needs to be reflected 
in our responses. Supply reduction measures, if they are to 
be effective, need to be reactive to change and, ideally, 
anticipate future developments. A wide perspective is also 
clearly called for. At the global level drugs are an important 
illicit commodity and form a nexus with other important 
security concerns, such as the fight against terrorism and the 
need to support social development and fight corruption. At 
the other end of the scale, within the EU, local drug markets 
are inextricably linked with broader crime and policing 
issues, with drugs exacerbating many of the social and 
health problems found in Europe today.
The impact of global developments on the 
European drug market
A theme running through this report is that it is impossible to 
understand the contemporary European drug market without 
locating it within a global context. An often overlooked point 
is that the world is undergoing a period of rapid 
development that is resulting in profound demographic and 
social changes. Data on the extent of drug use at the global 
level are poor, which means that quantification is 
disproportionately focused on developed regions, such as 
the EU. Awareness of important changes occurring in drug 
use in other areas is therefore insufficient or simply lacking.
This is a growing problem as urbanisation in low- and 
middle-income countries with large and young populations 
means that patterns of global drug demand are likely to be 
changing significantly. For example, domestic demand for 
cocaine in South America and for heroin in Asia is now 
estimated to be greater than in the EU. These changes have 
a number of potential implications for the drug market: drug 
flows are becoming more fluid; production is diversifying; 
and the existence of domestic markets in transit countries 
complicates drug control efforts. Moreover, the extent to 
which other markets are now competing with demand from 
the EU, and the resulting changes in trafficking flows, remain 
poorly understood.
Of growing importance for the EU is the changing situation 
in Africa. Weak legal and regulatory systems have made 
the region an important transit and storage area. A number 
of information sources suggest that domestic demand for 
drugs is growing and diversifying, but the overall picture is 
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can have a profound impact on the drug market. Mobile 
phones are a means of rapid and easy communication that 
preserves anonymity and reduces risks, as buyers and sellers 
no longer have to meet in a predefined geographical place. 
Today, the Internet, and the growth of all forms of social 
networking, is opening up new possibilities at a remarkable 
pace and at a low cost. Controlling unwanted activities in 
this medium is extremely challenging, and issues of 
jurisdiction are complex. We live in an increasingly joined-up 
world, with new communication options, and easy and 
unrestricted access to vast information resources that were 
Technology as a driver for innovation
Technological advancements have changed virtually all 
aspects of modern life, so it is unsurprising that they are also 
important drivers for changes occurring in the illicit drug 
market. The analysis offered in this report has repeatedly 
identified technology as a significant ‘game-changer’ in 
drug trafficking, production and distribution.
The advent of the widespread use of mobile phones provides 
a simple, but often overlooked, example of how technology 
Action points
•   Improve analysis of global trends: Analysis of 
developments in drug demand and drug supply in 
non-EU countries is necessary to provide an early 
warning of potential new threats and allow the better 
targeting of responses.
•   Engaging with producer and transit countries remains 
important: Changes in drug production and the more 
fluid nature of drug flows into Europe mean that it is 
now important to engage and cooperate with a larger 
number of source and transit countries.
•   Reduce production in, and trafficking from, the EU: 
Greater efforts are required to address the growing 
threat posed by drug production within the EU, and 
continued efforts are needed to suppress the trafficking 
of drugs and precursor chemicals from the EU.
•   Give special attention to Africa: Developments in Africa 
require special attention, informed by the fact that 
social, developmental, governance and crime issues 
are interlinked there. There is a critical lack of 
information on issues such as interactions between 
drug trafficking routes, local demand, money 
laundering and developments in drug production.
Overview
•  A changing global marketplace: Socioeconomic 
developments mean that the EU is likely to become 
relatively less important in global terms as patterns of 
drug demand change in the developing and 
transitional world. This has the potential to influence 
drug flows and availability and make interdiction 
efforts more challenging.
•   The need for international cooperation: Cooperation 
between the EU and non-EU countries, and appropriate 
regional and international initiatives, are of growing 
importance. Fruitful cooperation in this area needs to 
be informed by other EU measures to fight corrupt 
practices, support development and promote respect 
for human rights.
•   The growing importance of Africa: Africa has become 
an important transit and storage area for drugs, and 
domestic demand is also likely to be growing. Drug 
flows have become more complicated, with heroin, 
cocaine, cannabis and now synthetic drugs all playing 
a part.
•   The EU as a drug producer: The EU remains an 
important drug-producing region for some synthetic 
drugs and cannabis, although its relative importance 
for the export of synthetic drugs is declining. The EU is 
also an important global source of the heroin precursor 
chemical acetic anhydride.
•   North-West Europe remains important: Within the EU 
crime gangs based in North-West Europe continue to 
play a pivotal role in the inter-European trafficking and 
distribution of virtually all types of drugs.
Addressing a global marketplace
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has also facilitated research and development of new 
products by giving access to the scientific literature, patent 
information, as well chemical and pharmaceutical archives.
A related issue here is the use of the Internet for the sale of 
controlled and counterfeit medicines. Knowledge about the 
Internet sale of pre-precursors, other essential chemicals and 
controlled drugs has grown. The scale of this problem in 
respect of controlled drugs is difficult to assess but probably 
remains small at present. Nonetheless, the development of 
secure payment technology and restricted web areas could 
mean that this situation could change quickly. Although the 
Internet represents a new and challenging area for law 
enforcement and drug control in general, a model of value 
here can be found in work carried out to crack down on the 
sale of falsified, counterfeit and unlicensed medicines and to 
fight other forms of cyber crime. The approach has been to 
target websites and to work in partnership with major credit 
card issuers and other online payment providers. 
Internationally coordinated and parallel activities have 
previously unavailable. The communication opportunities 
provided by the Internet are now beginning to impact on the 
drug market. This is happening quite quickly and must be 
regarded as representing a considerable potential threat. 
Although other forms of cyber crime have until now attracted 
more attention, the anonymity afforded by the possibilities of 
an online drugs market is clearly attractive to those who want 
to sell illicit drugs.
The advantages of the Internet as a relatively secure 
communication medium for those involved in clandestine 
activities are obvious. More than this, however, the Internet 
has allowed information on drug use and production to 
spread rapidly, facilitating the diffusion of trends and 
‘know-how’. A whole new market for ‘new drugs’, 
unregulated psychoactive substances, that is global in nature 
and highly innovative, has quickly become established. The 
Internet has enabled contact between chemical producers 
and entrepreneurs located in different parts of the world and 
the marketing and sale of attractively packaged products. It 
Action points
•   Monitor the online market: Improved and more 
proactive monitoring of the Internet is necessary to 
provide a better understanding of the nature and scale 
of the online market and of new developments at both 
consumer and supply level and to provide early 
identification of new trends and threats.
•   Create barriers to Internet sales: Websites involved in 
illegal activities associated with the drug market need 
to be identified and action taken with service providers 
to restrict access. Partnerships with major credit card 
issuers and other online payment providers are 
required to inhibit payments. Effective actions in this 
area are likely to require EU coordinated activities. 
Complementary measures to raise awareness and 
increase vigilance among postal and courier services 
are also needed.
•   Innovate to anticipate and detect new threats: There is 
a need to develop and share information from sources 
sensitive to important changes in the drug market. 
Forensic data and profiling, including data on 
precursors and adulterants, wastewater analysis, and 
the analysis of data from production facilities are all 
currently underutilised but potentially valuable 
approaches.
Overview
•   The growing importance of the Internet: The Internet is 
now beginning to impact on the drug market by 
providing communication opportunities, access to 
knowledge and logistics, and a platform for the faster 
diffusion of new trends.
•   The potential for an online drug marketplace: The 
Internet has facilitated the development of a new 
market for unregulated psychoactive substances. Some 
precursors and drugs are also traded online. 
Information is limited on the scale of this problem but it 
has the potential to change quickly, especially with the 
introduction of new online payment technology.
•   Innovation in drug production: The use of specialist 
technology and more sophisticated approaches can be 
seen in cannabis cultivation, cocaine concealment and 
chemical extraction from various materials, and in 
synthetic drugs production as well as packaging and 
marketing of new psychoactive substances.
Technology and innovation as drivers of change
131
Chapter 10 | Conclusions and recommendations
cannabis—at the European level, and in most Member 
States, are stable or even showing a downwards trend. 
Despite this, levels of use remain high by historical standards 
and, although inter-country variations are considerable, drug 
use remains a major policy concern for all of Europe. 
Synthetic substances are also becoming more important, 
and this trend appears likely to continue. Moreover, drug 
markets appear to be increasingly fluid, dynamic and, 
importantly, responsive to countermeasures.
Heroin
Heroin remains at the heart of the EU drugs problem: even 
when prevalence of use is low, this drug is responsible for 
severe health and social problems. This is illustrated by the 
fact that the drug is associated with the majority of the 
7 000 drug-related overdoses currently reported every year 
in Europe. If indirect mortality associated with heroin use is 
also included, then this figure can probably be at least 
doubled. Heroin use also remains the most common reason 
for seeking drug treatment in the EU, and those with heroin 
problems typically require treatment over a protracted 
period of time, with relapse a common problem. This, 
together with the risk of infection associated with the use of 
this drug by injection, means that heroin is still responsible 
for a disproportionate amount of the health and social costs 
arising from drug use in the EU.
The heroin problem we see today in Europe to a large extent 
has it roots in the ‘drug epidemics’ seen in the 1990s. Recent 
data suggest that heroin use in Europe is now in a slow 
long-term decline. At market level, this is reflected in the 
latest data on purity, retail prices, seizures and heroin 
offences, all of which show a decrease. In some countries 
the drug has been replaced by other substances, including 
synthetic opioids such as diverted medicines and illicitly 
produced fentanyls. The heroin market collapsed almost a 
decade ago in parts of northern Europe, and has never fully 
recovered. More recently, short-term market shocks, 
probably resulting from successful interdiction efforts, have 
also been reported, with some countries experiencing a 
significant drought in 2010, from which the market has 
subsequently recovered only partially. Demand factors are 
also contributing to a market contraction. New recruitment is 
at a low level, and a large increase in the availability of 
substitution treatment has removed a significant proportion 
of the demand from the marketplace. In the global context, 
heroin use in the EU is now characterised by a relatively 
small and ageing population with high levels of service 
contact. Overall, it seems reasonable to conclude that the 
European heroin market is becoming less important in global 
terms. Nonetheless, threats in this area remain. They include 
the possibility of new ‘heroin epidemics’, especially during a 
proven to be particularly fruitful. As purchases are likely to 
be sent to buyers via postal and courier services, this 
reinforces the recommendations made above to develop 
greater interdiction capacities in this area. The speed of 
developments in this area means that Internet-monitoring 
and intelligence-gathering activities are likely to be 
fundamental to understanding of both the nature of the 
problem and the design and targeting of interventions. A 
more general point is that the central role of the Internet in 
the lives of many young people makes this medium of 
growing importance for research as well as communicating 
prevention, education and harm reduction messages.
Innovation in the drug market is not restricted to 
communication and the Internet. Innovation in drug 
production has been considerable, and, as noted already, 
the EU is a source of know-how and expertise. The use of 
specialist and increasingly sophisticated technology can be 
seen in cannabis cultivation and synthetic drug production in 
Europe, with an important development in the latter being a 
‘chemical downstreaming’ of the manufacturing processes. 
Responding to controls on precursor chemicals, producers 
have moved down the production chain and have innovated 
manufacturing processes using uncontrolled pre-precursors. 
At present, a ‘cat and mouse’ game appears to going on, 
with targeting by law enforcement of one group of 
chemicals leading drug producers to search for more easily 
available alternatives. Innovation in cocaine trafficking has 
seen not only the use of specialised vessels and concealment 
methods but also more sophisticated chemical approaches 
requiring secondary extraction within the EU.
An often overlooked additional negative consequence of 
synthetic drug production within the EU is the environmental 
damage and risk to community safety that comes from the 
dumping of chemical waste or from the poor storage of 
dangerous chemicals.
Innovation and adaptation to the threats posed by control 
can also be seen in the human organisation of trafficking 
and drug market activities. OCGs have always adopted 
organisational structures in which lower-value or expendable 
individuals are disproportionately put at risk. New 
approaches to this can be seen in cannabis cultivation and 
synthetic drug production. In both cases there is evidence of 
the increased use of a decentralised model for drug 
production and storage, thus decreasing the overall 
vulnerability of the organisation to law enforcement efforts.
Drugs in perspective
An important contextual starting point is that indicators of 
the use of the ‘established’ drugs—heroin, cocaine and 
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South-West Asia could also become more significant than is 
currently assumed to be the case. Historically, heroin 
production and trafficking has been strongly associated with 
areas in conflict, and the present situation in several 
countries of South-West Asia and the Middle East could 
prove to be fertile ground for the further expansion of 
production or trafficking networks.
Turkey continues to have a central role in the Balkan route as 
a transit country, and Turkish OCGs continue to play a 
significant part in the importation of heroin to the EU. 
However, other countries and groups appear to be becoming 
time of economic austerity, and the production or increased 
marketing of synthetic alternatives. To date, a number of 
drugs have been reported (depending on country) as 
substitutes for heroin, including synthetic opioids, synthetic 
cathinones, benzodiazepines and methamphetamine. There 
is some evidence that heroin trafficking organisations are 
showing interest in other drugs, including methamphetamine 
and cocaine.
A possible bounce-back driven by changes in opium 
production in Afghanistan or even South-East Asia also 
cannot be ruled out. Production outside Afghanistan in 
Action points
•   Invest in proven approaches: Strategically planned and 
intelligence-led operations, based on cooperation 
among countries along the classical heroin trafficking 
routes, have proven successful and should be continued 
and reinforced where possible.
•   Work beyond the EU: Diversification to new routes and 
groups is a major challenge and will require the 
development of corresponding information sources and 
strategic partnerships. Currently, African countries 
appear to be particularly important here.
•   Respond to a more joined-up threat: The particular 
threat posed by interaction between the heroin market 
and the market for synthetic drugs and cocaine implies 
the need for joined-up law enforcement strategies and 
more efforts in information sharing and analysis.
•   Remain vigilant: Trends in heroin production and 
demand developments require careful monitoring both 
in established areas and in areas where diversification 
or diffusion is possible.
•   Restrict access to precursors: An effective precursor 
monitoring and control framework, not just in the EU 
but globally, should remain a key objective. Increased 
synergy between monitoring activities and interdiction 
mechanisms is likely to increase the effectiveness of 
responses in this area.
•   Give equal priority to reducing demand: The 
importance of a balanced approach, especially with 
respect to increased availability of effective drug 
treatment, is essential if the heroin problem is to 
continue to diminish in the EU.
Overview
•  The heroin problem: Heroin use continues to be 
responsible for severe health and social problems 
although the market appears to be in long-term decline 
as a result of both supply and demand factors.
•   The global market: Non-EU heroin markets are larger 
and easier to penetrate and are thus probably 
becoming more important globally, and this may have 
a knock-on effect on availability within the EU.
•   Interactions with other drugs: OCGs appear to be 
increasingly active in the markets for other drugs, and 
interactions can be seen between the heroin market 
and the market for cocaine (through Africa and the 
Western Balkans). An important specific risk is the 
diversification of heroin networks into 
methamphetamine production and trafficking.
•   Diversification of routes: Recent diversification of heroin 
trafficking routes has been noted as organised crime 
responds to interdiction successes.
•   Precursor control: Europe remains an important source 
of precursors, but data are limited and control 
measures difficult to implement effectively.
•   Future threats: The production situation remains fluid 
and this, and the possible existence of stockpiles, could 
result in future increases in availability.
Heroin
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communities is growing, prompted by crimes of violence 
and other crimes linked to production and distribution. 
Despite this, the public is largely unaware of the extent of 
violent crime now associated with cannabis as much of 
this occurs between criminal groups. This does, however, 
put an increasing strain on often already stretched local 
police resources in the areas where production sites are 
located.
Domestic production is also now changing the drug flows 
between some EU Member States as it displaces imports 
from non-EU countries. Interdiction efforts targeting domestic 
production are becoming more sophisticated and are being 
scaled up in many countries. This appears to be resulting in 
increased use of a more decentralised production model in 
which vulnerable individuals are recruited or coerced into 
becoming small-scale cultivators. A closely related problem 
is human trafficking by South-East Asian transnational OCGs 
involved in cannabis production, with victims exploited as 
an expendable source of labour.
A relatively well-developed commercial grow shop industry 
supports illicit production and sometimes may be linked to 
distribution. The plurality of production sites and producers 
appears to be creating a new role for brokering activities in 
which OCGs are active. Policy initiatives in this area have to 
take account of the public perception of this drug, which is 
more equivocal than for other substances.
Differences in enforcement practices between countries can 
result in cross-border issues, sometimes resulting in 
displacement of the market. Despite the increasing 
importance of domestic production, it is also important not 
to ‘take the eye off the ball’ in respect of established and 
potential new external sources of production. The trafficking 
of cannabis into the EU remains a major criminal activity 
area. The Iberian Peninsula remains of paramount 
importance here, but the threat appears to be growing from 
production sites located in South-Eastern Europe and 
beyond, including Afghanistan.
more important, resulting in a diversification of trafficking 
routes and organisations. This is suggested by evidence of the 
increased importance of the Western Balkans and of heroin 
transit through African countries and the Middle East. 
Innovations that include the increased use of air transportation 
may also represent a threat to current interdiction strategies. A 
related and important issue is the role of European OCGs in 
sourcing and exporting the principal precursor chemical for 
heroin production, acetic anhydride. Despite a strong EU 
prevention mechanism and some notable interdiction 
successes, the principal trafficking routes for acetic anhydride 
remain difficult to identify and counter-measures have to be 
understood within the context of a chemical that has a large 
legitimate market and is therefore difficult to control.
Cannabis
The sheer magnitude of the cannabis market and the income 
it generates makes it a major policy challenge. The market 
has undergone important changes, the most important of 
these being an increase in production within the EU and 
developments in cannabis cultivation technologies, resulting 
in a potential increase in yield and potency. Domestic 
production of cannabis has implications for public health and 
certainly presents a greater challenge for drug enforcement 
efforts. Production sites range from small-scale cultivation of 
a few plants for personal use to major plantations. Sites are 
usually located close to consumers and difficult to detect. This 
is reflected in a relatively low volume of herbal seizures in 
comparison with seizures of cannabis resin (originating 
outside Europe). Cannabis production may now be seen as 
an attractive and easy to enter cash business for new and 
established crime groups, resulting in the increased 
involvement of organised crime. Some groups active in this 
area have a transnational presence, and the involvement of 
ethnically defined OCGs can be particularly challenging for 
enforcement efforts because of their closed nature.
The understanding of the negative impact these 
developments in these cannabis markets have had on local 
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standards. Survey data suggest some modest contraction in 
the market, but not on the same scale as the fall in seizure 
volumes since 2006. The bulk of EU seizures occur in the 
Iberian Peninsula, which remains the main point of entry into 
Europe of this drug, which is subsequently transported along 
broadly the same routes used for cannabis. There is concern 
about the security of countries on the supply routes for 
Cocaine
All cocaine indicators (both supply and demand) peaked in 
2008 and have declined since. The prevalence of cocaine 
use is high in a relatively small number of West European 
countries, although some ongoing spread is still evident. 
Demand in these countries remains high by historical 
Action points
•   Adopt a holistic approach: Interdiction efforts against 
any single source of production may result in 
replacement from alternative sources, emphasising the 
importance of a holistic and comprehensive approach.
•   Share expertise: Continued innovation and the sharing 
of know-how and technologies among Member States 
are important if Europe’s capacity to combat domestic 
cannabis production is to be improved.
•   Monitor production and trafficking: There is an urgent 
need to improve the monitoring of production and 
trafficking flows of cannabis into and between the EU 
countries and to better monitor domestic production 
yields and potency.
•   Act in key areas: Interdiction efforts targeting cannabis 
entering through the Iberian Peninsula remain important 
as does the need to actively engage with Morocco. In 
addition, responses are required to the threat that 
appears to be growing from production sites located in 
South-Eastern Europe and from areas that have not 
previously been important from an EU perspective.
•   Work with the community: Environmental drug 
prevention approaches, education and community 
awareness-raising and strategies to intervene with 
groups who may be vulnerable to involvement in the 
cannabis market are all necessary to support supply 
reduction measures.
Overview
•  A large and diverse market: The sheer scale of demand 
for cannabis and accompanying diversity and 
sophistication of the market, in terms of potential 
sources, players and products, makes it relatively 
resilient to interdiction efforts.
•   Current consumption: Annual cannabis consumption in 
the EU is currently estimated at around 2 500 tonnes. 
Extrapolating from the limited data on prices currently 
available, this would mean that the value of the EU 
cannabis market at street level is probably somewhere 
between EUR 18 and 30 billion.
•   A changing situation: There is now an overall shift to 
production within the EU, and this has been 
accompanied by developments in cultivation 
technologies that may result in increased yield and 
potency.
•   Production in the EU: Domestically produced cannabis 
can be more difficult to detect and increases local 
criminality, thereby posing a new challenge for law 
enforcement.
•   An ubiquitous problem: The cannabis market is 
lucrative and relatively easy to enter, and therefore 
attractive to both new and established crime groups.
•   North Africa remains important: Trafficking of cannabis 
resin, principally from Morocco, remains important and 
is sometimes linked to the importation of other illegal 
cargos.
•   The European dimension: Some groups active in this 
area have a transnational presence and are relatively 
flexible in terms of relocating activities between 
countries. Crime networks based on specific ethnic 
groups can be more difficult to penetrate.
•   Diffusion and displacement: Different legal frameworks, 
and judicial and policing practices, between European 
countries can impact on the location of cannabis 
production and sale.
Cannabis
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challenge is that legal businesses, particularly those involved 
in the importation of products in which cocaine could be 
concealed, are commonly infiltrated or set up to facilitate 
trade or launder profits.
Cocaine is produced in Latin America, and recently both 
UN and US sources have reported a moderate decrease in 
coca bush cultivation. The availability of cocaine in Europe 
is potentially influenced by levels of production, interdiction 
efforts in source and transit routes countries and competition 
from other markets. Historically, the main consumer market 
cocaine into Europe, particularly in West Africa. As noted 
above, interaction between cocaine and heroin trafficking 
organisations may be an important development. Recently, 
major seizures in the Black Sea ports of the Balkans area 
and in ports in the Eastern Baltic Sea area have been noted. 
Although Latin American OCGs continue to dominate the 
supply of cocaine to the European market, intelligence now 
points to some diversification, with European-based OCGs 
becoming more prominent. It also appears that traditional 
heroin trafficking networks and infrastructures are now 
being used for cocaine trafficking purposes. An ongoing 
Action points
•  Monitor growth in use in the EU: Although the use of 
cocaine appears to have peaked in high-prevalence 
countries, there is still considerable potential for 
further spread elsewhere. Monitoring of trends, 
especially along new trafficking routes, is therefore 
important.
•   Assess new threats: There is a need for better 
intelligence on cocaine importation in Europe, 
especially in the Black Sea and Balkan areas and via 
Africa. A parallel need is to improve the understanding 
on the use of secondary extraction laboratories, 
especially outside the Iberian Peninsula.
•   Put container trafficking in the spotlight: Of particular 
importance is developing awareness and multiagency 
working partnerships with customs, port authorities and 
commercial transport organisations as weaknesses in 
this area are increasingly being exploited.
•   Cooperate with Latin American countries: Support for 
precursor control activities in producer countries 
remains important.
Overview
•  A large but heterogeneous market: Europe now 
accounts for only about 9 % of global seizures. The 
European cocaine market is heterogeneous at country 
level, but overall the drug remains the second most 
commonly used illicit substance in Europe—
representing probably the third largest market in the 
world.
•   Trends in indicators of demand and supply: Demand 
for the drug remains high, but indicators of cocaine use 
at the EU level peaked around 2008 and have fallen 
slightly since then. Since 2006 there has been a large 
fall in seizure volumes that is not easily explained by 
contractions in demand.
•   Developments in trafficking: Spain and Portugal remain 
the main points of entry for cocaine into Europe, with 
trafficking through West Africa a particular concern. 
Evidence of new routes is also emerging. In all areas, 
cocaine concealed in container shipments is becoming 
more important, and recent major seizures have been 
made in the Black Sea and in the Eastern Baltic Sea 
areas.
•   Increasing links between organised crime groups: 
Interaction between cocaine and cannabis resin 
trafficking networks is well established. A more recent 
concern is interaction between cocaine and heroin 
trafficking groups.
•   Innovation: In addition to developing new routes and 
concealment methods to avoid detection, cocaine 
trafficking organisations have developed more 
sophisticated chemical techniques including 
incorporating the drug in legitimate products and the 
production of ‘odourless’ products.
•   Precursor availability: The main cocaine precursor 
(potassium permanganate) now seems to be 
manufactured illicitly in the cocaine-producing countries 
of South America rather than being diverted from 
legitimate sources.
Cocaine
136
EU drug markets report: a strategic analysis
Amphetamine, methamphetamine and ecstasy are in 
aggregate very widely used both in Europe and globally. 
The use of amphetamine and ecstasy, historically the most 
important synthetic drugs in Europe, appears to be largely 
stable or in slight decline. Overall, any decline in use is best 
understood as a reflection of diversification rather than any 
contraction in demand, with methamphetamine now 
becoming more important and other new substances also 
appearing.
In parts of Europe, the small-scale production of synthetic 
drugs for personal use is still found. The best example of this 
is methamphetamine production in the Czech Republic, 
where small user-producer cooperatives have a long history 
going back to the Communist period. More generally, 
however, the production of synthetic drugs involves OCGs 
reflecting economies of scale obtained by large production 
runs and the need to source equipment and precursor 
chemicals. Overall current trends in the organisation of 
synthetic drug production are clearly suggestive of a 
trajectory towards much greater organisation, scaling up in 
production runs, and greater integration.
In contrast to other parts of the world, in Europe 
amphetamine is far more commonly used than 
methamphetamine, although this situation may be beginning 
to change. Data on methamphetamine are difficult to 
interpret, but overall they suggest that the drug is becoming 
more commonly available. Production has been reported in 
more countries, which now include Bulgaria, Lithuania, the 
Netherlands, Poland and the United Kingdom. Recently, 
Germany has also expressed concern about increases in 
methamphetamine production and importation. Recent 
intelligence reports, for example, have identified 
methamphetamine produced in the Netherlands and 
Lithuania destined for export to Scandinavian consumer 
markets.
Some sources also suggest a possible growing interest in 
methamphetamine trafficking from OCGs that produce 
cannabis. And, as noted already, some data exist to suggest 
that opiate production and trading networks might be 
becoming more interested in methamphetamine production. 
In this context, Turkey is now reporting methamphetamine 
seizures and Iran appears to have become a producer 
country with production intended for Asian countries but 
potentially linking to countries along the Balkan heroin route.
The European ecstasy market has recently gone through a 
period in which the availability of tablets sold as ecstasy 
containing MDMA became quite rare. Tablets sold on the 
illicit market during this period often contained other drugs, 
including legally sourced piperazines, such as mCPP. The 
scarcity of MDMA in ecstasy tablets appears to have been 
for cocaine was the United States, but parts of Latin America 
appear to be becoming increasingly important. The 
Brazilian market, for example, is now estimated to be 
considerable. Cocaine trafficking groups have shown 
considerable innovation, responding to interdiction 
challenges by developing new routes and new concealment 
methods. Reflecting this, the problem of cocaine entering 
Europe concealed in commercial containers is attracting 
more attention. Chemical innovation has also been seen, 
with cocaine being chemically incorporated in legitimate 
products for secondary extraction within the EU. New 
methods of procuring precursor chemicals are also 
becoming apparent. Indeed, it seems that more of the main 
cocaine precursor (potassium permanganate) is now 
manufactured illicitly in the cocaine-producing countries of 
South America than is diverted from legitimate foreign 
sources. This development is similar to the use of ‘pre-
precursors’ to manufacture synthetic drugs (see below), and 
illustrates how successful interdiction measures may result in 
new challenges as drug manufacturers seek new ways to 
circumvent controls.
European responses in this area have taken a number of 
different forms—at both political and technical level; these 
range from bilateral projects to inter-regional cooperation 
initiatives and include intelligence sharing and joint 
operations. There has been some notable interdiction 
success, for example in the mid-Atlantic, resulting from 
cooperation. The European cocaine market is believed to 
be the third largest in the world, although Europe now 
seizes only about 9 % of the cocaine captured globally. 
Moreover, the large drop in quantities of cocaine seized 
noted after 2006 is difficult to explain in terms of the data 
available on levels of use. This suggests the need to 
consider other plausible explanations, one being a 
mixture of new trafficking routes and methods, combined 
with changes in the availability of law enforcement 
resources.
Synthetic drugs
The synthetic drug market is dominated by stimulant 
products, and in this context amphetamine, 
methamphetamine and ecstasy can all be seen as drugs 
competing in a similar consumer marketplace. They also 
share some aspects of synthesis, production and trafficking. 
Stimulants are often used for functional purposes and the 
other main ‘market player’ here is cocaine, the prototype 
stimulant drug. In any overall analysis it is important to 
consider the demand for stimulants as a group as well as 
independently since the substances are frequently 
interchangeable, and this can have an impact on the 
effectiveness of intervention measures.
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‘legal highs’ area, where non-controlled products replace 
controlled ones. This illustrates the increasing sophistication 
of drug production capacity within the EU and the ability to 
innovate to circumvent control measures. Border control 
strategies are therefore rendered less effective by producers 
moving ‘downstream’ in the chemical production chain.
A related phenomenon has been observed in the 
amphetamine market, where precursors have been 
chemically ‘masked’ to avoid existing border and sales 
related to shortages of the precursor PMK, possibly 
reflecting the success of interdiction efforts targeting this 
chemical. However, more recent data suggest that MDMA 
availability is again increasing.
MDMA production methods now appear to be based on 
either safrole or, increasingly, imported non-controlled 
chemicals, such as PMK glycidate, that are structurally 
similar, although not identical, to the controlled precursors 
hitherto used. A parallel exists here with developments in the 
Action points
•   Act against major production sites: Targeting inter-
regional production of synthetic drugs, which can be 
mobile, relocate quickly and result in large volumes, 
needs to remain a priority for law enforcement efforts, 
with greater emphasis given to coordinated and 
parallel actions.
•   Restrict access to necessary chemicals: Targeting the 
trade in precursor chemicals necessary for production 
requires both intra- and inter-regional activities. The 
identification of new methods and chemicals and 
measures to restrict their availability is becoming of 
critical importance.
•   Strengthen the international framework: Restricting the 
availability of new (pre)precursors will require 
international agreement. This is likely to be challenging 
in the case of those chemicals which have extensive 
legitimate uses.
•   Identify and target key producers: The growing 
diversity of synthetic drug use is accompanied by, and 
may trigger, an increasing integration of OCGs 
involved in production. This threat requires that priority 
be given to intelligence gathering to identify and target 
key organisations and individuals.
Overview
•  A rapidly developing area: Recent developments in the 
synthetic drug market include a bounce-back in ecstasy 
quality; increased availability of methamphetamine; 
greater technical sophistication; evidence of scaling up 
of production processes; and increasing interaction 
with the market for new psychoactive substances.
•   Innovation to avoid control: Producers have introduced 
new measures, in particular the sourcing of pre-
precursor chemicals and decentralised production 
processes to adapt to previously successful supply 
reduction efforts.
•   Increased replacement: There is increasing evidence of 
synthetic substances being used as replacements for 
both heroin and cocaine. Increasing interplay is also 
seen with the market for non-controlled new 
psychoactive substances.
•   Ecstasy on the rebound: Ecstasy use over the medium 
term has stabilised or even declined, due in large part 
to successful enforcement, albeit that demand for this 
drug may have been satisfied by other stimulants. The 
improved quality of ecstasy tablets, and now powders, 
available in Europe may, however, see a resurgence in 
interest in this drug.
•   EU production: Demand for synthetic drugs in Europe is 
met largely by laboratories located intraregionally, 
particularly in the Netherlands and, to a lesser extent, 
Belgium, Lithuania and Poland. However, trafficking in 
precursors—and pre-precursors—is on a global basis, 
and producers are proving versatile in finding new 
production methods. The EU remains an important 
exporter of amphetamine and ecstasy.
•   EU responses: There have been important initiatives at 
European level to improve coordination in tackling ATS, 
including action against trafficking and the trafficking 
of precursors; coordinated chemical profiling of seized 
drugs; and the funding of JITs and EMPACT.
Synthetic drugs
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development of this market. The factors underlying such 
globalisation include a growing capacity for complex, 
cheap chemical synthesis in emerging economies; the rise of 
the Internet as a means of communication, a forum for 
knowledge exchange and a marketplace; and air freight 
and postal systems that allow drugs or their precursors to be 
rapidly shipped to Europe. At the same time, the methods 
used to market and advertise many of these new drugs have 
also become increasingly innovative and sophisticated, with 
some countries seeing a rapid increase in retail outlets. As a 
result, new drugs can reach larger numbers of potential 
consumers, including some who would not typically use 
controlled substances.
The market has shown a considerable capacity to rapidly 
adapt to regulatory measures, with new product lines in 
development to anticipate controls. There is also a growing 
interplay between this new market and the established 
market for controlled drugs. Overall, these developments 
have posed serious challenges to existing approaches to 
drug control.
Although the source of the chemicals required to synthesise 
new drugs is unclear, there are indications that some are 
bought from manufacturers in Asia, with China and India 
often cited as countries of origin. Some new substances, such 
as mCPP, have also been legally sourced from within Europe, 
and some of the new substances are produced within Europe 
from precursors in illicit laboratories. These are usually 
intended to be sold directly on the illicit market as substitutes 
for controlled drugs. As a result, drug consumers may be 
unaware of the substances they are actually taking. The 
identification of substances in this area is a challenge not 
only for consumers. New psychoactive substances from 
numerous diverse and increasingly obscure chemical groups 
emerge rapidly and are incorporated in products whose 
component substances may change over time. This poses 
substantial problems for forensic and toxicological 
identification. It also means that consumers are exposed to 
substances of unknown toxicity. The initial identification of 
substances can be technologically demanding and costly, 
creating a strong argument for coordinated activities and the 
efficient sharing of data. Many of these substances will also 
go undetected if standard approaches are used. Thus, 
customs and border control forces can be poorly prepared to 
face the growing challenge of identifying a large number of 
different new substances.
As noted, there is an increasing interaction between the 
market in new drugs and those for controlled drugs. Some 
substances appear to have the potential to cross over to the 
illicit market once controls are put in place. Conversely, 
non-controlled psychoactive substances have been added 
control mechanisms, or where precursors (especially BMK) 
are manufactured illegally within Europe from non-controlled 
chemicals—so-called ‘pre-precursors’ such as alpha-
phenylacetoacetonitrile (APAAN). As producers become 
more technically sophisticated and seek out new ways to 
circumvent interdiction efforts and regulations, the possibility 
to modify and (re)convert substances represents another 
challenge to current drug control approaches.
Another precursor-related issue is the emergence of modified 
versions of controlled substances that may have additional 
harmful effects. In 2012, the EU early warning mechanism 
investigated 4-methylamphetamine after a number of deaths 
and emergencies were reported to be related to the use of this 
substance. The available information suggests that the 
precursor used for the manufacture of 4-methylamphetamine is 
4-methyl-benzyl methyl ketone (4-methyl-BMK), which is not 
under international control. There are indications from 
intelligence reports that producers believe that they are 
attempting to produce amphetamine using the precursor BMK, 
when they are in fact using 4-methyl-BMK and consequently 
producing 4-methylamphetamine. Alternatively, it has also 
been suggested that a mixture of BMK and 4-methyl-BMK is 
being used by illicit laboratories that have imported the 
precursors from China or Russia for amphetamine synthesis.
An overall conclusion is that, more than other illicit drug 
types, the control of synthetic drugs is clearly a dynamic 
process of adaptation and reaction. Control measures are 
met with rapid countermeasures and technological 
innovation. Ensuring effective action will require Member 
States and EU bodies to monitor developments closely, to 
coordinate interdiction efforts and to foster coordination with 
non-EU authorities. It can be confidently predicted that 
producer and trafficker groups will remain quick to adapt to 
new controls. It is also likely in the coming decade that the 
logic of the illicit drug market will be towards an increasing 
importance of synthetic products, especially those that can 
be produced close to consumer markets.
New psychoactive substances
Over the past few years Europe has seen an unprecedented 
growth in the number, type and availability of new 
psychoactive substances (new drugs). In 2012, for the fourth 
consecutive year, a record number of 73 substances were 
detected for the first time in Europe, up from 49 substances 
in 2011, 41 in 2010 and 24 in 2009. Overall, the EU early 
warning system currently monitors more than 250 new 
psychoactive substances.
The ongoing process of globalisation, tightly coupled with 
technological innovations, has been essential to the 
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products. Both these findings, along with seizure 
information, suggest a growing interest in this market by 
OCGs, although to date activity levels appear to have been 
relatively low. However, an equal threat appears to be that 
this area is attractive to new groups who see an opportunity 
to, or sold in the place of, established illicit drugs such as 
ecstasy. Examples of the interchangeable nature of licit and 
illicit drugs markets are the presence of licit mephedrone in 
tablets sold as ecstasy tablets and, conversely, the inclusion 
of controlled drugs, such as PMMA, in ‘legal high’ 
Action points
•   Respond to a growing problem: The EU mechanism for 
identifying, monitoring and responding to new drugs 
needs to be strengthened to keep pace with the 
challenges posed by this rapidly developing 
phenomenon.
•   Rise to the forensic challenge: The need to identify and 
assess increasingly diverse sets of chemicals, and the 
costs of doing so, requires forensic science capacity to 
be strengthened and the sharing of chemical data, 
reference samples and expertise. There is a parallel 
need to improve capacity to enable the detection of 
new substances at borders and within the postal and 
transport services.
•   Take a proactive approach: Responses can be 
strengthened by a proactive approach to monitoring of 
the Internet, including test purchasing and by 
developing partnerships with industry to restrict illegal 
activities.
•   Respond to the illicit market: There is a need to analyse 
and respond robustly to the growing interplay between 
the new drugs market and the established market in 
controlled drugs.
•   Take rapid action to protect public health: Some new 
substances pose an immediate and pronounced threat 
to public health. This requires a fast-track EU-wide alert 
mechanism that will allow Member States to take 
immediate precautionary measures.
Overview
•  The challenge of identification: New substances, from 
diverse chemical groups, emerge rapidly and are sold 
in products that may contain mixtures of substances 
that change over time. This poses a substantial 
challenge for forensic and toxicological identification 
and means that consumers are exposed to substances 
whose toxicity is unknown.
•   Dramatic rise in introduction of new psychoactive 
substances: There has been a growth in the number, 
type and availability of new substances in Europe. In 
2012, a record 73 substances were detected for the first 
time. Overall, the EU early warning system currently 
monitors more than 250 substances.
•   A multifaceted problem: The new drugs market can be 
seen as two broad and overlapping groups of non-
controlled substances and products: those sold directly 
on the illicit market and the so-called ‘legal highs’.
•   A potential for growth in use: New drugs can diffuse 
rapidly and may also be attractive to consumers who 
do not typically use controlled drugs.
•   Crossover to drug market: Non-controlled psychoactive 
substances have also been added to, or sold in the 
place of, established illicit drugs such as ecstasy 
(MDMA). Some ‘legal highs’ appear to have crossed 
over into the illicit drug market once controls have been 
put in place.
•   Globalisation and the Internet play a key role in the 
emergence of ‘legal highs’: Synthesis usually takes 
place outside the EU, and similar products have 
appeared in many parts of the world. However, 
EU-based entrepreneurs play an important role in 
importing, packaging and marketing. The Internet is 
both a source of supply and a provider of information 
to consumers, traders and producers.
•   Competing with the illicit market: Interaction between 
the illicit drug market and the market for ‘legal highs’ 
exists, but is currently limited. However, given the large 
profits, and low risk, of operating in this area a 
considerable potential exists for both established and 
new criminal organisations to become more active.
New psychoactive substances
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sometimes like a distraction from more valuable activities. 
However, good intentions do not always deliver good 
results, and a sound analysis of the situation is necessary if 
activities are to be effectively targeted and their impact over 
time assessed. This is probably even more important now as 
a strong message coming from the analysis found in this 
report is the increasing speed and dynamic nature of the 
modern drug market.
The purpose of the analysis provided in this report is to 
provide a strategic overview of the situation with a focus on 
how value can be accrued from coordination and 
cooperation at the European level. The issues of the 
standardisation and comparability of those data available at 
EU level are of critical importance here. Currently, in contrast 
to demand-side indicators, the ability to compare even 
relatively simple quantitative measures between countries is 
quite poor. Similarly, both the timeliness of data availability 
and the coverage of data sets of the EU as a whole is 
frequently inadequate. This means that an EU-level analysis 
must be made with caution, and quantification of the scale 
of the market with any degree of rigour is often impossible 
in most areas. The weakness of statistical data is widely 
recognised, and the EMCDDA, Europol and the European 
Commission are currently working to improve the situation. 
The current focus of this work is to establish basic 
standardised key indicators for supply and supply reduction 
to provide the building blocks to permit a more robust time 
series analysis to be developed. Standardised statistical 
information sets, whilst important for strategic-level analysis, 
clearly do not serve all the information needs in this area. 
Research and intelligence sharing are plainly also important 
and can provide complementary data. This report has 
benefited considerably from the ongoing work to coordinate 
intelligence by Europol. This information is primarily 
intended for operational purposes, but when appropriately 
treated it can inform a more general analysis without 
compromising either sources or ongoing activities. It is 
therefore sufficient here to simply note the need for, and the 
value of, sharing operational data at the European level for 
both operational and analytical purposes.
The forensic science domain is one area where information 
sharing is clearly of both operational and analytical 
importance. The increasing presence of synthetic drugs, new 
drugs and mixtures thereof in the European drug market 
suggests that the importance of this area is growing. It has 
been noted in many parts of this report how understanding 
of this area is hampered by a lack of capacity. It is also an 
area in which added value can clearly be derived by 
sharing information and coordinated activities. Examples 
here are easy to find but can be summarised as improving 
forensic data quality as well as data on the availability on 
to move into an area characterised by low risks, high 
growth potential and easy profits.
Numerous factors drive the availability of new drugs. For 
many, the simple fact that there are few restrictions on the 
manufacture, transport, importation, sale and possession is 
crucial. Not only can this reduce costs, as well as risks to 
manufacturers and distributors, but it can also make new 
drugs more attractive and socially acceptable to consumers, 
especially when they are attractively packaged. The appeal 
of the strong visual images used in the packaging of these 
products is attested by the fact that similar packaging is now 
being adopted by some legitimate products targeting the 
youth market.
Online social networks are playing a growing role in how 
consumers learn about new drugs, buy them and, 
subsequently, share their experiences. This makes them a 
potent vehicle for further diffusion. Despite the importance of 
the Internet in this respect, it is not currently the principal 
route by which most consumers obtain these products. 
Studies have found that many users source ‘legal highs’ from 
friends, specialised shops or even illicit dealers rather than 
directly from the Internet. That said, it is clear from Internet 
monitoring that there is a growing number of online shops 
offering ‘legal highs’ and medicines for sale to consumers 
both in the EU and in other countries. Moreover, the Internet 
may be the initial source of supply for products that are 
subsequently sold on through commercial or social networks.
Understanding the consumer market for new drugs is difficult 
given the limited research currently available. Some insight 
is provided by a recent EU-wide study which estimated that, 
among those aged 15–24, the prevalence lifetime use of 
‘legal highs’ was 5 %. There was large variation between 
countries, but rates of use were relatively high in some 
countries, with the United Kingdom, Latvia, Poland and 
Ireland reporting estimates of 8 %, 9 %, 9 % and 16 % 
respectively. This illustrates the potential of the products to 
spread rapidly, although the sampling approach used in this 
exercise, and the fact that the situation appears to be 
changing rapidly, means that further studies of drug 
prevalence in this area are urgently needed. To address the 
complexity of the new drugs phenomenon and to strengthen 
the EU response in this area, the European Commission is 
currently working on a new legislative proposal. This draws 
on a thorough analysis of the current situation and on an 
assessment of the existing legislative framework (Council 
Decision 2005/387/JHA).
Information needs
From an operational perspective, the investment of time and 
resources needed to develop robust data sets may seem 
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cannabis plants, in particular, are currently poorly 
standardised and difficult to interpret.
There are a number of challenges that need to be overcome 
when attempting to scale up European data on supply 
issues. The speed at which changes are occurring and the 
parallel need to respond rapidly to new developments is a 
challenge to conventional statistical reporting models. The 
sustainability of any information collection system is often 
contingent on the data providers getting sufficient reward 
from their efforts. This would imply that rapid feedback and 
analysis relevant to local needs will be important. A good 
model here may be the current EU early warning system on 
new drugs. The benefits of rapidly sharing information using 
this system are reflected in the high degree of commitment 
the chemical make-up of seized substances including 
recording of purity and adulterants. Chemical and other 
forms of profiling can also allow a better understanding of 
market changes. Better information on the number and 
characteristics of dismantled drug production sites would 
also be helpful and allow a better understanding of issues 
such as the extent to which the processing and extraction of 
cocaine is occurring within the EU.
More standardised and detailed information on drug 
seizures must also be regarded as a priority. A good 
illustrative example of the issues here is cannabis. Current 
monitoring in this market does not allow products to be 
distinguished or the relative potency of available cannabis 
products to be determined. Data on herbal cannabis and 
Action points
•   Establish high-quality indicators of drug supply: 
Standardised key indicators to provide the building 
blocks to permit a more robust time series analysis 
need to be established.
•   Develop and share forensic science information: There 
is a need to scale up and develop expertise, networks 
and analytical forensic capacity at the EU level. 
Maximum value will be accrued by sharing of 
information through integrated databases using 
common standards.
•   Estimate size and value of markets: Estimates of both 
the scale and value of drug markets are informed by 
demand and supply indicators. Functional longitudinal 
models that will allow the monitoring of changes on 
an ongoing basis need to be developed to allow 
better quantification of important aspects of the drug 
market.
•   Identify research priorities: There is a need to identify 
emerging research needs in this area and encourage 
cross-national and multidisciplinary studies.
Overview
•   The need for an integrated information model: 
Understanding a complex phenomenon such as the 
drug market requires a critical analysis informed by 
both supply- and demand-side data.
•   Statistical data on supply remains a weak link: 
Improving the measurement of drug markets and 
effectiveness of supply reduction responses requires 
that data are based on common definitions and 
standards.
•   Forensic science at EU level is underutilised: Forensic 
information has both operational and strategic 
importance, yet capacity at EU level is currently 
insufficient. Sharing of information and improving the 
coordination of actions at EU level can also add value 
to national efforts.
•   Maximising the strategic value of intelligence: 
Operational intelligence, used with appropriate 
safeguards, can enrich strategic analysis and 
complement information obtained from statistical and 
other sources.
•   Quantifying the drug market: An estimate of the size of 
the market is essential for improved threat analysis, and 
to better target, and measure the impact of, supply and 
demand interventions.
•   The importance of research: Dedicated research studies 
are necessary to complement statistical data, and, 
within a European context, key research priorities 
require identification.
Information needs
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a greater degree of confidence important analytical 
questions such as the size of European drug markets and 
obtain better estimates of both scale and value of production 
and consumption.
In conclusion, it is clear that monitoring and evaluation are 
in some respects secondary tasks to the primary business of 
the operational work necessary to pursue supply and 
demand reduction objectives. Nonetheless, actions that are 
not based on an understanding of the nature of the problem 
risk being poorly conceived and poorly targeted. This can 
result in an overall approach that is likely to be at best 
ineffective and at worst counterproductive. Without impact 
evaluation, resources may be wasted as ineffective 
strategies continue to be pursued. And, similarly, without 
information systems that are proactive and sensitive to 
change, important new threats may be overlooked and 
opportunities for early intervention missed. This is 
recognised in the European strategic response to drugs, 
which can be characterised as placing a central emphasis 
on the need for actions to be evidence based. It is also the 
rationale for this report and it is why recommendations to 
improve the information base are important inclusions here.
shown by data providers. It is likely that technology can also 
be helpful here, and, as noted already, online systems have 
the capacity to provide benefit by proving rapid and secure 
communication and allow information to be collected and 
accessed in more creative ways. Methodological technical 
developments may also prove helpful; for example, current 
developments in wastewater analysis offer the potential for a 
rapid reporting tool on trends in drug consumption at the 
population level.
Despite the challenges that exist, even moderate 
improvements in data quality could deliver some important 
returns. All data sources in this area are by their very nature 
partial, and the best insight comes from the multi-indicator 
analysis of time series data. To understand a complex 
phenomenon such as drug use and the drug market, both 
supply and demand data are essential. It is, for example, 
impossible to understand the current European heroin market 
without considering the impact that widespread substitution 
has had in removing a significant component of consumer 
demand. Looking at data availability overall, it can be 
concluded that a window of opportunity now exists that may 
allow, in the not too distant future, the ability to address with 
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2C-I 2,5-dimethoxy-4-iodophenethylamine
ADAM Automated Donor Assistance Mechanism
AIRCOP Airport Communication Project
APAAN alpha-phenylacetoacetonitrile 
AQIM Al Qaeda in the Islamic Maghreb
ATS amphetamine-type stimulants
AWF analysis work file
BMK benzyl methyl ketone
BOMCA  Border Management Programme in Central 
Asia 
BZP 1-benzylpiperazine
CAAT Airport Anti-Traffics Cells
CADAP Central Asian Drug Action Programme
CAN Andean Community
CARDS  Community Assistance for Reconstruction, 
Development and Stabilisation 
CAST Cannabis Abuse Screening Test
CBD cannabidiol
CCP Cargo Container Programme
CeCLAD-M  Centre de Coordination pour la Lutte Anti 
Drogue en Méditerranée
CNA central national authority 
CO-LA-CAO  Law Enforcement and Intelligence 
Cooperation Against Cocaine Trafficking from 
Latin America to West Africa
COPOLAD  Cooperation Programme on Drug Policies 
between Latin America and the European 
Union
COSI  Standing Committee on Operational 
Cooperation on Internal Security
EC European Commission
ECCCS  Europol Cannabis Cultivation site Comparison 
System
ECLS Europol Cocaine Logo System
ECOWAS Economic Community of West African States
EDPS European Drug Profiling System
EEGC European Expert Group on Cannabis
EELS Europol Ecstasy Logo System 
EILCS Europol Illicit Laboratory Comparison System
ELSC Europol Logo System on Cannabis
EMCDDA  European Monitoring Centre for Drugs and 
Drug Addiction
EMPACT  European Multidisciplinary Platform against 
Criminal Threats
ESDS Europol Synthetic Drug System
ESMC  Europol Specific Means of Concealment 
System
ENP European Neighbourhood Policy
ENPI  European Neighbourhood and Partnership 
Instrument
ESPAD  European School Survey Project on Alcohol 
and other Drugs
EU European Union
EUROSUR European border surveillance system
EWS Early Warning System
FARC Revolutionary Armed Forces of Colombia
GHB gamma-hydroxybutyrate
GPS global position system
HCV hepatitis C virus
HDG Horizontal Working Party on Drugs
HIV human immunodeficiency virus
INCB International Narcotics Control Board
IPA Instrument for Pre-Accession Assistance
JAITF joint airport interdiction task force
JCO joint customs operation 
JIT joint investigation team
LAC Latin American countries
MAOC-N  Maritime Analysis and Operation Centre—
Narcotics
MASP multiannual strategic action plan
mCPP meta-chlorophenylpiperazine
MDMA 3,4-methylenedioxy-methamphetamine
4-MMC 4-methylmethcathinone (mephedrone)
MMDMG  methyl-3-[3’4’-(methylenedioxy)phenyl]-2-
methyl glycidate
MDPV methylenedioxypyrovalerone
NPS new psychoactive substances
NSA National Strategic Analysts
OAP operational action plan
OCG organised crime group
OCTA Organised Crime Threat Assessment
OMCG outlaw motorcycle gang
P2P 1-phenyl-2-propanone
PCU port control unit
PEN Pre-export Notification
PKK Kurdistan Workers’ Party
PMK piperonyl methyl ketone
PMMA para-methoxyamphetamine
Abbreviations
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SOCTA  Serious and Organised Crime Threat 
Assessment 
THC tetrahydrocannabinol
UN United Nations
UNODC United Nations Office on Drugs and Crime
WCO World Customs Organization
PRADI-CAN  Progama Antidrogas Ilícitas en la Comunidad 
Andina
SEACOP Seaport Cooperation Programme
SMART  Global Synthetics Monitoring: Analyses, 
Reporting and Trends 
SOCA Serious Organised Crime Agency
European Monitoring Centre for Drugs and Drug Addiction and Europol
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About this report
The EU drug markets report provides the first comprehensive overview of illicit drug markets 
in the European Union. The report combines Europol’s strategic perspective and operational 
understanding of trends and developments in organised crime with the EMCDDA’s ongoing 
monitoring and analysis of various aspects of the drug phenomenon in Europe and beyond.
The EU drug market is complex, and the analysis provided here spans numerous topics such 
as production, consumer markets, trafficking, organised crime and policy responses. Taking 
a multi-source approach, the report reviews the markets for heroin, cocaine, cannabis, 
amphetamine, methamphetamine, ecstasy and new psychoactive substances. It also provides 
concrete action points for the areas where the current EU response to the drug market and its 
consequent harms may be improved.
This publication is an essential reference for law enforcement professionals, policymakers, the 
academic community and indeed for anyone seeking up-to-date information and analysis on 
drug markets in Europe.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the hub of drug-related 
information in Europe. Its mission is to provide the EU 
and its Member States with ‘factual, objective, reliable 
and comparable information’ on drugs, drug addiction 
and their consequences. Established in 1993, it opened 
its doors in Lisbon in 1995 and is one of the EU’s 
decentralised agencies. With a strong multidisciplinary 
team, the agency offers policymakers the evidence base 
they need for drawing up drug laws and strategies. It 
also helps professionals and researchers pinpoint best 
practice and new areas for analysis. As well as 
gathering information on the demand and reduction of 
the demand for drugs, the agency in recent years has 
extended its monitoring and reporting on drug supply, 
supply reduction and illicit drug markets.
www.emcdda.europa.eu
About Europol
Europol is the European Union’s law enforcement 
agency. Its aim is to improve the effectiveness of, and 
cooperation between, the competent authorities in the 
EU Member States in preventing and combating serious 
international organised crime and terrorism. 
Operational since 1999 and based in The Hague, the 
organisation employs some 600 staff to support 
national law-enforcement agencies in their everyday 
work, including efforts to tackle illicit drug trafficking, 
money laundering, cyber crime and terrorism. Europol 
comes into play when an organised criminal structure is 
involved and two or more EU Member States are 
affected. Among others, it facilitates cross-country 
information exchange and provides analysis of 
operations.
www.europol.europa.eu
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